0000919956-17-000039.txt : 20170803 0000919956-17-000039.hdr.sgml : 20170803 20170803160703 ACCESSION NUMBER: 0000919956-17-000039 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170803 DATE AS OF CHANGE: 20170803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diversicare Healthcare Services, Inc. CENTRAL INDEX KEY: 0000919956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 621559667 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12996 FILM NUMBER: 171004919 BUSINESS ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: 6157717575 MAIL ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: ADVOCAT INC DATE OF NAME CHANGE: 19940309 10-Q 1 dvcr-20170630x10q.htm 10-Q 2017 Q2 Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________ 
FORM 10-Q
________________________________ 
CHECK ONE:
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: June 30, 2017
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .

Commission file No.: 1-12996
________________________________ 
Diversicare Healthcare Services, Inc.
(exact name of registrant as specified in its charter)
 ________________________________
Delaware
 
62-1559667
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
1621 Galleria Boulevard, Brentwood, TN 37027
(Address of principal executive offices) (Zip Code)
(615) 771-7575
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨(do not check if a smaller reporting company)
Smaller reporting company
 
ý
 
 
 
Emerging growth company
 
¨
       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 
¨


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
6,458,836
(Outstanding shares of the issuer’s common stock as of July 28, 2017)
 



Part I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands)
 
 
June 30,
2017
 
December 31,
2016
 
(Unaudited)
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
3,900

 
$
4,263

Receivables, less allowance for doubtful accounts of $12,066 and $10,326, respectively
64,633

 
62,152

Other receivables
1,519

 
1,193

Prepaid expenses and other current assets
2,959

 
3,623

Deposit in escrow
8,673

 
—

Income tax refundable
490

 
431

Current assets of discontinued operations
42

 
28

Total current assets
82,216

 
71,690

PROPERTY AND EQUIPMENT, at cost
133,802

 
128,822

Less accumulated depreciation and amortization
(73,790
)
 
(69,022
)
Property and equipment, net
60,012

 
59,800

OTHER ASSETS:
 
 
 
Deferred income taxes, net
20,757

 
21,185

Deferred lease and other costs, net
167

 
193

Acquired leasehold interest, net
6,883

 
7,075

Other noncurrent assets
3,045

 
3,108

Total other assets
30,852

 
31,561

 
$
173,080

 
$
163,051

The accompanying notes are an integral part of these interim consolidated financial statements.

2


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(continued)
 
 
June 30,
2017
 
December 31,
2016
 
(Unaudited)
 
 
CURRENT LIABILITIES:
 
 
 
Current portion of long-term debt and capitalized lease obligations
$
10,373

 
$
7,715

Trade accounts payable
10,859

 
12,972

Current liabilities of discontinued operations
440

 
427

Accrued expenses:
 
 
 
Payroll and employee benefits
18,857

 
20,108

Self-insurance reserves, current portion
10,196

 
9,401

Provider taxes
2,508

 
3,114

Other current liabilities
5,299

 
4,432

Total current liabilities
58,532

 
58,169

NONCURRENT LIABILITIES:
 
 
 
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net
81,449

 
72,145

Self-insurance reserves, less current portion
11,417

 
11,766

Other noncurrent liabilities
8,789

 
9,551

Total noncurrent liabilities
101,655

 
93,462

COMMITMENTS AND CONTINGENCIES

 

SHAREHOLDERS’ EQUITY:
 
 
 
Common stock, authorized 20,000,000 shares, $.01 par value, 6,691,000 and 6,592,000 shares issued, and 6,459,000 and 6,361,000 shares outstanding, respectively
67

 
66

Treasury stock at cost, 232,000 shares of common stock
(2,500
)
 
(2,500
)
Paid-in capital
22,270

 
21,935

Accumulated deficit
(7,306
)
 
(8,276
)
Accumulated other comprehensive income
362

 
195

Total shareholders’ equity
12,893


11,420

 
$
173,080

 
$
163,051

The accompanying notes are an integral part of these interim consolidated financial statements.

3


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Three Months Ended June 30,
 
2017
 
2016
PATIENT REVENUES, net
$
142,550

 
$
95,805

EXPENSES:
 
 
 
Operating
113,166

 
78,385

Lease and rent expense
13,763

 
6,854

Professional liability
2,724

 
1,934

General and administrative
8,221

 
6,881

Depreciation and amortization
2,620

 
2,060

Lease termination costs
—

 
2,008

Total expenses
140,494

 
98,122

OPERATING INCOME (LOSS)
2,056

 
(2,317
)
OTHER INCOME (EXPENSE):
 
 
 
Equity in net income of unconsolidated affiliate
—

 
28

Interest expense, net
(1,541
)
 
(1,158
)
Total other expense
(1,541
)
 
(1,130
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
515

 
(3,447
)
BENEFIT (PROVISION) FOR INCOME TAXES
(134
)
 
1,297

INCOME (LOSS) FROM CONTINUING OPERATIONS
381

 
(2,150
)
LOSS FROM DISCONTINUED OPERATIONS:
 
 
 
Operating loss, net of tax expense of ($18) and $0, respectively
(28
)
 
—

NET INCOME (LOSS)
$
353

 
$
(2,150
)
NET INCOME (LOSS) PER COMMON SHARE:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
0.06

 
$
(0.35
)
Discontinued operations
—

 
—

 
$
0.06

 
$
(0.35
)
Per common share – diluted
 
 
 
Continuing operations
$
0.06

 
$
(0.35
)
Discontinued operations
—

 
—

 
$
0.06

 
$
(0.35
)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.055

 
$
0.055

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,294

 
6,211

Diluted
6,472

 
6,211

                              
The accompanying notes are an integral part of these interim consolidated financial statements.

4


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 
Three Months Ended June 30,
 
2017
 
2016
NET INCOME (LOSS)
$
353

 
$
(2,150
)
OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
146

 
181

Less: reclassification adjustment for amounts recognized in net income
(116
)
 
(119
)
Total other comprehensive income
30

 
62

COMPREHENSIVE INCOME (LOSS)
$
383

 
$
(2,088
)

The accompanying notes are an integral part of these interim consolidated financial statements.

5


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Six Months Ended June 30,
 
2017
 
2016
PATIENT REVENUES, net
$
284,050

 
$
193,750

EXPENSES:
 
 
 
Operating
223,833

 
157,003

Lease and rent expense
27,506

 
14,106

Professional liability
5,394

 
4,000

General and administrative
17,194

 
13,615

Depreciation and amortization
5,107

 
4,063

Lease termination costs
—

 
2,008

Total expenses
279,034

 
194,795

OPERATING INCOME (LOSS)
5,016

 
(1,045
)
OTHER INCOME (EXPENSE):
 
 
 
Equity in net income of unconsolidated affiliate
—

 
61

Gain on sale of investment in unconsolidated affiliate
733

 
—

Interest expense, net
(3,024
)
 
(2,228
)
Debt retirement costs
—

 
(351
)
Total other expense
(2,291
)
 
(2,518
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
2,725

 
(3,563
)
BENEFIT (PROVISION) FOR INCOME TAXES
(996
)
 
1,339

INCOME (LOSS) FROM CONTINUING OPERATIONS
1,729

 
(2,224
)
LOSS FROM DISCONTINUED OPERATIONS:
 
 
 
Operating loss, net of tax benefit (expense) of ($27) and $21, respectively
(43
)
 
(37
)
NET INCOME (LOSS)
$
1,686

 
$
(2,261
)
NET INCOME (LOSS) PER COMMON SHARE:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
0.28

 
$
(0.36
)
Discontinued operations
(0.01
)
 
(0.01
)
 
$
0.27

 
$
(0.37
)
Per common share – diluted
 
 
 
Continuing operations
$
0.27

 
$
(0.36
)
Discontinued operations
(0.01
)
 
(0.01
)
 
$
0.26

 
$
(0.37
)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.11

 
$
0.11

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,263

 
6,185

Diluted
6,458

 
6,185


The accompanying notes are an integral part of these interim consolidated financial statements.

6


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 
Six Months Ended June 30,
 
2017
 
2016
NET INCOME (LOSS)
$
1,686

 
$
(2,261
)
OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
400

 
492

Less: reclassification adjustment for amounts recognized in net income
(233
)
 
(263
)
Total other comprehensive income
167

 
229

COMPREHENSIVE INCOME (LOSS)
$
1,853

 
$
(2,032
)

The accompanying notes are an integral part of these interim consolidated financial statements.


7


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
 
 
Six Months Ended June 30,
 
2017
 
2016
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income (loss)
$
1,686

 
$
(2,261
)
Discontinued operations
(43
)
 
(37
)
Income (loss) from continuing operations
1,729

 
(2,224
)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
 
 
 
Depreciation and amortization
5,107

 
4,063

Provision for doubtful accounts
4,187

 
3,661

Deferred income tax provision (benefit)
403

 
(1,689
)
Provision for self-insured professional liability, net of cash payments
(309
)
 
1,595

Stock-based compensation
504

 
486

Equity in net income of unconsolidated affiliate, net of investment
—

 
(61
)
Gain on sale of unconsolidated affiliate
(733
)
 
—

Debt retirement costs
—

 
351

Provision for leases in excess of cash payments
(304
)
 
(1,093
)
Lease termination costs, net of cash payments
—

 
1,958

Deferred bonus
600

 
—

Other
247

 
358

Changes in assets and liabilities affecting operating activities:
 
 
 
Receivables, net
(7,313
)
 
(710
)
Prepaid expenses and other assets
620

 
(384
)
Trade accounts payable and accrued expenses
(2,647
)
 
1,688

Net cash provided by continuing operations
2,091

 
7,999

Discontinued operations
(329
)
 
(2,879
)
Net cash provided by operating activities
1,762

 
5,120

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(5,121
)
 
(10,055
)
Deposit in escrow
(8,673
)
 
—

Proceeds from sale of unconsolidated affiliate
1,100

 
—

Change in restricted cash
—

 
1,658

Net cash used in continuing operations
(12,694
)
 
(8,397
)
Discontinued operations
—

 
—

Net cash used in investing activities
(12,694
)
 
(8,397
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repayment of debt obligations
(14,166
)
 
(66,422
)
Proceeds from issuance of debt
26,074

 
71,066

Financing costs
(226
)
 
(1,795
)
Issuance and redemption of employee equity awards
(94
)
 
(96
)
Payment of common stock dividends
(692
)
 
(683
)
Payment for preferred stock restructuring
(327
)
 
(317
)
Net cash provided by financing activities
10,569

 
1,753

Discontinued operations
—

 
—

Net cash provided by financing activities
$
10,569

 
$
1,753

The accompanying notes are an integral part of these interim consolidated financial statements.

8


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
(continued)
 
 
Six Months Ended June 30,
 
2017
 
2016
NET DECREASE IN CASH AND CASH EQUIVALENTS
$
(363
)
 
$
(1,524
)
CASH AND CASH EQUIVALENTS, beginning of period
4,263

 
4,585

CASH AND CASH EQUIVALENTS, end of period
$
3,900

 
$
3,061

SUPPLEMENTAL INFORMATION:
 
 
 
Cash payments of interest
$
2,563

 
$
1,904

Cash payments of income taxes
$
625

 
$
332

SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:

 
 
 
Acquisition of equipment through capital lease
$
7

 
$
—

The accompanying notes are an integral part of these interim consolidated financial statements.

9


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2017 AND 2016

1.
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of June 30, 2017, the Company’s continuing operations consist of 76 nursing centers with 8,453 licensed nursing beds. The Company owns 17 and leases 59 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted and residential living beds.

2.
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the profits and losses from this investment are reported as equity in earnings of investment in an unconsolidated affiliate and the proceeds received from the sale are reported under the heading "Gain on sale of investment in unconsolidated affiliate" in the accompanying interim consolidated statements of operations. The sale resulted in a $1,366,000 gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of $733,000 for the six-month period ended June 30, 2017, related to the liquidation of remaining assets affiliated with the partnership.
The interim consolidated financial statements for the six month periods ended June 30, 2017 and 2016, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at June 30, 2017, and the results of operations for the three and six month periods ended June 30, 2017 and 2016, and cash flows for the six month periods ended June 30, 2017 and 2016. The Company’s balance sheet information at December 31, 2016, was derived from its audited consolidated financial statements as of December 31, 2016.
The results of operations for the periods ended June 30, 2017 and 2016 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

3.
RECENT ACCOUNTING GUIDANCE
In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. The ASU will be effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016. The Company will adopt the requirements of this standard effective January 1, 2018. The new standard may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). The Company plans to elect to apply the modified retrospective approach upon adoption. Additionally, the new guidance requires enhanced disclosures, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The Company is developing a plan for adoption and determining the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operation and cash flows. The Company is in the process of reviewing revenue sources and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectibility, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. We expect to complete this process in 2017. The Company is also in the process of assessing the impact of the new standard on various reimbursement programs that represent variable

10


consideration, including settlements with government payors, state Medicaid programs and bundled payment of care programs. Due to the many forms of calculation and reimbursement that these programs take that vary from state to state, the application of the new standard could have an impact on the revenue recognized for variable consideration. Industry guidance is continuing to develop, and any conclusions in the final industry guidance that is inconsistent with the Company's application could result in changes to the Company's expectations regarding the impact of the new standard on the Company's financial statements. Additionally, the adoption of the new standard will impact the presentation on the Company's statement of operations. After the adoption, the majority of what is currently classified as bad debt expense will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenues. The ASU will have a material impact on the amounts presented in certain categories on our consolidated statement of operations, but we do not expect it to have a material impact on our financial position, results of operations or cash flows.
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which changes how deferred taxes are classified on the Company's balance sheets. The Company adopted ASU No. 2015-17 as of January 1, 2017, and the new standard was applied on a retrospective basis. The adoption of this guidance resulted in a $7,644,000 reclassification between current deferred income taxes and non-current deferred income taxes.
In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for building and equipment operating leases and will result in a significant increase in the assets and liabilities on the consolidated balance sheet.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for shared-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which will require the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this standard will have on our consolidated financial statements.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017. The Company plans to adopt this standard on January 1, 2018, and is currently evaluating the impact this standard will have on our consolidated financial statements.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017, with early adoption permitted in certain circumstances.  The Company is still evaluating the effect, if any, the standard will have on the

11


Company’s consolidated financial condition and results of operations.  The Company does not expect the adoption of this standard to have a material impact on its consolidated financial condition and results of operations.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. Early adoption is permitted. The Company does not presently believe adoption of this new standard will be material to its consolidated financial statements.
 
4.
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increases the Company's borrowing capacity to $100,000,000 allocated between a $72,500,000 Mortgage Loan ("Amended Mortgage Loan") and a $27,500,000 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000,000 term loan facility and a $12,500,000 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162,000 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500,000 with a five-year maturity through February 26, 2021, and a $27,500,000 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000,000. The Amended Mortgage Loan balance was $67,970,000 as of June 30, 2017, consisting of $65,470,000 on the term loan facility with an interest rate of 5.25% and $2,500,000 on the acquisition loan facility with an interest rate of 6.0%. The Amended Mortgage Loan is secured by seventeen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500,000 in the Amended Revolver to $52,250,000; provided that the maximum revolving facility be reduced to $42,250,000 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250,000.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modifies the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10,000,000 to $15,000,000.
Effective June 30, 2017, the Company entered into a Second Amendment to the Second Amended (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amends the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500,000.
As of June 30, 2017, the Company had $24,500,000 borrowings outstanding under the Amended Revolver compared to $15,000,000 outstanding as of December 31, 2016. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,408,000 outstanding as of June 30, 2017. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $40,751,000, the balance available for borrowing under the Amended Revolver was $842,000 at June 30, 2017.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at June 30, 2017.
Interest Rate Swap Transaction
As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the

12


February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $28,985,000 as of June 30, 2017. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at June 30, 2017, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net liability of $62,000 at June 30, 2017. The fair value of the interest rate swap is included in “other noncurrent liabilities” on the Company’s interim consolidated balance sheet. The liability related to the change in the interest rate swap included in accumulated other comprehensive income at June 30, 2017 is $38,000, net of the income tax benefit of $24,000. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.

5.
COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, and Texas. The SHC policy provides coverage limits of either $500,000 or $1,000,000 per medical incident with a sublimit per center of $1,000,000 and total annual aggregate policy limits of $5,000,000. The remaining nursing centers are covered by one of seven claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of $1,000,000 per claim and have sublimits of $3,000,000 per center, with varying self-insured retention levels per claim and varying aggregate policy limits. 
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $19,384,000 as of June 30, 2017. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of June 30, 2017, the Company is engaged in 74 professional liability lawsuits. Seventeen lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $4,338,000 and $1,542,000 for the six months ended June 30, 2017 and 2016, respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Civil Investigative Demand ("CID")
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee (DOJ) had commenced a civil investigation of potential violations of the False Claims Act (FCA).
In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against two of its centers. In response to civil investigative demands (“CIDs”) and informal requests, the Company has provided to the DOJ documents and information relating to the Company’s practices and policies for rehabilitation and other services, relating to the preadmission evaluation forms ("PAEs") required by TennCare, and relating to the Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. The DOJ has also issued CID’s for testimony from current and former employees of the Company. The DOJ’s civil investigation has been focused on six of our centers, but the DOJ has indicated that all of the Company’s centers are the subject of the investigation related to rehabilitation therapy.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs. The Company has responded to this subpoena and provided additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers’ compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely self-insured for workers' compensation exposure. From July 1, 2008 through June 30, 2017, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500,000 per claim, subject to an aggregate maximum of $3,000,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $957,000 at June 30, 2017. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,628,000 as of June 30, 2017. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of June 30, 2017, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $175,000 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,272,000 at June 30, 2017. The differences between actual settlements and reserves are included in expense in the period finalized.

6.
STOCK-BASED COMPENSATION

Overview of Plans
In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (“2005 Plan”). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, 700,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. This plan has expired and no new grants may be made under the 2005 Plan. All grants under this plan expire 10 years from the date the grants were authorized by the Board of Directors.
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers . The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150,000 shares to 350,000 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-

13


Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from 380,000 shares to 680,000 shares. No grants can be made under the Long-Term Incentive Plan after May 31, 2027.
Equity Grants and Valuations
During the six months ended June 30, 2017 and 2016, the Compensation Committee of the Board of Directors approved grants totaling approximately 88,000 and 83,000 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.
Prior to 2016, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2016
231,000

 
$
6.97

Granted
—

 
—

Exercised
—

 
—

Expired or cancelled
(17,000
)
 
11.29

Outstanding, June 30, 2017
214,000

 
$
6.64

 
 
 
 
Exercisable, June 30, 2017
209,000

 
$
6.55


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2016
153,000

 
$
9.47

Granted
88,000

 
9.98

Dividend Equivalents
2,000

 
9.85

Vested
(74,000
)
 
9.03

Cancelled
—

 
—

Outstanding, June 30, 2017
169,000

 
$
9.93


14


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2016
54,000

 
$
11.10

Granted
26,000

 
9.98

Dividend Equivalents
1,000

 
9.85

Vested
(37,000
)
 
12.11

Cancelled
—

 
—

Outstanding, June 30, 2017
44,000

 
$
9.58


The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

While no SOSARs or Options were granted during 2017 and 2016, previously granted SOSARs and Options remain outstanding as of June 30, 2017. The following table summarizes information regarding stock options and SOSAR grants outstanding as of June 30, 2017:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.21 to $10.88
 
$
10.63

 
46,000

 
$
—

 
41,000

 
$
—

$2.37 to $6.21
 
$
5.55

 
168,000

 
$
630,000

 
168,000

 
$
630,000

 
 
 
 
214,000

 
 
 
209,000

 
 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $504,000 and $486,000 in the six month periods ended June 30, 2017 and 2016, respectively.

7.
EARNINGS (LOSS) PER COMMON SHARE
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Net income (loss)
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
381

 
$
(2,150
)
 
1,729

 
(2,224
)
Loss from discontinued operations, net of income taxes
(28
)
 
—

 
(43
)
 
(37
)
Net income (loss)
$
353

 
$
(2,150
)
 
$
1,686

 
$
(2,261
)
 

15


 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.06

 
$
(0.35
)
 
$
0.28

 
$
(0.36
)
Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – basic
$
0.06

 
$
(0.35
)
 
$
0.27

 
$
(0.37
)
Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.06

 
$
(0.35
)
 
$
0.27

 
$
(0.36
)
Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – diluted
$
0.06

 
$
(0.35
)
 
$
0.26

 
$
(0.37
)
Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,294

 
6,211

 
6,263

 
6,185

Diluted
6,472

 
6,211

 
6,458

 
6,185

The effects of 46,000 and 62,000 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the six months ended June 30, 2017 and 2016, respectively, because these securities would have been anti-dilutive.

8. EQUITY METHOD INVESTMENT
The Company had one equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the net profits and losses of the unconsolidated affiliate are reported as equity in net earnings or losses of unconsolidated affiliate in our statement of operations. For the six-month period ended June 30, 2017, the equity in the net income of an unconsolidated affiliate was zero compared to $61,000 for the six-month period ended June 30, 2016. The proceeds received from the sale are considered in the calculation of the gain on sale of investment in unconsolidated affiliate in our statement of operations. For the six-month period ended June 30, 2017, the gain on the sale of investment in unconsolidated affiliate was $733,000, related to the liquidation of remaining assets affiliated with the partnership.

9.
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
2017 Acquisition
On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750,000. In connection with the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by $7,500,000, which is described in Note 4 to the interim consolidated financial statements herein. The acquisition transaction closed subsequent to June 30, 2017, on July 1, 2017. Therefore, at June 30, 2017, the Company maintained the funds in escrow to finance the acquisition, which are presented in the Company's interim consolidated balance sheet. Refer to to Note 10 to the interim consolidated financial statements for further discussion on this acquisition.
Golden Living Transaction
On August 15, 2016, the Company entered into an Operation Transfer Agreement with Golden Living (the "Lessor") to assume the operations of 22 centers in Alabama and Mississippi.
On October 1, 2016, the Company entered into a Master Lease Agreement (the "Lease") with Golden Living to directly lease eight centers located in Mississippi from the Lessor, which include: (i) a 152-bed skilled nursing center known as Golden Living Center - Amory; (ii) a 130-bed skilled nursing center known as Golden Living Center - Batesville; (iii) a 58-bed skilled nursing center known as Golden Living Center - Brook Manor; (iv) a 119-bed skilled nursing center known as Golden Living Center - Eupora; (v) a 140-bed skilled nursing center known as Golden Living Center - Ripley; (vi) a 140-bed skilled nursing center known as Golden Living Center - Southaven; (vii) a 120-bed skilled nursing center known as Golden Living Center - Eason Blvd; (viii) a 60-bed skilled nursing center known as Golden Living Center - Tylertown. The Lease is triple net and has an initial term of ten years with two separate five year options to extend the term. The Company also assumed the individual leases of a 120-bed center known as Broadmoor Nursing Home, with an initial lease term of ten years with first year rent of $540,000, escalating

16


to $780,000 in the second year, and 2% annually thereafter, and a 99-bed skilled nursing center known as Leake County Nursing Home, with a lease term of two years with annual rent of $300,000.
On November, 1 2016, the Company amended and restated the Lease ("Amended Lease") with the Lessor to directly lease an additional twelve centers located in Alabama from the Lessor, which include: (i) a 87-bed skilled nursing center known as Golden Living Center - Arab; (ii) a 180-bed skilled nursing center known as Golden Living Center - Meadowood; (iii) a 132-bed skilled nursing center known as Golden Living Center - Riverchase; (iv) a 100-bed skilled nursing center known as Golden Living Center - Boaz; (v) a 154-bed skilled nursing center known as Golden Living Center - Foley; (vi) a 50-bed skilled nursing center known as Golden Living Center - Hueytown; (vii) a 85-bed skilled nursing center known as Golden Living Center - Lanett; (viii) a 138-bed skilled nursing center known as Golden Living Center - Montgomery; (ix) a 120-bed skilled nursing center known as Golden Living Center - Oneonta; (x) a 173-bed skilled nursing center known as Golden Living Center - Oxford; (xi) a 94-bed skilled nursing center known as Golden Living Center - Pell City; (xii) a 123-bed skilled nursing center known as Golden Living Center - Winfield. The Amended Lease is triple net and has an initial term of ten years with two separate five years options to extend the term. Base rent for the amended lease is $24,675,000 for the first year and escalates 2% annually thereafter.
2016 Acquisitions
On February 26, 2016, the Company exercised its purchase options to acquire the real estate assets for Diversicare of Hutchinson in Hutchinson, Kansas and Clinton Place in Clinton, Kentucky for $4,250,000 and $3,300,000, respectively. The Company has operated these facilities since February 2015 and April 2012, respectively. Hutchinson is an 85-bed skilled nursing facility, and Clinton is an 88-bed skilled nursing facility. As a result of the consummation of the Agreements, the Company allocated the purchase price and acquisition costs between the assets acquired. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the assets acquired is as follows:
 
 
Hutchinson
Clinton Place
Purchase Price
$
4,250,000

$
3,300,000

Acquisition Costs
43,000

34,000

 
$
4,293,000

$
3,334,000

 
 
 
Allocation:
 
 
Buildings
3,443,000

2,898,000

Land
365,000

267,000

Furniture, Fixtures and Equipment
485,000

169,000

 
$
4,293,000

$
3,334,000


2016 Lease Termination
On May 31, 2016, the Company entered into an Agreement with Avon Ohio, LLC to amend the original lease agreement, thus terminating the Company's right of possession of the facility. As a result, the Company incurred lease termination costs of $2,008,000 in the second quarter of 2016. Under the amended agreement, the Company is required to pay $300,000 per year through the term of the original lease agreement, July 31, 2024. For accounting purposes, this transaction was not reported as a discontinued operation, which is in accordance with the modified authoritative guidance for reporting discontinued operations, effective January 1, 2015. A disposal is now required to be reported in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results.
2016 Sale of Investment in Unconsolidated Affiliate
On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366,000 gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of $733,000 for the six-month period ended June 30, 2017, related to the final liquidation of remaining net assets affiliated with the partnership.

10.
SUBSEQUENT EVENTS
On July 1, 2017 the Company acquired a 103-bed skilled nursing center in Selma, Alabama, including certain land, improvements, furniture, fixtures and equipment, personal property and intangible property from Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC for an aggregate purchase price of $8,750,000. This facility is expected to contribute in excess of $8,000,000 in annual revenues.


17


ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of June 30, 2017, the Company’s continuing operations consist of 76 nursing centers with 8,453 licensed nursing beds. The Company owns 17 and leases 59 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted living and residential beds.
Strategic Operating Initiatives
We identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives include: improving skilled mix in our nursing centers, improving our average Medicare rate, implementing and maintaining Electronic Medical Records (“EMR”) to improve Medicaid capture, and completing strategic acquisitions. We have experienced success in these initiatives and expect to continue to build on these improvements.
Improving skilled mix and average Medicare rate:
Our strategic operating initiatives of improving our skilled mix and our average Medicare rate required investing in nursing and clinical care to treat more acute patients along with nursing center-based marketing representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract payor sources for patients covered by Medicare and Managed Care. The Company's skilled mix for the three months ended June 30, 2017 and 2016 was 15.6% and 15.2%, respectively. The graph below illustrates our success with increasing our average Medicare rate per day:
medicarerateperdaygrapha05.jpg

18


Implementing Electronic Medical Records to improve Medicaid capture:
As another part of our strategic operating initiatives, we implemented EMR to improve Medicaid acuity capture, primarily in our states where the Medicaid payments are acuity based. We completed the implementation of EMR in all our nursing centers in December 2011, on time and under budget, and since implementation, have increased our average Medicaid rate despite rate cuts in certain acuity based states by accurate and timely capture of care delivery. The graph below illustrates our success with increasing our average Medicaid rate per day since implementation:
medicaidrateperdaygrapha06.jpg
Completing strategic acquisitions and dispositions:
Our strategic operating initiatives include a renewed focus on completing strategic acquisitions and dispositions. We continue to pursue and investigate opportunities to acquire, lease or develop new centers, focusing primarily on opportunities within our existing geographic areas of operation.
On July 1, 2017, we acquired a 103-bed skilled nursing center in Selma, Alabama, including certain land, improvements, furniture, fixtures and equipment, personal property and intangible property for an aggregate purchase price of approximately $8.8 million. The completion of this acquisition brings the Company's operations to 77 nursing centers, real estate of 18 owned, with 8,556 skilled nursings beds. This center is expected to contribute in excess of $8.0 million in annual revenues. Refer to Note 10 to the interim consolidated financial statements for further discussion on this acquisition.
On October 1, 2016 and November 1, 2016, we assumed the operations of ten centers in Mississippi and 12 centers in Alabama, respectively, which is further discussed in Note 9 to the interim consolidated financial statements. These acquired facilities are expected to contribute in excess of $185 million in annual revenues.
As part of our strategic efforts, we have also performed thorough analysis on our existing centers in order to determine whether continuing operations within certain markets or regions was in line with the short-term and long-term strategy of the business. As a result, in May 2016, we ceased operations at our Avon, Ohio, facility, thus terminating our lease with Avon Ohio, LLC. This transaction was not reported as a discontinued operation as described in Note 9 to the interim consolidated financial statements.
Basis of Financial Statements
Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our operating expenses include the costs, other than lease, professional liability, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.

Critical Accounting Policies and Judgments
A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments often involving estimates of the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income or loss to vary significantly from period to period. Our critical accounting policies are more fully described in our 2016 Annual Report on Form 10-K.

19


Revenue Sources
We classify our revenues from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and other. Medicaid revenues are composed of the traditional Medicaid program established to provide benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B of the Medicare program. Managed Care revenues include payments for patients who are insured by a third-party entity, typically called a Health Maintenance Organization, often referred to as an HMO plan, or are Medicare beneficiaries who assign their Medicare benefits to a Managed Care replacement plan often referred to as Medicare replacement products. The Private Pay and other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and other payors are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.
The following table sets forth net patient and resident revenues related to our continuing operations by payor source for the periods presented (dollar amounts in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Medicaid
$
73,510

 
51.6
%
 
$
48,339

 
50.5
%
 
$
146,383

 
51.5
%
 
$
95,545

 
49.3
%
Medicare
38,900

 
27.3

 
26,397

 
27.6

 
76,911

 
27.1

 
54,418

 
28.1

Managed Care
9,959

 
7.0

 
6,531

 
6.8

 
20,764

 
7.3

 
13,933

 
7.2

Private Pay and other
20,181

 
14.1

 
14,538

 
15.1

 
39,992

 
14.1

 
29,854

 
15.4

Total
$
142,550

 
100.0
%
 
$
95,805

 
100.0
%
 
$
284,050

 
100.0
%
 
$
193,750

 
100.0
%

The following table sets forth average daily skilled nursing census by payor source for our continuing operations for the periods presented: 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
2016
 
2017
 
2016
Medicaid
4,630

 
68.6
%
 
3,138

 
68.3
%
 
4,640

 
68.6
%
 
3,113

 
67.4
%
Medicare
810

 
12.0

 
538

 
11.7

 
801

 
11.8

 
556

 
12.0

Managed Care
243

 
3.6

 
161

 
3.5

 
258

 
3.8

 
170

 
3.7

Private Pay and other
1,065

 
15.8

 
758

 
16.5

 
1,061

 
15.8

 
781

 
16.9

Total
6,748

 
100.0
%
 
4,595

 
100.0
%
 
6,760

 
100.0
%
 
4,620

 
100.0
%
Consistent with the nursing home industry in general, changes in the mix of a facility’s patient population among Medicaid, Medicare, Managed Care, and Private Pay and other can significantly affect the profitability of the facility’s operations.

Health Care Industry
The health care industry is subject to numerous federal, state, and local laws and regulations, which are frequently subject to change. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of patient care and Medicare and Medicaid fraud and abuse. Compliance with such laws and regulations is subject to ongoing government review and interpretation, as well as regulatory actions in which government agencies seek to impose fines and penalties. The Company is involved in regulatory actions of this type from time to time.
The U.S. Congress and certain state legislatures have introduced and passed significant proposals and legislation concerning health care and health insurance. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), impacts our Company, our employees and our patients in a variety of ways, some of which may result in increased operating expenses and involve changes or reductions to our Medicaid and Medicare reimbursement. For example, the Affordable Care Act, as currently structured, expands the role of home-based and community services, which may place downward pressure on our sustaining population of Medicaid patients. However, there is substantial uncertainty regarding the ongoing net effect of the Affordable Care Act. The 2016 federal elections resulted in a presidential administration that, along with certain members of Congress, have stated their intent to repeal or make significant changes to the Affordable Care Act, its implementation and/or its interpretation. We are unable to predict whether, when, and how the Affordable Care Act will be changed, what alternative provisions, if any, will be enacted, the timing of enactment and implementation of alternative provisions, and the impact of alternative provisions on providers as well as other healthcare industry participants. In addition, a presidential executive order has been signed that directs agencies to minimize “economic and regulatory burdens” of the Affordable Care Act, but it is unclear how this will be implemented or how federal agencies will implement

20


provisions of the Affordable Care Act. Further, any changes to the Affordable Care Act could eliminate or alter provisions beneficial to us while leaving in place provisions reducing our reimbursement. Government efforts to repeal or change the Affordable Care Act may have an adverse effect on our business, results of operations, cash flow, capital resources and liquidity.


Contractual Obligations and Commercial Commitments
We have certain contractual obligations of continuing operations as of June 30, 2017, summarized by the period in which payment is due, as follows (dollar amounts in thousands):
Contractual Obligations
Total
 
Less than
1  year
 
1 to 3
Years
 
3 to 5
Years
 
After
5 Years
Long-term debt obligations (1)
$
107,022

 
$
14,251

 
$
34,095

 
$
58,676

 
$
—

Settlement obligations (2)
318

 
318

 
—

 
—

 
—

Elimination of Preferred Stock Conversion feature (3)
859

 
687

 
172

 
—

 
—

Operating leases (4)
1,103,785

 
57,523

 
118,066

 
122,122

 
806,074

Required capital expenditures under operating leases (5)
12,873

 
1,231

 
2,459

 
2,458

 
6,725

Total
$
1,224,857

 
$
74,010

 
$
154,792

 
$
183,256

 
$
812,799

 
(1)
Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our capital lease obligations. Our long-term debt obligations increased $11.8 million between December 31, 2016 and June 30, 2017, which is related to assumption of operation for the Golden Living centers and purchase of the center in Selma, Alabama. See Note 4, "Long-Term Debt and Interest Rate Swap," to the interim consolidated financial statements included in this report for additional information.
(2)
Settlement obligations relate to professional liability cases that are expected to be paid within the next twelve months. The professional liabilities are included in our current portion of self-insurance reserves.
(3)
Payments to Omega Health Investors ("Omega"), from which we lease 35 nursing centers, for the elimination of the preferred stock conversion feature in connection with restructuring the preferred stock and master lease agreements. Monthly payments of approximately $57,000 will be made through the end of the initial lease period that ends in September 2018.
(4)
Represents lease payments under our operating lease agreements. Assumes all renewal periods are enacted. Our operating lease obligations decreased $28.0 million between December 31, 2016 and June 30, 2017.
(5)
Includes annual expenditure requirements under operating leases. Our required capital expenditures decreased $0.4 million between December 31, 2016 and June 30, 2017.
We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined therein), or upon a change of control of the Company (as defined therein). The maximum contingent liability under these agreements is approximately $1.8 million as of June 30, 2017. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee. In addition, upon the occurrence of any triggering event, those certain members of management may elect to require that we purchase equity awards granted to them for a purchase price equal to the difference in the fair market value of our common stock at the date of termination versus the stated equity award exercise price. Based on the closing price of our common stock on June 30, 2017, the potential contingent liability for the repurchase of the equity grants is $0.4 million.


21


Results of Operations
The following tables present the unaudited interim statements of operations and related data for the three and six month periods ended June 30, 2017 and 2016:
 
(in thousands)
Three Months Ended June 30,
 
2017
 
2016
 
Change
 
%
PATIENT REVENUES, net
$
142,550

 
$
95,805

 
$
46,745

 
48.8
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
113,166

 
78,385

 
34,781

 
44.4
 %
Lease and rent expense
13,763

 
6,854

 
6,909

 
100.8
 %
Professional liability
2,724

 
1,934

 
790

 
40.8
 %
General and administrative
8,221

 
6,881

 
1,340

 
19.5
 %
Depreciation and amortization
2,620

 
2,060

 
560

 
27.2
 %
Lease termination costs
—

 
2,008

 
(2,008
)
 
100.0
 %
Total expenses
140,494

 
98,122

 
42,372

 
43.2
 %
OPERATING INCOME (LOSS)
2,056

 
(2,317
)
 
4,373

 
188.7
 %
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net income of unconsolidated affiliate
—

 
28

 
(28
)
 
(100.0
)%
Interest expense, net
(1,541
)
 
(1,158
)
 
(383
)
 
(33.1
)%
 
(1,541
)
 
(1,130
)
 
(411
)
 
(36.4
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
515

 
(3,447
)
 
3,962

 
114.9
 %
BENEFIT (PROVISION) FOR INCOME TAXES
(134
)
 
1,297

 
(1,431
)
 
(110.3
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS
$
381

 
$
(2,150
)
 
$
2,531

 
117.7
 %

(in thousands)
Six Months Ended June 30,
 
2017
 
2016
 
Change
 
%
PATIENT REVENUES, net
$
284,050

 
$
193,750

 
$
90,300

 
46.6
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
223,833

 
157,003

 
66,830

 
42.6
 %
Lease and rent expense
27,506

 
14,106

 
13,400

 
95.0
 %
Professional liability
5,394

 
4,000

 
1,394

 
34.9
 %
General and administrative
17,194

 
13,615

 
3,579

 
26.3
 %
Depreciation and amortization
5,107

 
4,063

 
1,044

 
25.7
 %
Lease termination costs
—

 
2,008

 
(2,008
)
 
100.0
 %
Total expenses
279,034

 
194,795

 
84,239

 
43.2
 %
OPERATING INCOME (LOSS)
5,016

 
(1,045
)
 
6,061

 
580.0
 %
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net income of unconsolidated affiliate
—

 
61

 
(61
)
 
(100.0
)%
Gain on sale of investment in unconsolidated affiliate
733

 
—

 
733

 
100.0
 %
Interest expense, net
(3,024
)
 
(2,228
)
 
(796
)
 
(35.7
)%
Debt retirement costs
—

 
(351
)
 
351

 
(100.0
)%
 
(2,291
)
 
(2,518
)
 
227

 
9.0
 %
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
2,725

 
(3,563
)
 
6,288

 
176.5
 %
BENEFIT (PROVISION) FOR INCOME TAXES
(996
)
 
1,339

 
(2,335
)
 
(174.4
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS
$
1,729

 
$
(2,224
)
 
$
3,953

 
177.7
 %

22


Percentage of Net Revenues
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
PATIENT REVENUES, net
100.0
%
 
100.0
 %
 
100.0
%
 
100.0
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
79.4

 
81.8

 
78.8

 
81.0

Lease and rent expense
9.7

 
7.2

 
9.7

 
7.3

Professional liability
1.9

 
2.0

 
1.9

 
2.1

General and administrative
5.8

 
7.2

 
6.1

 
7.0

Depreciation and amortization
1.8

 
2.2

 
1.8

 
2.1

Lease termination costs
—

 
2.1

 
—

 
1.0

Total expenses
98.6

 
102.5

 
98.3

 
100.5

OPERATING INCOME (LOSS)
1.4

 
(2.5
)
 
1.7

 
(0.5
)
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net losses of unconsolidated affiliate
—

 
—

 
—

 
—

Gain on sale of investment in unconsolidated affiliate
—

 
—

 
0.3

 
—

Interest expense, net
(1.1
)
 
(1.2
)
 
(1.1
)
 
(1.1
)
Debt retirement costs
—

 
—

 
—

 
(0.2
)
 
(1.1
)
 
(1.2
)
 
(0.8
)
 
(1.3
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
0.3

 
(3.7
)
 
0.9

 
(1.8
)
BENEFIT (PROVISION) FOR INCOME TAXES
(0.1
)
 
1.4

 
(0.4
)
 
0.7

INCOME (LOSS) FROM CONTINUING OPERATIONS
0.2
%
 
(2.3
)%
 
0.5
%
 
(1.1
)%

23


Three Months Ended June 30, 2017 Compared With Three Months Ended June 30, 2016
Patient Revenues
Patient revenues were $142.6 million and $95.8 million for the three months ended June 30, 2017 and 2016, respectively, an increase of $46.8 million. The following table summarizes the revenue fluctuations attributable to our portfolio growth (in thousands):
 
Three Months Ended June 30,
 
2017
 
2016
 
Change
Same-store revenue
$
96,570

 
$
95,805

 
$
765

2016 acquisition revenue
45,980

 
—

 
45,980

Total revenue
$
142,550

 
$
95,805

 
$
46,745

The overall increase in revenues of $46.8 million is primarily attributable to revenue contributions from the acquisition of the Golden Living operations in Alabama and Mississippi during the fourth quarter of 2016 of $46.0 million.
On a same-store center basis, the average Medicare and Medicaid rate per patient day for the second quarter of 2017 increased compared to the second quarter of 2016, resulting in increases in revenue of $0.5 million and $0.5 million, respectively, or 2.4% and 0.9%, respectively. Our same-store Medicare average daily census for the second quarter of 2017 increased $0.6 million, or 2.8%, and conversely our Medicaid average daily census for the second quarter of 2017 decreased $1.1 million, or 2.2%. Revenue related to ancillary services increased for the second quarter of 2017 compared to the second quarter of 2016 by $0.2 million.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Three Months Ended June 30,
 
 
 
2017
 
 
 
2016
 
 
Skilled nursing occupancy
79.8
%
 
 
 
76.7
%
 
 
As a percent of total census:
 
 
 
 
 
 
 
Medicare census
12.0
%
 
 
 
11.7
%
 
 
Medicaid census
68.6
%
 
 
 
68.3
%
 
 
Managed Care census
3.6
%
 
 
 
3.5
%
 
 
As a percent of total revenues:
 
 
 
 
 
 
 
Medicare revenues
27.3
%
 
 
 
27.6
%
 
 
Medicaid revenues
51.6
%
 
 
 
50.5
%
 
 
Managed Care revenues
7.0
%
 
 
 
6.8
%
 
 
Average rate per day:
 
 
 
 
 
 
 
Medicare
$
453.02

 
  
 
$
456.91

 
 
Medicaid
$
173.92

 
  
 
$
168.36

 
 
Managed Care
$
391.60

 
  
 
$
388.45

 
 

24


Operating Expense
Operating expense increased in the second quarter of 2017 to $113.2 million as compared to $78.4 million in the second quarter of 2016. Operating expense decreased as a percentage of revenue at 79.4% for the second quarter of 2017 as compared to 81.8% for the second quarter of 2016. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):
 
Three Months Ended June 30,
 
2017
 
2016
 
Change
Same-store operating expense
$
76,991

 
$
78,385

 
$
(1,394
)
2016 acquisition expense
36,175

 
—

 
36,175

Total expense
$
113,166

 
$
78,385

 
$
34,781

The overall increase in operating expense of $34.8 million is primarily attributable the acquisition of the Golden Living operations in Alabama and Mississippi during the fourth quarter of 2016 of $36.2 million.
On a same-store center basis, operating expenses decreased by $1.4 million, which is attributable to a favorable variance in bad debt expense and health insurance costs of $1.0 million and $0.2 million, respectively, in second quarter of 2017 compared to the second quarter of 2016.
One of the largest components of operating expenses is wages, which increased to $65.8 million during the second quarter of 2017 as compared to $45.1 million in the second quarter of 2016, which consistent with above is due to acquisition activity.
Lease Expense
Lease expense increased in the second quarter of 2017 to $13.8 million as compared to $6.9 million in the second quarter of 2016. The increase in lease expense was primarily attributable to the 22 newly leased centers in Alabama and Mississippi, which occurred during the fourth quarter of 2016.
Professional Liability
Professional liability expense was $2.7 million and $1.9 million in the second quarters of 2017 and 2016, respectively. Our cash expenditures for professional liability costs of continuing operations were $2.3 million and $0.9 million for the second quarters of 2017 and 2016, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

General and Administrative Expense
General and administrative expense was $8.2 million in the second quarter of 2017 as compared to $6.9 million in the second quarter of 2016, an increase of $1.3 million, but conversely decreased as a percentage of revenue from 7.2% in 2016 to 5.8% in 2017. The increase in general and administrative expense is attributable to an increase in corporate wages and payroll taxes and travel by $1.3 million and $0.1 million, respectively, which is due to the acquisition of 22 new centers during the fourth quarter of 2016.
Depreciation and Amortization
Depreciation and amortization expense was approximately $2.6 million in the second quarter of 2017 as compared to $2.1 million in 2016. The increase in depreciation expense relates to fixed assets at the newly leased centers.
Interest Expense, Net
Interest expense was $1.5 million in the second quarter of 2017 and $1.2 million in the second quarter of 2016, an increase of $0.3 million. The increase was primarily attributable to higher debt balances in 2017 as a result of the change in ownership processes for the newly leased Alabama and Mississippi centers.
Income (loss) from Continuing Operations before Income Taxes; Income (loss) from Continuing Operations per Common Share
As a result of the above, continuing operations reported income of $0.5 million before income taxes for the second quarter of 2017 as compared to a loss of $3.4 million for the second quarter of 2016. The provision for income taxes was $0.1 million for the second quarter of 2017, and the benefit for income taxes $1.3 million was for the second quarter of 2016. Both basic and diluted income per common share from continuing operations were $0.06 for the second quarter of 2017 as compared to both basic and diluted loss per common share from continuing operations of $0.35 in the second quarter of 2016.

25


Six Months Ended June 30, 2017 Compared With Six Months Ended June 30, 2016
Patient Revenues
Patient revenues were $284.1 million and $193.8 million for the six months ended June 30, 2017 and 2016, respectively, an increase of $90.3 million. The following table summarizes the revenue fluctuations attributable to our portfolio growth (in thousands):
 
Six Months Ended June 30,
 
2017
 
2016
 
Change
Same-store revenue
$
192,392

 
$
193,750

 
$
(1,358
)
2016 acquisition revenue
91,658

 
—

 
91,658

Total revenue
$
284,050

 
$
193,750

 
$
90,300

The overall increase in revenues of $90.3 million is primarily attributable to revenue contributions from the acquisition of the Golden Living operations in Alabama and Mississippi during the fourth quarter of 2016 of $91.7 million. The increase from the acquisition activity was partially offset by a decrease in same-store revenue of $1.4 million which is explained in more detail below.
For same-store centers, the six months ended June 30, 2017 experienced one less day of operations compared to the six months ended June 30, 2016, resulting in a decrease in revenue of $0.5 million or 0.3%.
On a same-store basis, our Medicare and Medicaid average daily census for the six months ended June 30, 2017 decreased compared to the six months ended June 30, 2016, resulting in decreases in revenue of $1.4 million and $1.5 million, respectively, or 3.1% and 1.5%, respectively. The average Medicare and Medicaid rate per patient day for same-store centers in 2017 increased $1.2 million and $0.9 million, respectively, or 2.6% and 1.0%, respectively.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Six Months Ended June 30,
 
 
 
2017
 
 
 
2016
 
 
Skilled nursing occupancy
80.0
%
 
 
 
76.7
%
 
 
As a percent of total census:
 
 
 
 
 
 
 
Medicare census
11.8
%
 
 
 
12.0
%
 
 
Medicaid census
68.6
%
 
 
 
67.4
%
 
 
Managed Care census
3.8
%
 
 
 
3.7
%
 
 
As a percent of total revenues:
 
 
 
 
 
 
 
Medicare revenues
27.1
%
 
 
 
28.1
%
 
 
Medicaid revenues
51.5
%
 
 
 
49.3
%
 
 
Managed Care revenues
7.3
%
 
 
 
7.2
%
 
 
Average rate per day:
 
 
 
 
 
 
 
Medicare
$
452.15

 
  
 
$
455.15

 
 
Medicaid
$
173.83

 
  
 
$
167.86

 
 
Managed Care
$
386.31

 
  
 
$
391.86

 
 

26


Operating Expense
Operating expense increased for the six months ended June 30, 2017 to $223.8 million as compared to $157.0 million for the six months ended June 30, 2016. Operating expense decreased as a percentage of revenue at 78.8% in 2017 as compared to 81.0% in 2016. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):
 
Six Months Ended June 30,
 
2017
 
2016
 
Change
Same-store operating expense
$
152,374

 
$
157,003

 
$
(4,629
)
2016 acquisition expense
71,459

 
—

 
71,459

Total expense
$
223,833

 
$
157,003

 
$
66,830

The overall increase in operating expense of $66.8 million is primarily attributable the acquisition of the Golden Living operations in Alabama and Mississippi during the fourth quarter of 2016 of $71.5 million.
On a same-store center basis, operating expenses decreased by $4.6 million, which is attributable to a provider tax refund of $2.2 million from the state of Kentucky. Additionally, our bad debt expense decreased by $1.6 million, which is partially offset by an increase in health insurance costs of $0.5 million in 2017.
One of the largest components of operating expenses is wages, which increased to $130.8 million during 2017 as compared to $90.2 million in, which is due to the centers acquired in 2016.
Lease Expense
Lease expense increased for the six months ended June 30, 2017 to $27.5 million as compared to $14.1 million for the six months ended June 30, 2016. The increase in lease expense was primarily attributable to the 22 newly leased centers in Alabama and Mississippi, which occurred during the fourth quarter of 2016.
Professional Liability
Professional liability expense was $5.4 million and $4.0 million for the six months ended June 30, 2017 and 2016, respectively. Our cash expenditures for professional liability costs of continuing operations were $4.3 million and $1.5 million for the six months ended June 30, 2017 and 2016, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

General and Administrative Expense
General and administrative expense was $17.2 million for the six months ended June 30, 2017 as compared to $13.6 million for the six months ended June 30, 2016, an increase of $3.6 million, but conversely a decrease as a percentage of revenue from 7.0% in 2016 to 6.1% in 2017. The increase in general and administrative expense is primarily attributable to an increase in wages, travel and consulting fees by $3.0 million, $0.2 million and $0.2 million, respectively, which is due to the acquisition of 22 new centers during the fourth quarter of 2016.
Depreciation and Amortization
Depreciation and amortization expense was approximately $5.1 million in 2017 as compared to $4.1 million in 2016. The increase in depreciation expense relates to fixed assets at the newly leased centers.
Gain on sale of investment in unconsolidated affiliate
Gain on the sale of investment in unconsolidated affiliate was $0.7 million for the six months ended June 30, 2017. The Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture in the fourth quarter of 2016. A gain of $1.4 million was recognized for the period ended December 31, 2016. The additional gain recognized in the first quarter of 2017 is related to the final liquidation of remaining net assets affiliated with the partnership.
Interest Expense, Net
Interest expense was $3.0 million for the six months ended June 30, 2017 and $2.2 million for the six months ended June 30, 2016, an increase of $0.8 million. The increase was primarily attributable to higher debt balances in 2017 as a result of the change in ownership processes for the newly leased Alabama and Mississippi centers.

27


Income (loss) from Continuing Operations before Income Taxes; Income (loss) from Continuing Operations per Common Share
As a result of the above, continuing operations reported income of $2.7 million before income taxes for the six months ended June 30, 2017 as compared to a loss of $3.6 million for the six months ended June 30, 2016. The provision for income taxes was $1.0 million for the six months ended June 30, 2017, and the benefit for income taxes was $1.3 million for the six months ended June 30, 2016. The basic and diluted income per common share from continuing operations was $0.28 and $0.27, respectively, for the six months ended June 30, 2017 as compared to both basic and diluted loss per common share from continuing operations of $0.36 for the six months ended June 30, 2016.
Liquidity and Capital Resources
Liquidity
Our primary source of liquidity is the net cash flow provided by the operating activities of our centers. We believe that these internally generated cash flows will be adequate to service existing debt obligations, fund required capital expenditures as well as provide cash flows for investing opportunities. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long-term. Options for our cash include, but are not limited to, capital improvements, dividends, purchase of additional shares of our common stock, acquisitions, payment of existing debt obligations as well as initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.
Net cash provided by operating activities of continuing operations totaled $2.1 million for the six months ended June 30, 2017, compared to net cash provided by operating activities of continuing operations of $8.0 million in the same period of 2016. One primary driver of the decline in cash provided by operating activities from continuing operations is the acquisition activity that occurred during the fourth quarter of 2016. The Company is required to complete a Change in Ownership ("CHOW") process for each of the nursing centers for which we assumed operations which results in limited cash inflows from the operations at these centers during this initial process.
Our cash expenditures related to professional liability claims of continuing operations were $4.3 million and $1.5 million for six months ended June 30, 2017 and 2016, respectively. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our being unable to meet all of our cash needs as they become due.
Investing activities of continuing operations used cash of $12.7 million and $8.4 million in 2017 and 2016, respectively. The fluctuation is primarily attributable to the asset purchases of Hutchinson and Clinton in February 2016.
Financing activities of continuing operations provided cash of $10.6 million in 2017 primarily due to draws on the Company's revolving credit facility. In 2016, financing activities of continuing operations provided cash of $1.8 million primarily due to the new debt associated with the Company's refinance in February 2016.

Dividends
On July 27, 2017, the Board of Directors declared a quarterly dividend of $0.055 per common share payable to shareholders of record as of September 30, 2017, to be paid on October 16, 2017. While the Board of Directors intends to pay quarterly dividends, the Board will make the determination of the amount of future cash dividends, if any, to be declared and paid based on, among other things, the Company’s financial condition, funds from operations, the level of its capital expenditures and its future business prospects and opportunities.
Professional Liability
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. On a per claim basis, coverage for losses in excess of those covered by SHC is maintained through unaffiliated commercial reinsurance carriers. All of the Company's nursing centers in Florida and Tennessee are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy include coverage limits of $0.5 million or $1.0 million per medical incident with a sublimit per center of $1.0 million and total annual aggregate policy limits of $5.0 million. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide coverage limits of $1.0 million per claim and have sublimits of $3.0 million per center, with varying aggregate policy limits and deductibles. 

28


As of June 30, 2017, we have recorded total liabilities for reported and settled professional liability claims and estimates for incurred, but unreported claims of $19.4 million. Our calculation of this estimated liability is based on an assumption that the Company will not incur a severely adverse judgment with respect to any asserted claim; however, a significant judgment could be entered against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.
Capital Resources
As of June 30, 2017, we had $94.0 million of outstanding long-term debt and capital lease obligations. The $94.0 million total includes $1.5 million in capital lease obligations and $24.5 million currently outstanding on the revolving credit facility. The balance of the long-term debt is comprised of $68.0 million owed on our mortgage loan, which includes $65.5 million on the term loan facility and $2.5 million on the acquisition loan facility.
On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increases the Company's borrowing capacity to $100.0 million allocated between a $72.5 million Mortgage Loan ("Amended Mortgage Loan") and a $27.5 million Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60 million term loan facility and a $12.5 million acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2.2 million and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $72.5 million with a five-year maturity through February 26, 2021, and a $27.5 million Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30.0 million. As of June 30, 2017, the interest rate related to the Amended Mortgage Loan was 5.25%. The Amended Mortgage Loan is secured by seventeen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27.5 million in the Amended Revolver to $52.3 million; provided that the maximum revolving facility be reduced to $42.3 million on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52.3 million.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modifies the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10.0 million to $15.0 million.
Effective June 30, 2017, the Company entered into a Second Amendment to the Second Amended (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amends the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7.5 million.
As of June 30, 2017, the Company had $24.5 million borrowings outstanding under the Amended Revolver compared to $15.0 million outstanding as of December 31, 2016. The outstanding borrowings on the revolver primarily compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under the Amended Revolver are 3.00% of the amount outstanding. The Company has eleven letters of credit with a total value of $13.4 million outstanding as of June 30, 2017. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of 40.8 million, the balance available for borrowing under the Amended Revolver was $0.8 million at June 30, 2017.
Our lending agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. We are in compliance with all such covenants at June 30, 2017.

29


Our calculated compliance with financial covenants is presented below:
 
 
Requirement
  
Level at
June 30, 2017
Minimum fixed charge coverage ratio
1.05:1.00
 
1.10:1.00
Minimum adjusted EBITDA
$11.5 million
 
$16.7 million
EBITDAR (mortgaged centers)
$10.0 million
 
$15.1 million
Current ratio (as defined in agreement)
1.00:1.00
 
1.37:1.00
As part of the debt agreements entered into in February 2016, we amended our interest rate swap agreement with a member of the bank syndicate as the counterparty. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and carries an initial notional amount of $30.0 million. The interest rate swap agreement requires us to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to us based on LIBOR on the same notional amounts. We entered into the interest rate swap agreement to mitigate the variable interest rate risk on our outstanding mortgage borrowings.
Receivables
Our operations could be adversely affected if we experience significant delays in reimbursement from Medicare, Medicaid or other third-party revenue sources. Our future liquidity will continue to be dependent upon the relative amounts of current assets (principally cash, accounts receivable and inventories) and current liabilities (principally accounts payable and accrued expenses). In that regard, accounts receivable can have a significant impact on our liquidity. Continued efforts by governmental and third-party payors to contain or reduce the acceleration of costs by monitoring reimbursement rates, by increasing medical review of bills for services, or by negotiating reduced contract rates, as well as any delay by us in the processing of our invoices, could adversely affect our liquidity and financial position.
Accounts receivable attributable to patient services of continuing operations totaled $76.7 million at June 30, 2017 compared to $72.5 million at December 31, 2016, representing approximately 46 days and 47 days revenue in accounts receivable, respectively. The decrease in accounts receivable is due to an increase in Medicaid collections from the centers undergoing the change in ownership process.
The allowance for bad debt was $12.1 million at June 30, 2017 as compared to $10.3 million at December 31, 2016. We continually evaluate the adequacy of our bad debt reserves based on patient mix trends, aging of older balances, payment terms and delays with regard to third-party payors, collateral and deposit resources, as well as other factors. We continue to evaluate and implement additional procedures to strengthen our collection efforts and reduce the incidence of uncollectible accounts.
Off-Balance Sheet Arrangements
We have eleven letters of credit outstanding with an aggregate value of approximately $13.4 million as of June 30, 2017. Eleven of these letters of credit serve as a security deposits for certain center leases, while one was issued in conjunction with the initial funding of our wholly-owned captive insurance company. These letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility.

Forward-Looking Statements
The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our interim consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "will," "should," "expect," "believe," "estimate," "intend," and similar words indicating possible future expectations, events or actions. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to, our ability to successfully integrate the operations of our new nursing centers in Alabama, Mississippi, Kansas and Kentucky, as well as successfully operate all of our centers, our ability to increase census at our centers, changes in governmental reimbursement, government regulation, the impact of the recently adopted federal health care reform or any future health care reform, any increases in the cost of borrowing under our credit agreements, our ability to extend or replace our current credit facility, our ability to comply with covenants contained in those credit agreements, our ability to renew or extend our leases at or prior to the end of the existing lease terms, the outcome of professional liability lawsuits and claims, our ability to control ultimate professional liability costs, the accuracy of our estimate of our anticipated professional liability expense, the impact of future licensing surveys, the outcome of proceedings alleging violations of state or Federal False Claims Acts, laws and regulations governing quality of care or other laws and regulations applicable to our business including HIPAA and laws governing reimbursement from government payors, the costs of investing in our business initiatives and development, our ability to control

30


costs, changes to our valuation of deferred tax assets, changes in occupancy rates in our centers, changing economic and competitive conditions, changes in anticipated revenue and cost growth, changes in the anticipated results of operations, the effect of changes in accounting policies as well as others. Investors also should refer to the risks identified in this “Management's Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Part I. Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2016, for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of June 30, 2017, we had outstanding borrowings of approximately $92.5 million, $63.5 million of which was subject to variable interest rates. In connection with our February 2016 financing agreement, we entered into an interest rate swap with an initial notional amount of $30.0 million to mitigate the floating interest rate risk of a portion of such borrowing. In the event that interest rates were to change 1%, the impact on future pre-tax cash flows would be approximately $0.6 million annually, representing the impact of increased or decreased interest expense on variable rate debt.

ITEM 4. CONTROLS AND PROCEDURES
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of June 30, 2017. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is properly recorded, processed, summarized and reported within the time periods required by the Securities and Exchange Commission’s rules and forms. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures that, by their nature, can provide only reasonable assurance regarding management’s control objectives. Management does not expect that its disclosure controls and procedures will prevent all errors and fraud. A control system, irrespective of how well it is designed and operated, can only provide reasonable assurance, and cannot guarantee that it will succeed in its stated objectives.
Based on an evaluation of the effectiveness of the design and operation of disclosure controls and procedures, our chief executive officer and chief financial officer concluded that, as of June 30, 2017, our disclosure controls and procedures were effective in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits alleging malpractice, negligence, violations of false claims acts, product liability, or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and are potentially subject to the increased scrutiny of regulators for issues related to compliance with health care fraud and abuse laws and with respect to the quality of care provided to residents of our facilities. Like other health care providers, in

31


the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.
As of June 30, 2017, we are engaged in 74 professional liability lawsuits. Seventeen lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted. We have limited, and sometimes no, professional liability insurance with regard to most of these claims. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA"). In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against two of its centers. In response to civil investigative demands (“CIDs”) and informal requests, the Company has provided to the DOJ documents and information relating to the Company’s practices and policies for rehabilitation and other services, relating to the preadmission evaluation forms ("PAEs") required by TennCare, and relating to the Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. The DOJ has also issued CID’s for testimony from current and former employees of the Company. The DOJ’s civil investigation has been focused on six of our centers, but the DOJ has indicated that all of the Company’s centers are the subject of the investigation related to rehabilitation therapy.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs. The Company has responded to this subpoena and provided additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Center”). The Company answered the original complaint in 2009, and there was no other activity in the case until May 2017. At that time, plaintiff filed an amended complaint asserting new causes of action. The amended complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Center over a multi-year period by failing to meet minimum staffing requirements, failing to otherwise adequately staff the Center and failing to provide a clean and safe living environment in the Center. The Company has filed an answer to the amended complaint denying plaintiffs’ allegations and has asked the Court to dismiss the new causes of action asserted in the amended complaint because the Company was prejudiced by plaintiff’s long delay in filing the amended complaint. The lawsuit remains in its early stages and has not yet been certified by the court as a class action. The Company intends to defend the lawsuit vigorously.
We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. Our reserve for professional liability expenses does not include any amounts for the pending DOJ investigation or the purported class action against the Arkansas centers. An unfavorable outcome in any of these lawsuits or any of our professional liability actions, any regulatory action, any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims Act case could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.


32


ITEM 1A. RISK FACTORS.
In addition to the other information contained in this Quarterly Report, the risks and uncertainties that we believe could materially affect our business, financial condition or future results and are most important for you to consider are discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 2, 2017. Additional risks and uncertainties which are not presently known to us, which we currently deem immaterial or which are similar to those faced by other companies in our industry or business in general, may also materially and adversely affect any of our business, financial position or future results.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURE.
Not applicable.
ITEM 5. OTHER INFORMATION.
None.

ITEM 6. EXHIBITS
The exhibits filed as part of this report on Form 10-Q are listed in the Exhibit Index immediately following the signature page.

33


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
Diversicare Healthcare Services, Inc.
 
 
 
August 3, 2017
 
 
 
 
 
 
 
By:
 
/s/ Kelly J. Gill
 
 
 
Kelly J. Gill
 
 
 
President and Chief Executive Officer, Principal Executive Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant
 
 
 
 
By:
 
/s/ James R. McKnight, Jr.
 
 
 
James R. McKnight, Jr.
 
 
 
Executive Vice President and Chief Financial Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant

34


 
 
 
Exhibit
Number
  
Description of Exhibits
3.1

  
Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
3.2

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2006).
 
 
3.3

  
Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
3.4

  
Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company’s annual report on Form 10-K for the year ended December 31, 2007).
 
 
3.5

  
Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company’s Form 8-A filed March 30, 1995).
 
 
3.6

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2001).
 
 
3.7

 
Certificate of Ownership and Merger of Diversicare Healthcare Services, Inc. with and into Advocat Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K filed March 14, 2013).
 
 
 
3.8

 
Amendment to Certificate of Incorporation dated June 9, 2016 (incorporated by reference to Exhibit 3.8 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).
 
 
 
3.9

 
Bylaw Second Amendment adopted April 14, 2016.
 
 
 
4.1

 
Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company's Registration Statement No. 33-76150 on Form S-1).
 
 
 
10.1

 
Fourth Amendment to Third Amended and Restated Revolving Loan and Security Agreement dated June 30, 2107.
 
 
 
10.2

 
Second Amendment to Second Amended and Restated Term Loan and Security Agreement dated June 30, 2017.
 
 
 
31.1

  
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 
31.2

  
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 
32

  
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
 
 
101.INS

  
XBRL Instance Document
 
 
101.SCH

  
XBRL Taxonomy Extension Schema Document
 
 
101.CAL

  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.LAB

  
XBRL Taxonomy Extension Labels Linkbase Document
 
 
101.PRE

  
XBRL Taxonomy Extension Presentation Linkbase Document


35
 EX-10.1 2 dvcr-101fourthamendmentrev.htm EXHIBIT 10.1 Exhibit

FOURTH AMENDMENT TO THIRD
AMENDED AND RESTATED REVOLVING LOAN AND SECURITY AGREEMENT

THIS FOURTH AMENDMENT TO THIRD AMENDED AND RESTATED REVOLVING LOAN AND SECURITY AGREEMENT (this “Amendment”) dated as of June 30, 2017, is by and among THE PRIVATEBANK AND TRUST COMPANY, an Illinois banking corporation (together with its successors and assigns, “Administrative Agent”) in its capacity as administrative agent for the Lenders (as defined below), the Lenders, DIVERSICARE MANAGEMENT SERVICES CO., a Tennessee corporation, and certain of its affiliates parties hereto identified on the signature pages as “Original Borrower” (individually and collectively, “Original Borrower”), and DIVERSICARE OF SELMA, LLC, a Delaware limited liability company (“New Opco”) and DIVERSICARE SELMA PROPERTY, LLC, a Delaware limited liability company (“New Propco”; New Propco together with New Opco are hereinafter referred to, individually and collectively, as “New Borrower”). New Borrower and Original Borrower are hereinafter referred to individually and collectively as, “Borrower”.
RECITALS:
WHEREAS, Original Borrower, Administrative Agent, and the financial institutions signatories thereto (the “Lenders”) are parties to that certain Third Amended and Restated Revolving Loan and Security Agreement dated as of February 26, 2016 (as the same has been, and may hereafter be, amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”; all capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Loan Agreement as amended by this Amendment); and
WHEREAS, Borrower, Administrative Agent and Lenders desire to amend the Loan Agreement as provided in and subject to the terms and conditions of this Amendment.
NOW, THEREFORE, for and in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto (intending to be legally bound) hereby agree as follows:
1.Joinder and Assumption. From and after the date hereof, New Borrower hereby absolutely and unconditionally (i) joins as and becomes a party to the Loan Agreement as a Borrower thereunder and to each Financing Agreement to which Original Borrower is a party, (ii) assumes, as a joint and several obligor thereunder, all of the obligations, liabilities and indemnities of a Borrower under the Loan Agreement and all other Financing Agreements, (iii) covenants and agrees to be bound by and adhere to all of the terms, covenants, waivers, releases, agreements and conditions of or respecting a Borrower with respect to the Loan Agreement and the other Financing Agreements and all of the representations and warranties contained in the Loan Agreement and the other Financing Agreements with respect to a Borrower, and (iv) collaterally assigns and transfers to Administrative Agent (for the benefit of Lenders and itself) and hereby grants to Administrative Agent (for the benefit of Lenders and itself) a continuing first-priority security interest in all of New Borrower’s now owned and existing and hereafter acquired and arising Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all of the Liabilities, subject to any applicable Intercreditor Agreements. New Borrower hereby authorizes Administrative Agent to file at any time uniform commercial code financing statements in such jurisdictions and offices as Administrative Agent deems necessary in connection with the perfection of a security interest in all of New Borrower’s now owned or hereafter arising or acquired Collateral, including, without limitation, Accounts and Deposit Accounts of New Borrower, and all proceeds and products thereof. From and after the date hereof, any reference to the term “Borrower” in the Loan Agreement and the Financing Agreements shall also include New Borrower.
2.    Supplementation of Certain Disclosure Schedules. In connection with the joinder of New Borrower to the Loan Agreement, Schedule 1.1(a) (Borrowers), Schedule 1.1(b) (Affiliated Term Borrowers), Schedule 1.1(c) (Propco Borrowers), Schedule 1.1(f) (Facilities, Locations, Real Property, Operators, Owners, Leases), Schedule 7.8 (Names), Schedule 7.12 (Organizational Chart), Schedule 7.33 (Capitalization) and Schedule 7.36 (Commercial Leases) of the Loan Agreement shall be supplemented from and after the date of this Amendment as set forth on the applicable and respective schedules attached hereto and made a part hereof so that such schedules shall reflect the matters intended to be shown thereon as of the date of this Amendment.
3.    Amendments to Loan Agreement. Subject to the satisfaction of the conditions set forth in Section 6 below and in reliance upon the representations and warranties set forth in Section 5 below, Borrower, Administrative Agent and Lenders hereby amend the Loan Agreement as follows:
(a)    Subsection (d) of the definition of “Change of Control” in Section 1.1 of the Loan Agreement shall be amended and restated in its entirety to read as follows:
(d) Diversicare Holding Company, LLC shall at any time after the Closing Date have control and voting power over less than all of the issued and outstanding Stock of Diversicare Kansas, LLC, Diversicare of Glasgow, LLC, Diversicare of Fulton, LLC and Diversicare of Selma, LLC,
(b)    The definition of “Financing Agreements” in Section 1.1 of the Loan Agreement shall hereafter be deemed to also include this Amendment and each of the documents identified in Sections 6(c), (d), (e), (f), (g) and (p) in this Amendment.
(c)    The definition of “Libor Base Rate” contained in Section 1.1 of the Loan Agreement is hereby amended by deleting the last sentence at the end of such definition.
(d)    The definition of “Maximum Revolving Facility” in Section 1.1 of the Loan Agreement shall be amended and restated in its entirety as follows:
“Maximum Revolving Facility” means an amount equal to Fifty-Two Million Two Hundred Fifty Thousand and No/100 Dollars ($52,250,000.00).
(e)    Section 9.3 of the Loan Agreement shall be amended to amend and restate the second proviso therein to read as follows:
provided further, that, subject to the terms and conditions of the Term Loan Agreement, the Hutchinson Propco (as defined therein), Clinton Propco (as defined therein) and Selma Propco (as defined therein) may enter into the Hutchinson Acquisition (as defined therein), Clinton Acquisition (as defined therein) and Selma Acquisition (as defined therein), respectively, an Affiliated Term Loan Borrower may enter into a Permitted Acquisition (as defined therein) subject to satisfaction of all of the related conditions precedent thereto.
(f)    Annex A (Lenders, Pro Rata Shares/Dollar Allocations, and Notice Information) to the Loan Agreement shall be amended and restated and replaced with Annex A attached hereto.
4.    No Other Amendments. Borrower acknowledges and expressly agrees that this Amendment is limited to the extent expressly set forth herein and shall not constitute a modification or amendment of the Loan Agreement or any other Financing Agreements or a course of dealing at variance with the terms or conditions of the Loan Agreement or any other Financing Agreements (other than as expressly set forth in this Amendment and the other instruments, agreements, certificates and documents required to be executed and delivered in connection herewith, including those identified in Sections 6(c), (d), (e), (f), (g) and (p)).
5.    Representations and Warranties. In order to induce Administrative Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Administrative Agent and Lenders (which representations and warranties shall survive the execution and delivery hereof), both before and after giving effect to this Amendment that:
(a)    Each of the representations and warranties of each Borrower (including Original Borrower and New Borrower) contained in the Loan Agreement and the other Financing Agreements to which Borrower is a party are true and correct in all material respects (without duplication of any materiality carve out already provided therein) on and as of the date hereof, in each case as if made on and as of such date, other than representations and warranties that expressly relate solely to an earlier date (in which case such representations and warranties were true and correct on and as of such earlier date); the principal place of business and chief executive office for New Borrower is as set forth on Schedule 1.1(a) (as revised pursuant to Section 2 hereof);
(b)    Borrower has the corporate or limited liability company (as applicable) power and authority (i) to enter into the Loan Agreement as amended by this Amendment and (ii) to do all acts and things as are required or contemplated hereunder to be done, observed and performed by Borrower;
(c)    This Amendment has been duly authorized, validly executed and delivered by one or more Duly Authorized Officers of Borrower, and each of this Amendment, the Loan Agreement as amended hereby, and each of the other Financing Agreements to which Borrower is a party, constitutes the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, subject to bankruptcy, insolvency or other similar laws affecting the enforcement of creditor’s rights and remedies generally;
(d)    The execution and delivery of this Amendment and performance by Borrower under this Amendment, the Loan Agreement and each of the other Financing Agreements to which Borrower is a party do not and will not require the consent or approval of any regulatory authority or governmental authority or agency having jurisdiction over Borrower that has not already been obtained, nor be in contravention of or in conflict with the organizational documents of Borrower, or any provision of any statute, judgment, order, indenture, instrument, agreement, or undertaking, to which Borrower is party or by which Borrower’s respective assets or properties are bound; and
(e)    No Default or Event of Default will result after giving effect to this Amendment, and no event has occurred that has had or could reasonably be expected to have a Material Adverse Effect after giving effect to this Amendment.
6.    Conditions Precedent to Effectiveness of this Amendment. The joinder contained in Section 1 and the amendments contained in Sections 2 and 3 of this Amendment shall become effective on the date hereof as long as each of the following conditions precedent is satisfied as determined by Administrative Agent:
(a)    all of the representations and warranties of Borrower under Section 5 hereof, which are made as of the date hereof, are true and correct;
(b)    receipt by Administrative Agent of duly executed signature pages to this Amendment from Borrower and Lenders;
(c)    receipt by Administrative Agent of duly executed signature pages to the modifications to promissory notes dated as of the date hereof by Borrower in favor of each Lender;
(d)    Administrative Agent shall have received a duly executed Reaffirmation of Second Amended and Restated Guaranty in the form attached hereto;
(e)    receipt by Administrative Agent of duly executed signature pages to the First Amendment to and Reaffirmation of Second Amended and Restated Pledge Agreement dated as of the date hereof, among Diversicare Holding Company, LLC, New Opco and Administrative Agent (the “Diversicare Holding Company Pledge Agreement Amendment”), in form and substance reasonably acceptable to Administrative Agent;
(f)    receipt by Administrative Agent of duly executed signature pages to the First Amendment to and Reaffirmation of Second Amended and Restated Pledge Agreement dated as of the date hereof, among Diversicare Property Co., LLC, New Propco and Administrative Agent (the “Diversicare Property Co. Pledge Agreement Amendment”), in form and substance reasonably acceptable to Administrative Agent;
(g)    Administrative Agent shall have received a duly executed Reaffirmation of Pledge Agreements in the form attached hereto;
(h)    receipt by Administrative Agent of copies of resolutions of the governing body of New Borrower authorizing the execution, delivery and performance by New Borrower of the Loan Agreement, as amended by this Amendment, and each of the other instruments, agreements and documents entered into in connection with this Amendment to which New Borrower is a party (including with respect to the security interest and equity pledge provided in favor of Administrative Agent), certified by a Duly Authorized Officer of New Borrower;
(i)    receipt by Administrative Agent of copies of resolutions of the governing body of Original Borrower authorizing the execution, delivery and performance by Original Borrower of this Amendment and each of the other instruments, agreements and documents entered into in connection with this Amendment to which Original Borrower is a party, certified by a Duly Authorized Officer of Original Borrower;
(j)    receipt by Administrative Agent of UCC tax, lien, pending suit, bankruptcy and judgment searches on New Borrower, each as of a recent date, the results of which must be in form and substance acceptable to Administrative Agent;
(k)    receipt by Administrative Agent of good standing certificates for New Borrower from the Delaware Secretary of State and certificates of authorization for New Borrower from the Secretary of State of the State of Alabama (as of a recent date);
(l)    receipt by Administrative Agent of an opinion of Bass Berry & Sims, PLC, the legal counsel to Borrower and Guarantor, in form and substance reasonably satisfactory to Administrative Agent;
(m)    receipt by Administrative Agent of a certified copy of New Borrower’s certificate of formation, certified by the Delaware Secretary of State (as of a recent date);
(n)    receipt by Administrative Agent of a true, correct and complete copy of the operating agreement of New Borrower, certified by a Duly Authorized Officer of New Borrower;
(o)    UCC Financing Statements, as requested by Administrative Agent, naming New Borrower as debtor and Administrative Agent as secured party with respect to the Collateral, together with such UCC termination statements necessary to release all Liens (other than Permitted Liens) in any of the Collateral except Administrative Agent, and other documents as Administrative Agent deems necessary or appropriate, shall have been filed in all jurisdictions that Administrative Agent deems necessary or advisable;
(p)    receipt of a duly executed Second Amendment to Second Amended and Restated Blocked Account Agreement, in form and substance reasonably acceptable to Administrative Agent;
(q)    receipt of certificates from Borrower’s insurance carriers evidencing Administrative Agent as additional insured with respect to New Borrower’s general liability insurance;
(r)    receipt by Administrative Agent of a true, correct and complete copy of the Management Agreement between New Opco and Manager available as of the date hereof, certified by a Duly Authorized Officer of New Borrower;
(s)    receipt by Administrative Agent of a true, correct and complete copy of the Leases for the Property of New Borrower available as of the date hereof, and each certified by a Duly Authorized Officer of New Borrower;
(t)    receipt by Administrative Agent of a duly signed and completed perfection certificate with respect to New Borrower;
(u)    UCC Financing Statement naming Diversicare Holding Company, LLC as debtor and Administrative Agent as secured party with respect to the equity of New Opco pledged pursuant to the Diversicare Holding Company Pledge Agreement Amendment shall have been filed in all jurisdictions that Administrative Agent deems necessary or advisable (including the Delaware Secretary of State);
(v)    UCC Financing Statement naming Diversicare Property Co., LLC as debtor and Administrative Agent as secured party with respect to the equity of New Propco pledged pursuant to the Diversicare Property Co. Pledge Agreement Amendment shall have been filed in all jurisdictions that Administrative Agent deems necessary or advisable (including the Delaware Secretary of State);
(w)    receipt by Administrative Agent of copies of resolutions of the governing body of Diversicare Holding Company, LLC authorizing the execution, delivery and performance by Diversicare Holding Company, LLC of the Diversicare Holding Company Pledge Agreement Amendment, certified by a Duly Authorized Officer of Diversicare Holding Company, LLC;
(x)    receipt by Administrative Agent of copies of resolutions of the governing body of Diversicare Property Co., LLC authorizing the execution, delivery and performance by Diversicare Property Co., LLC of the Diversicare Property Co. Pledge Agreement Amendment, certified by a Duly Authorized Officer of Diversicare Property Co., LLC;
(y)    receipt by Administrative Agent of copies of resolutions of the governing body of Guarantor authorizing the execution, delivery and performance by Guarantor of the Guaranty Reaffirmation, certified by a Duly Authorized Officer of Guarantor;
(z)    receipt by Administrative Agent of copies of the supplemented Schedule 1.1(a) (Borrowers), Schedule 1.1(b) (Affiliated Term Borrowers), Schedule 1.1(c) (Propco Borrowers), Schedule 1.1(f) (Facilities, Locations, Real Property, Operators, Owners, Leases), Schedule 7.8 (Names), Schedule 7.12 (Organizational Chart), Schedule 7.33 (Capitalization) and Schedule 7.36 (Commercial Leases) of the Loan Agreement;
(aa)    receipt of any applicable Letter of Credit Document (including an amendment to the Master Letter of Credit Agreement or an entirely new Master Letter of Credit Agreement) as Administrative Agent may require in connection with this Amendment; and
(bb)    receipt by Administrative Agent of such other certificates, schedules, exhibits, documents, opinions, instruments, reaffirmations, amendments or consents Administrative Agent may reasonably require, if any.
7.    Reaffirmation; References to Loan Agreement; Additional Agreements and Covenants; Etc.
(a)    Borrower acknowledges and agrees that all of Borrower’s obligations and Liabilities under the Loan Agreement and the other Financing Agreements, as amended hereby, are and shall be valid and enforceable and shall not be impaired or limited by the execution or effectiveness of this Amendment. The first priority perfected security interests and Liens and rights in the Collateral securing payment of the Liabilities are hereby ratified and confirmed by Borrower in all respects.
(b)    Upon the effectiveness of this Amendment, each reference in the Loan Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Loan Agreement, as amended by this Amendment.
(c)    The failure by Administrative Agent, at any time or times hereafter, to require strict performance by any Borrower of any provision or term of the Loan Agreement, this Amendment or any of the Financing Agreements shall not waive, affect or diminish any right of Administrative Agent hereafter to demand strict compliance and performance herewith or therewith. Any suspension or waiver by Administrative Agent of a breach of this Amendment or any Event of Default under or pursuant to the Loan Agreement shall not, except as expressly set forth in a writing signed by Administrative Agent, suspend, waive or affect any other breach of this Amendment or any Event of Default under or pursuant to the Loan Agreement, whether the same is prior or subsequent thereto and whether of the same or of a different kind or character. None of the undertakings, agreements, warranties, covenants and representations of any Borrower contained in this Amendment, shall be deemed to have been suspended or waived by Administrative Agent unless such suspension or waiver is (i) in writing and signed by Administrative Agent (and, if applicable, the Required Lenders) and (ii) delivered to Borrower by Administrative Agent or its counsel.
(d)    In no event shall Administrative Agent’s execution and delivery of this Amendment establish a course of dealing among Administrative Agent, any Borrower, pledgor or Guarantor or any other obligor, or in any other way obligate Administrative Agent to hereafter provide any amendments or modifications or, if at any time applicable, consents or waivers with respect to the Loan Agreement or any other Financing Agreement. The terms and provisions of this Amendment shall be limited precisely as written and shall not be deemed (x) to be a consent to any amendment or modification of any other term or condition of the Loan Agreement or of any of the Financing Agreements (except as expressly provided herein or in any of the other instruments, agreements, certificates and documents required to be executed and delivered in connection herewith, including those identified in Sections 6(c), (d), (e), (f), (g) and (p)); or (y) to prejudice any right or remedy which Administrative Agent may now have under or in connection with the Loan Agreement or any of the other Financing Agreements. In the event an ambiguity or question of intent or interpretation arises, this Amendment shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Amendment.
(e)    Except as expressly provided herein (or in any of the other instruments, agreements, certificates and documents required to be executed and delivered in connection herewith, including those identified in Sections 6(c), (d), (e), (f), (g) and (p)), the Loan Agreement and all of the other Financing Agreements shall remain unaltered, and the Loan Agreement and all of the other Financing Agreements shall remain in full force and effect and are hereby ratified and confirmed in all respects.
(f)    Borrower shall deliver to Administrative Agent promptly upon receipt evidence that New Opco has received its Medicare and Medicaid provider numbers for the Selma Facility.
8.    Release.
(a)    In consideration of, among other things, the consent and amendments provided for herein, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, Borrower and Guarantor (on behalf of themselves and their respective subsidiaries, Affiliates, successors and assigns), and, to the extent permitted by applicable law and the same is claimed by right of, through or under the above, for their past, present and future employees, directors, members, managers, partners, agents, representatives, officers, directors, and equity holders (all collectively, with Borrower and Guarantor, the “Releasing Parties”), do hereby unconditionally, irrevocably, fully, and forever remise, satisfy, acquit, release and discharge Administrative Agent, Issuing Lender, and Lenders and each of Administrative Agent’s, Issuing Lender’s and Lender’s past, present and future officers, directors, agents, employees, attorneys, parent, shareholders, successors, assigns, subsidiaries and Affiliates and all other persons and entities to whom Administrative Agent or Lenders would be liable if such persons or entities were found in any way to be liable to any of the Releasing Parties (collectively, the “Lender Parties”), of and from any and all manner of action and actions, cause and causes of action, claims, cross-claims, charges, demands, counterclaims, suits, proceedings, disputes, debts, dues, sums of money, accounts, bonds, covenants, contracts, controversies, damages, judgments, liabilities, damages, costs, expenses, executions, liens, claims of liens, claims of costs, penalties, attorneys’ fees, or any other compensation, recovery or relief on account of any liability, obligation, demand, proceedings or cause of action of whatever nature, whether in law, equity or otherwise (including, without limitation, those arising under 11 U.S.C. §§ 541-550 and interest or other carrying costs, penalties, legal, accounting and other professional fees and expenses, and incidental, consequential and punitive damages payable to third parties), whether known or unknown, fixed or contingent, joint and/or several, secured or unsecured, due or not due, primary or secondary, liquidated or unliquidated, contractual or tortious, direct, indirect, or derivative, asserted or unasserted, foreseen or unforeseen, suspected or unsuspected, now existing, heretofore existing or which may have heretofore accrued against any or all of Lender Parties, whether held in a personal or representative capacity, that the Releasing Parties (or any of them) have or may have against the Lender Parties or any of them (whether directly or indirectly) and which are based on any act, fact, event, action or omission or any other matter, condition, cause or thing occurring at or from any time prior to and including the date hereof in any way, directly or indirectly arising out of, connected with or relating to this Amendment, the Loan Agreement or any other Financing Agreement and the transactions contemplated hereby and thereby, the Collateral or the Liabilities, and all other agreements, certificates, instruments and other documents and statements (whether written or oral) related to any of the foregoing, other than any applicable good faith claim as to which a final determination is made in a judicial proceeding (in which Administrative Agent and any of the Released Parties have had an opportunity to be heard) which determination includes a specific finding that Administrative Agent acted in a grossly negligent manner or with actual willful misconduct or illegal activity. Borrower and Guarantor each acknowledges that Administrative Agent and Lenders are specifically relying upon the representations, warranties and agreements contained herein and that such representations, warranties and agreements constitute a material inducement to Administrative Agent and Lenders in entering into this Amendment.
(b)    Borrower and Guarantor each understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.
(c)    To the furthest extent permitted by law, Borrower and Guarantor each hereby knowingly, voluntarily, intentionally and expressly waives and relinquishes any and all rights and benefits that it respectively may have as against Lender Parties under any law, rule or regulation of any jurisdiction that would or could have the effect of limiting the extent to which a general release extends to claims which a Lender Party or Releasing Party does not know or suspect to exist as of the date hereof. Borrower and Guarantor each hereby acknowledges that the waiver set forth in the prior sentence was separately bargained for and that such waiver is an essential term and condition of this Amendment (and without which the joinder in Section 1 and the amendments in Sections 2 and 3 hereof would not have been agreed to by Administrative Agent and Lenders).
9.    Costs and Expenses. Without limiting the obligation of Borrower to reimburse Administrative Agent for all costs, fees, disbursements and expenses incurred by Administrative Agent as specified in the Loan Agreement, Borrower agrees to and shall pay on demand all reasonable costs, fees, disbursements and expenses of Administrative Agent in connection with the preparation, negotiation, revision, execution and delivery of this Amendment and the other agreements, amendments, modifications, reaffirmations, instruments and documents contemplated hereby, including, without limitation, reasonable attorneys’ fees and out-of-pocket expenses. All obligations provided herein shall survive any termination of this Amendment and the Loan Agreement as amended hereby.
10.    Financing Agreement. This Amendment shall constitute a Financing Agreement.
11.    Titles. Titles and section headings herein shall be without substantive meaning and are provided solely for the convenience of the parties.
12.    Severability; Etc. Whenever possible, each provision of this Amendment shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Amendment shall be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Amendment. The parties hereto have participated jointly in the negotiation and drafting of this Amendment. In the event an ambiguity or question of intent or interpretation arises, this Amendment shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Amendment.
13.    Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns; provided, however, no Borrower may assign any of its respective rights or obligations under this Amendment without the prior written consent of Administrative Agent.
14.    Further Assurances. Borrower shall, at its own cost and expense, cause to be promptly and duly taken, executed, acknowledged and delivered all such further acts, certificates, instruments, reaffirmations, amendments, documents and assurances as may from time to time be necessary or as Administrative Agent may from time to time reasonably request in order to more fully carry out the intent and purposes of this Amendment or any of the other instruments, agreements, certificates and documents required to be executed and delivered in connection herewith, including those identified in Sections 6(c), (d), (e), (f), (g) and (p).
15.    Counterparts; Faxes. This Amendment may be executed in multiple counterparts, each of which shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes.
16.    Governing Law. This Amendment shall be governed by and construed and enforced in accordance with the internal laws of the State of Illinois, without regard to conflict of law principles that would require the application of any other laws.
[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Fourth Amendment to Third Amended and Restated Revolving Loan and Security Agreement as of the day and year first above written.

BORROWER: 
 
ORIGINAL BORROWER:
ADVOCAT FINANCE, INC.
DIVERSICARE MANAGEMENT SERVICES CO.
DIVERSICARE LEASING CORP.
STERLING HEALTH CARE MANAGEMENT, INC.
DIVERSICARE TEXAS I, LLC
DIVERSICARE HOLDING COMPANY, LLC
DIVERSICARE KANSAS, LLC
DIVERSICARE LEASING COMPANY II, LLC
DIVERSICARE PROPERTY CO., LLC


By:
/s/ James R. McKnight, Jr.
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer
SENIOR CARE CEDAR HILLS, LLC
SENIOR CARE GOLFCREST, LLC
SENIOR CARE GOLFVIEW, LLC
SENIOR CARE SOUTHERN PINES, LLC
BY:
SENIOR CARE FLORIDA LEASING, LLC, its sole member
 
BY:
DIVERSICARE LEASING CORP., its sole member
 
By:
/s/ James R. McKnight, Jr.
 
Name:
James R. McKnight, Jr.
 
Its:
Executive Vice President & Chief Financial Officer



SENIOR CARE FLORIDA LEASING, LLC
DIVERSICARE AFTON OAKS, LLC
DIVERSICARE BRIARCLIFF, LLC
DIVERSICARE CHISOLM, LLC
DIVERSICARE HARTFORD, LLC
DIVERSICARE HILLCREST, LLC
DIVERSICARE LAMPASAS, LLC
DIVERSICARE PINEDALE, LLC
DIVERSICARE WINDSOR HOUSE, LLC
DIVERSICARE YORKTOWN, LLC
DIVERSICARE ROSE TERRACE, LLC
DIVERSICARE THERAPY SERVICES, LLC
DIVERSICARE CLINTON, LLC
DIVERSICARE HIGHLANDS, LLC

BY:
DIVERSICARE LEASING CORP., its sole member
 
By:
/s/ James R. McKnight, Jr.
 
Name:
James R. McKnight, Jr.
 
Its:
Executive Vice President & Chief Financial Officer
 

DIVERSICARE BALLINGER, LLC
DIVERSICARE DOCTORS, LLC
DIVERSICARE ESTATES, LLC
DIVERSICARE HUMBLE, LLC
DIVERSICARE KATY, LLC
DIVERSICARE NORMANDY TERRACE, LLC DIVERSICARE TREEMONT, LLC
DIVERSICARE PARIS, LLC 
BY:
DIVERSICARE TEXAS I, LLC, its sole member
 
By:
/s/ James R. McKnight, Jr.
 
Name:
James R. McKnight, Jr.
 
Its:
Executive Vice President & Chief Financial Officer

DIVERSICARE OF CHANUTE, LLC
DIVERSICARE OF COUNCIL GROVE, LLC
DIVERSICARE OF HAYSVILLE, LLC
DIVERSICARE OF SEDGWICK, LLC
DIVERSICARE OF HUTCHINSON, LLC
DIVERSICARE OF LARNED, LLC
BY:
DIVERSICARE KANSAS, LLC
its sole member
 
 
 
By:
/s/ James R. McKnight, Jr.
 
Name:
James R. McKnight, Jr.
 
Its:
Executive Vice President & Chief Financial Officer
DIVERSICARE OF SENECA PLACE, LLC
DIVERSICARE OF BRADFORD PLACE, LLC
DIVERSICARE OF PROVIDENCE, LLC
DIVERSICARE OF SIENA WOODS, LLC
DIVERSICARE OF ST. THERESA, LLC
DIVERSICARE OF BIG SPRINGS, LLC
DIVERSICARE OF NICHOLASVILLE, LLC
DIVERSICARE OF AVON, LLC
DIVERSICARE OF MANSFIELD, LLC
DIVERSICARE OF RIVERSIDE, LLC
DIVERSICARE OF CHATEAU, LLC
DIVERSICARE OF ST. JOSEPH, LLC
DIVERSICARE OF GREENVILLE, LLC


By:
DIVERSICARE LEASING COMPANY II, LLC, its sole member

By:_ /s/ James R. McKnight, Jr._____________
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer



DIVERSICARE AFTON OAKS PROPERTY, LLC
DIVERSICARE BRIARCLIFF PROPERTY, LLC
DIVERSICARE CHANUTE PROPERTY, LLC
DIVERSICARE CHISOLM PROPERTY, LLC
DIVERSICARE COUNCIL GROVE PROPERTY, LLC
DIVERSICARE HAYSVILLE PROPERTY, LLC
DIVERSICARE HARTFORD PROPERTY, LLC
DIVERSICARE HILLCREST PROPERTY, LLC
DIVERSICARE HUTCHINSON PROPERTY, LLC
DIVERSICARE LAMPASAS PROPERTY, LLC
DIVERSICARE LARNED PROPERTY, LLC
DIVERSICARE SEDGWICK PROPERTY, LLC
DIVERSICARE WINDSOR HOUSE PROPERTY, LLC
DIVERSICARE YORKTOWN PROPERTY, LLC
DIVERSICARE GLASGOW PROPERTY, LLC
DIVERSICARE CLINTON PROPERTY, LLC
DIVERSICARE FULTON PROPERTY, LLC

By:
DIVERSICARE PROPERTY CO., LLC, its sole member


By:_ /s/ James R. McKnight, Jr._________    
Name: James R. McKnight, Jr.
Its:
Executive Vice President & Chief
Financial Officer


DIVERSICARE OF GLASGOW, LLC
DIVERSICARE OF FULTON, LLC

By:
DIVERSICARE HOLDING COMPANY, LLC, its sole member


By:_ /s/ James R. McKnight, Jr.___________    
Name: James R. McKnight, Jr.
Its:
Executive Vice President & Chief
Financial Officer


DIVERSICARE LEASING COMPANY III, LLC

By:_ /s/ James R. McKnight, Jr.____________
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer

DIVERSICARE OF ARAB, LLC
DIVERSICARE OF BOAZ, LLC
DIVERSICARE OF FOLEY, LLC
DIVERSICARE OF HUEYTOWN, LLC
DIVERSICARE OF LANETT, LLC
DIVERSICARE OF BESSEMER, LLC
DIVERSICARE OF MONTGOMERY, LLC
DIVERSICARE OF ONEONTA, LLC
DIVERSICARE OF OXFORD, LLC
DIVERSICARE OF PELL CITY, LLC
DIVERSICARE OF RIVERCHASE, LLC
DIVERSICARE OF WINFIELD, LLC
DIVERSICARE OF AMORY, LLC
DIVERSICARE OF BATESVILLE, LLC
DIVERSICARE OF BROOKHAVEN, LLC
DIVERSICARE OF CARTHAGE, LLC
DIVERSICARE OF EUPORA, LLC
DIVERSICARE OF MERIDIAN, LLC
DIVERSICARE OF RIPLEY, LLC
DIVERSICARE OF SOUTHAVEN, LLC
DIVERSICARE OF TUPELO, LLC
DIVERSICARE OF TYLERTOWN, LLC


By:
DIVERSICARE LEASING COMPANY III, LLC, its sole member

By:__ /s/ James R. McKnight, Jr.__________
Name:
James R. McKnight, Jr.
Its:
Executive Vice President & Chief Financial Officer

NEW BORROWER:

DIVERSICARE OF SELMA, LLC

By:
DIVERSICARE HOLDING COMPANY, LLC, its sole member


By:_ /s/ James R. McKnight, Jr.__________    
Name: James R. McKnight, Jr.
Its:
Executive Vice President & Chief
Financial Officer


DIVERSICARE SELMA PROPERTY, LLC

By:
DIVERSICARE PROPERTY CO., LLC, its sole member


By:_ /s/ James R. McKnight, Jr.__________    
Name: James R. McKnight, Jr.
Its:
Executive Vice President & Chief
Financial Officer





Acknowledged and Agreed:
DIVERSICARE HEALTHCARE SERVICES, INC.
/s/ Kelly J. Gill
 
Name:
Kelly J. Gill
 
Its:
President and Chief Executive Officer
 


ADMINISTRATIVE AGENT:

THE PRIVATEBANK AND TRUST COMPANY, in its capacity as administrative agent

By:_/s/ Adam D. Panos_________________
Name: Adam D. Panos
Its: Managing Director


LENDER:

THE PRIVATEBANK AND TRUST COMPANY

By:_/s/ Adam D. Panos_____________
Name: Adam D. Panos
Its: Managing Director


LENDER:
BANKERS TRUST COMPANY
By: _/s/ Jon M. Doll_______________
 
Name:
Jon M. Doll
 
Its:
Vice President
 


LENDER:
BOKF, NA D/B/A BANK OF OKLAHOMA
By: _/s/ Ky Chaffin_________________
 
Name:
Ky Chaffin
 
Its:
Senior Vice President
 


LENDER:
CIT BANK, N.A.
By: _/s/ Edward Shuster____________
 
Name:
Edward Shuster
 
Its:
Director
 


LENDER:
OPUS BANK,  
a California commercial bank

By: _/s/ Randy Boba______________
 
Name:
Randy Boba
 
Its:
SVP, Healthcare Banking
 


LENDER:
FRANKLIN SYNERGY BANK

By: _/s/ Lisa Fletcher______________
 
Name:
Lisa Fletcher
 
Its:
Senior Vice President
 



REAFFIRMATION OF SECOND AMENDED AND RESTATED GUARANTY

Dated as of June 30, 2017
The undersigned (“Guarantor”) hereby: (i) confirms and agrees with The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as administrative agent (together with its successors and assigns, “Administrative Agent”) that Guarantor’s Second Amended and Restated Guaranty dated as of February 26, 2016 made in favor of Administrative Agent (as amended or modified, “Guaranty”), remains in full force and effect and is hereby ratified and confirmed in all respects, including with regard to the Third Amended and Restated Revolving Loan and Security Agreement dated as of February 26, 2016, as amended prior to the date hereof and as further amended by the foregoing Fourth Amendment to Third Amended and Restated Revolving Loan and Security Agreement (“Amendment”), and each reference to the term “Borrower” in the Guaranty shall also include New Borrower (as defined in the Amendment) and each reference to the “Loan Agreement” shall refer to the Loan Agreement as amended by the Amendment; (ii) represents and warrants to Administrative Agent, which representations and warranties shall survive the execution and delivery hereof, that Guarantor’s representations and warranties contained in the Guaranty are true and correct as of the date hereof, with the same effect as though made on the date hereof, except to the extent that such representations expressly related solely to an earlier date, in which case such representations were true and correct on and as of such earlier date (and except for the representations in Section 10(b) thereof which were true and correct on and as of the date when made); (iii) agrees and acknowledges that such ratification and confirmation is not a condition to the continued effectiveness of the Amendment or the Guaranty; and (iv) agrees that neither such ratification and confirmation, nor Administrative Agent’s solicitation of such ratification and confirmation, constitutes a course of dealing giving rise to any obligation or condition requiring a similar or any other ratification or confirmation from the undersigned with respect to subsequent amendments or modifications, if any, to the Loan Agreement, as amended by the Amendment or any other Financing Agreement (as defined in the Loan Agreement, as amended by the Amendment). The execution, delivery and effectiveness of this instrument shall not operate as a waiver of any right, power or remedy of Administrative Agent under or pursuant to the Guaranty. Guarantor acknowledges and agrees that Guarantor has received and reviewed a fully-executed copy of the Amendment (and any other instrument, document or agreement executed or delivered in connection therewith) and understands the contents thereof. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes. This instrument shall be governed by and construed and enforced in accordance with the internal laws of the State of Illinois, without regard to conflict of law principles that would require the application of any other laws.
[Signature Page Follows]

DIVERSICARE HEALTHCARE SERVICES, INC.


By:    /s/ Kelly J. Gill            
Name:    Kelly J. Gill
Its:    President and Chief Executive Officer


REAFFIRMATION OF PLEDGE AGREEMENTS

Dated as of June 30, 2017
For good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the undersigned, respectively and as applicable hereby (a) confirms and agrees with The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as administrative agent (together with its successors and assigns, “Administrative Agent”), that (i) Second Amended and Restated Pledge Agreement by and between Diversicare Management Services Co. and Administrative Agent dated as of February 26, 2016, (ii) Second Amended and Restated Pledge Agreement by and between Advocat Finance, Inc. and Administrative Agent dated as of February 26, 2016, (iii) Second Amended and Restated Pledge Agreement by and between Diversicare Leasing Corp. and Administrative Agent dated as of February 26, 2016, (iv) Second Amended and Restated Pledge Agreement by and between Senior Care Florida Leasing Corp. and Administrative Agent dated as of February 26, 2016, (v) Amended and Restated Pledge Agreement by and between Diversicare Leasing Company II, LLC and Administrative Agent dated as of February 26, 2016, (vi) Amended and Restated Pledge Agreement by and between Diversicare Kansas, LLC and Administrative Agent dated as of February 26, 2016, (vii) Second Amended and Restated Pledge Agreement by and between Diversicare Healthcare Services, Inc. (f/k/a Advocat Inc.) and Administrative Agent dated as of February 26, 2016 and (viii) Pledge Agreement by and between Diversicare Leasing Company III, LLC and Administrative Agent dated as of October 1, 2016 and effective as of October 3, 2016 (the foregoing, as the same may be amended, restated, supplemented or otherwise modified from time to time, individually, “Pledge Agreement” and, collectively, “Pledge Agreements”), each remains in full force and effect and is hereby ratified and confirmed in all respects, including with regard to the Third Amended and Restated Revolving Loan and Security Agreement dated as of February 26, 2016 by and among Diversicare Management Services Co., a Tennessee corporation, and those certain affiliates of Diversicare Management Services Co. that are signatories thereto as borrowers, Administrative Agent and the Lenders, as the same has been amended prior to the date hereof and as amended by the foregoing Fourth Amendment to Third Amended and Restated Revolving Loan and Security Agreement dated of even date herewith (“Amendment”), and each reference to the term “Borrower” in each Pledge Agreement shall also include New Borrower (as defined in the Amendment) and each reference to the “Loan Agreement” shall refer to the Loan Agreement as amended by the Amendment, and all of the undersigned’s respective liabilities and obligations under and pursuant to the respective Pledge Agreement, as modified by the Amendment (if and as applicable), are and shall be valid and enforceable and shall not be impaired or limited in any way by the execution, delivery or effectiveness of the Amendment; (b) acknowledges and agrees that each Pledge Agreement is hereby amended to include Diversicare of Selma, LLC, a Delaware limited liability company, and Diversicare Selma Property, LLC, a Delaware limited liability company, as an additional “Borrower” thereunder for all purposes; (c) represents and warrants to Administrative Agent and Lenders, which representations and warranties shall survive the execution and delivery hereof, that each of the undersigned’s representations and warranties contained in the Pledge Agreement are true and correct as of the date hereof, with the same effect as though made on the date hereof, except to the extent that such representations expressly related solely to an earlier date, in which case such representations were true and correct on and as of such earlier date, each of the undersigned has the full right, authority and power to enter into this Reaffirmation and this Reaffirmation constitutes the legal, valid and binding obligation of each of the undersigned, enforceable against each of the undersigned in accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency, reorganization or similar law affecting creditor’s rights generally and general principles of equity; (d) agrees and acknowledges that such ratification and confirmation is not a condition to the continued effectiveness of the Amendment or the Pledge Agreement; and (e) agrees that neither such ratification and confirmation, nor the solicitation of such ratification and confirmation by Administrative Agent and Lenders, constitutes a course of dealing giving rise to any obligation or condition requiring a similar or any other ratification or confirmation from the undersigned with respect to subsequent amendments or modifications, if any, to the Loan Agreement, as amended by the Amendment or any other Financing Agreement (as defined in the Loan Agreement). The execution, delivery and effectiveness of this instrument shall not operate as a waiver of any right, power or remedy of Administrative Agent or Lenders under the Pledge Agreements. Each of the undersigned acknowledges and agrees that it has received and reviewed a fully-executed copy of the Amendment and understands the contents thereof. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes. Illinois law shall govern the construction, interpretation and enforcement of this instrument.
[Signature Pages Follows]

IN WITNESS WHEREOF, each of the undersigned has duly executed this Reaffirmation of Pledge Agreements on and as of the date above.
DIVERSICARE MANAGEMENT SERVICES CO., a Tennessee corporation


By: __ /s/ James R. McKnight, Jr.___________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer

ADVOCAT FINANCE INC., a Delaware corporation


By: _ /s/ James R. McKnight, Jr.___________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer


DIVERSICARE LEASING CORP.,
a Tennessee corporation


By: _ /s/ James R. McKnight, Jr.___________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer



SENIOR CARE FLORIDA LEASING, LLC, a Delaware limited liability company

By: Diversicare Leasing Corp., its sole member


By:_ /s/ James R. McKnight, Jr.___________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer





DIVERSICARE LEASING COMPANY II, LLC, a Delaware limited liability company


By:_ /s/ James R. McKnight, Jr.____________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer



DIVERSICARE KANSAS, LLC, a Delaware limited liability company

By:    DIVERSICARE HOLDING COMPANY, LLC, its sole member

By:_ /s/ James R. McKnight, Jr._____________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer


DIVERSICARE LEASING COMPANY III, LLC,
a Delaware limited liability company


By:_ /s/ James R. McKnight, Jr.____________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer


DIVERSICARE HEALTHCARE SERVICES, INC., a Delaware limited liability company


By:_/s/ Kelly J. Gill____________________
Kelly J. Gill, President & Chief Executive Officer
SUPPLEMENTAL SCHEDULE 1.1(a)
to Third Amended and Restated Revolving Loan and Security Agreement
(Fourth Amendment)

BORROWERS

Name
State of Formation
Principal Place of Business and
Chief Executive Office
Organizational Number
Diversicare of Selma, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323833
Diversicare Selma Property, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323836


SUPPLEMENTAL SCHEDULE 1.1(b)
to Third Amended and Restated Revolving Loan and Security Agreement
(Fourth Amendment)

AFFILIATED TERM BORROWERS

Name
State of Formation
Principal Place of Business and
Chief Executive Office
Organizational Number
Diversicare of Selma, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323833
Diversicare Selma Property, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323836

SUPPLEMENTAL SCHEDULE 1.1(c)
to Third Amended and Restated Revolving Loan and Security Agreement
(Fourth Amendment)

PROPCO BORROWERS

Name
State of Formation
Principal Place of Business and
Chief Executive Office
Organizational Number
Diversicare Selma Property, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323836



SUPPLEMENTAL SCHEDULE 1.1(f)
to Third Amended and Restated Revolving Loan and Security Agreement
(Fourth Amendment)

FACILITIES; LOCATIONS; REAL PROPERTY; OPERATORS; OWNERS; LEASES


Facility Name
Real Property/ Location Address
Owner / Lessor
Operator / Lessee
Lease Expiration Date and Options to Extend
Park Place
100 Park Place
Selma, AL 36701
Diversicare Selma Property, LLC
Diversicare of Selma, LLC
June 30, 2027; two 5-year renewals



SUPPLEMENTAL SCHEDULE 7.8
to Third Amended and Restated Revolving Loan and Security Agreement
(Fourth Amendment)

OTHER NAMES


Diversicare of Selma, LLC does business in the State of Alabama as “Park Place.”

SUPPLEMENTAL SCHEDULE 7.12
to Third Amended and Restated Revolving Loan and Security Agreement
(Fourth Amendment)

ORGANIZATIONAL CHART

See attached.

SUPPLEMENTAL SCHEDULE 7.33
to Third Amended and Restated Revolving Loan and Security Agreement
(Fourth Amendment)

CAPITALIZATION

Borrower
Number of Authorized Stock/LLC Interests
Holder of Equity Securities
Ownership Percentage
Diversicare of Selma, LLC
N/A
Diversicare Holding Company, LLC
100%
Diversicare Selma Property, LLC
N/A
Diversicare Property Co., LLC
100%


SUPPLEMENTAL SCHEDULE 7.36
to Third Amended and Restated Revolving Loan and Security Agreement
(Fourth Amendment)

COMMERCIAL LEASES

Lease Agreement dated as of July 1, 2017 by and between Diversicare Selma Property, LLC, as Lessor, and Diversicare of Selma, LLC, as Lessee, with respect to (i) that certain nursing home facility formerly known as “Park Place Nursing and Rehabilitation Center” and located at 100 Park Place, Selma, Dallas County, Alabama and (ii) the currently vacant building formerly used as an assisted living facility and located at 903 Medical Center Parkway, Selma, Dallas County, Alabama.

ANNEX A
(LENDERS, PRO RATA SHARES/DOLLAR ALLOCATIONS, AND NOTICE INFORMATION)
Lender
Contact Information

Pro Rata Shares
 
 
 
The PrivateBank and Trust Company
120 South LaSalle Street
Chicago, IL 60603
Attn.: Adam D. Panos
Managing Director
Tel.: (312) 564-1278
Fax: (312) 683-0446

Dollar Allocation:
$19,250,000.00

36.84210526%
CIT Bank, N.A.

11 West 42nd Street
New York, NY 10036
Attn.: Edward Shuster
Director
Tel.: (212) 771-9303

Dollar Allocation:
$11,000,000.00

21.05263158%
Bankers Trust Company
453 7th Street
Des Moines, IA 50304-0897
Attn.: Jon M. Doll
Vice President
Tel.: (515) 245-2837
Fax: (515) 245-5216

Dollar Allocation:
$8,250,000.00
15.78947368%
 
 
 

BOKF, NA d/b/a Bank of Oklahoma

One Williams Center, Suite 8NE
Tulsa, OK 74172
Attn.: Ky Chaffin
Senior Vice President
Tel.: (918) 588-6866
Fax: (918) 280-3368

Dollar Allocation:
$2,750,000.00
5.26315789%

Opus Bank

19900 MacArthur Blvd.
12th Floor
Irvine, CA 92612
Attn.: Randy Boba
SVP, Healthcare Banking
Tel.: (949) 251-8123
Fax: (949) 250-9988

Dollar Allocation:
$5,500,000.00

10.52631579%
Franklin Synergy Bank

722 Columbia Ave.
Franklin, TN 37064
Chicago, IL 60606
Attn.: Lisa Fletcher
Senior Vice President
Tel.: (615) 564-6374
Fax: (312) 564-7375

Dollar Allocation:
$5,500,000.00
10.52631579%



DM3\4648329.3
 EX-10.2 3 dvcr-ex102secondamendment.htm EXHIBIT 10.2 Exhibit

SECOND AMENDMENT TO
SECOND AMENDED AND RESTATED TERM LOAN AND SECURITY AGREEMENT
THIS SECOND AMENDMENT TO SECOND AMENDED AND RESTATED TERM LOAN AND SECURITY AGREEMENT (this “Amendment”) dated as of June 30, 2017, by and among THE PRIVATEBANK AND TRUST COMPANY, an Illinois banking corporation (together with its successors and assigns, “Administrative Agent”) in its capacity as administrative agent for the Lenders (as defined below), the Lenders, the Affiliates of Diversicare Healthcare Services, Inc. identified on the signature pages as “Original Borrower” (individually and collectively, “Original Borrower”), and DIVERSICARE OF SELMA, LLC, a Delaware limited liability company (“New Opco”), and DIVERSICARE SELMA PROPERTY, LLC, a Delaware limited liability company (“New Propco”; New Propco together with New Opco are hereinafter referred to, individually and collectively, as “New Borrower”). New Borrower and Original Borrower are hereinafter referred to individually and collectively as, “Borrower”.
WHEREAS, Original Borrower, Administrative Agent, and the financial institutions signatories thereto (the “Lenders”) are parties to that certain Second Amended and Restated Term Loan and Security Agreement dated as of February 26, 2016 (as the same has been, and may hereafter be, amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”; all capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Loan Agreement as amended by this Amendment); and
WHEREAS, Borrower, Administrative Agent and Lenders desire to amend the Loan Agreement as provided in and subject to the terms and conditions of this Amendment.
NOW, THEREFORE, for and in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto (intending to be legally bound) hereby agree as follows:
1.Consent. Subject to the satisfaction of the conditions set forth in Section 7 below and in reliance upon the representations and warranties set forth in Section 6 below, Administrative Agent and the Lenders hereby consent to the disbursement of One Million Five Hundred Thousand and no/100 Dollars ($1,500,000.00) from the Acquisition Loan to Borrowers, to be used by New Borrower to acquire that certain skilled nursing facility located at 100 Park Place, Selma, Alabama 36701, known as “Park Place Nursing & Rehabilitation Center” and defined herein as the Selma Acquisition.
2.    Joinder and Assumption. From and after the date hereof, New Borrower hereby absolutely and unconditionally (i) joins as and becomes a party to the Loan Agreement as a Borrower thereunder and to each Financing Agreement to which Original Borrower is a party, (ii) assumes, as a joint and several obligor thereunder, all of the obligations, liabilities and indemnities of a Borrower under the Loan Agreement and all other Financing Agreements, (iii) covenants and agrees to be bound by and adhere to all of the terms, covenants, waivers, releases, agreements and conditions of or respecting a Borrower with respect to the Loan Agreement and the other Financing Agreements and all of the representations and warranties contained in the Loan Agreement and the other Financing Agreements with respect to a Borrower, and (iv) collaterally assigns and transfers to Administrative Agent (for the benefit of Lenders and itself) and hereby grants to Administrative Agent (for the benefit of Lenders and itself) a continuing first-priority security interest in all of New Borrower’s now owned and existing and hereafter acquired and arising Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all of the Liabilities, subject to any applicable Intercreditor Agreements. New Borrower hereby authorizes Administrative Agent to file at any time uniform commercial code financing statements in such jurisdictions and offices as Administrative Agent deems necessary in connection with the perfection of a security interest in all of New Borrower’s now owned or hereafter arising or acquired Collateral, including, without limitation, Accounts and Deposit Accounts of New Borrower, and all proceeds and products thereof. From and after the date hereof, any reference to the term “Borrower” in the Loan Agreement and the Financing Agreements shall also include New Borrower.
3.    Supplementation of Certain Disclosure Schedules. In connection with the joinder of New Borrower to the Loan Agreement, Schedule 1.1(a) (Borrowers), Schedule 1.1(b) (Propco Borrowers), Schedule 1.1(c) (Affiliated Revolving Borrowers), Schedule 1.1(d) (Facilities, Locations, Real Property, Operators, Owners, Leases), Schedule 7.8 (Names), Schedule 7.12 (Organizational Chart), and Schedule 7.33 (Capitalization) of the Loan Agreement shall be supplemented from and after the date of this Amendment as set forth on the applicable and respective schedules attached hereto and made a part hereof so that such schedules shall reflect the matters intended to be shown thereon as of the date of this Amendment.
4.    Amendments to Loan Agreement. Subject to the satisfaction of the conditions set forth in Section 7 below and in reliance upon the representations and warranties set forth in Section 6 below, Borrower, Administrative Agent and Lenders hereby amend the Loan Agreement as follows:
(a)    The following definitions shall be inserted in correct alphabetical order in Section 1.1 of the Loan Agreement:
“Second Amendment Effective Date” shall mean June 30, 2017.
“Selma Acquisition” means the sale/purchase transaction intended to be consummated on the Second Amendment Effective Date pursuant to and in accordance with the Selma Acquisition Documents.
“Selma Acquisition Agreement” means that certain Asset Purchase Agreement dated as of June 8, 2017 by and among the Sellers (as defined therein) and New Opco, as amended by the First Amendment dated as of June 19, 2017.
“Selma Acquisition Documents” means, collectively, the Selma Acquisition Agreement, and any and all of the other material documents, instruments and agreements executed or delivered in connection therewith, in each case as the same may be amended or modified in conformity with Section 9.16 of this Agreement.
(b)    Section 1.1 of the Loan Agreement shall be amended by amending and restating the following definitions therein in their entirety to read as follows:
“Maximum Facility” means an amount equal to $77,969,996.
“Maximum Term Loan Facility” means an amount equal to $65,469,996.
(c)    Subsection (d) of the definition of “Change of Control” in Section 1.1 of the Loan Agreement shall be amended and restated in its entirety to read as follows:
(d) Diversicare Holding shall at any time after the Closing Date have control and voting power over less than all of the issued and outstanding Stock of Diversicare Kansas, LLC, Diversicare of Glasgow, LLC, Diversicare of Fulton, LLC and Diversicare of Selma, LLC,
(d)    The definition of “Libor Base Rate” contained in Section 1.1 of the Loan Agreement is hereby amended by deleting the last sentence at the end of such definition.
(e)    The definition of “Restricted Agreements” in Section 1.1 of the Loan Agreement shall be amended to add “the Selma Acquisition Documents” immediately following “the Clinton Acquisition Documents,” therein.
(f)    Section 2.1 of the Loan Agreement shall be amended by amending and restating the first and second sentence therein in their entirety to read as follows:
On the terms and subject to the conditions set forth in this Agreement, and provided there does not then exist a Default or an Event of Default, each Lender with a Term Loan Commitment, severally and for itself alone, agrees to make in Dollars such Lender’s Pro Rata Share of a term loan (the “Term Loan”) (i) in one advance to the Borrower on the Closing Date in the aggregate amount of (x) the Maximum Term Loan Facility (as defined as of the Closing Date) minus (y) the outstanding aggregate principal amount of the “Term Loan” (as defined in the Original Term Loan Agreement) on the date hereof and (ii) in one advance to the Borrower on the Second Amendment Effective Date in the aggregate amount of $7,500,000. (w) As of the Closing Date, the outstanding aggregate principal amount of the “Term Loan” (as defined in the Original Term Loan Agreement) is equal to Forty-Two Million Two Hundred Twenty-Four Thousand Nine Hundred Ninety-Nine and 82/100 Dollars ($42,224,999.82), (x) immediately after giving effect to such advance on the Closing Date, the outstanding aggregate principal amount of the “Term Loan” (as defined in this Agreement) is equal to $60,000,000, (y) as of the Second Amendment Effective Date, the outstanding aggregate principal amount of the “Term Loan” (as defined in this Agreement) is equal to $57,969,996 and (z) immediately after giving effect to such advance on the Second Amendment Effective Date, the outstanding aggregate principal amount of the “Term Loan” (as defined in this Agreement) is equal to the Maximum Term Loan Facility.
(g)    Section 2.1(b) of the Loan Agreement shall be amended by amending and restating the amortization schedule set forth therein as follows:
Year 1:
$1,610,000 ($134,167/month)
Year 2 (on or prior to June 1, 2017):
$1,680,000 ($140,000/month)
Year 2 (on and after July 1, 2017):
$1,830,000 ($152,500/month)
Year 3:
$1,920,000 ($160,000/month)
Year 4:
$2,010,000 ($167,500/month)
Year 5:
$2,110,000 ($175,833/month)
(h)    Section 2.16 of the Loan Agreement shall be amended and restated in its entirety to read as follows:
2.16    Closing Fee. On the Closing Date, the Borrower shall pay to the Administrative Agent a one-time closing fee pursuant to a Fee Letter in immediately available funds, which fee shall be nonrefundable and deemed fully earned as of such date (“Closing Date Closing Fee”). On the Second Amendment Effective Date, the Borrower shall pay to the Administrative Agent a one-time closing fee pursuant to a Fee Letter in immediately available funds, which fee shall be nonrefundable and deemed fully earned as of such date (“Second Amendment Closing Fee”; and together with the Closing Date Closing Fee, collectively, the “Closing Fee”).
(i)    Section 9.3 of the Loan Agreement shall be amended to add “, the Selma Acquisition” immediately following “the Clinton Acquisition” therein.
(j)    Section 9.7 of the Loan Agreement shall be amended by adding a new subsection (f) therein immediately following subsection (e) to read as follows:
(f)    to finance the consummation of the Selma Acquisition.
(k)    Annex A (Lenders, Pro Rata Shares/Dollar Allocations, and Notice Information) to the Loan Agreement shall be amended and restated and replaced with Annex A attached hereto.
5.    No Other Amendments. Borrower acknowledges and expressly agrees that this Amendment is limited to the extent expressly set forth herein and shall not constitute a modification or amendment of the Loan Agreement or any other Financing Agreements or a course of dealing at variance with the terms or conditions of the Loan Agreement or any other Financing Agreements (other than as expressly set forth in this Amendment and the other instruments, agreements, certificates and documents required to be executed and delivered in connection herewith, including those identified in Sections 7(c), (d), (e), (f), (g), (p), (q), (t), (ee), (ff), (gg), (hh) and (ii)).
6.    Representations and Warranties. In order to induce Administrative Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Administrative Agent and Lenders (which representations and warranties shall survive the execution and delivery hereof), both before and after giving effect to this Amendment that:
(a)    Each of the representations and warranties of each Borrower (including Original Borrower and New Borrower) contained in the Loan Agreement and the other Financing Agreements to which Borrower is a party are true and correct in all material respects (without duplication of any materiality carve out already provided therein) on and as of the date hereof, in each case as if made on and as of such date, other than representations and warranties that expressly relate solely to an earlier date (in which case such representations and warranties were true and correct on and as of such earlier date); the principal place of business and chief executive office for New Borrower is as set forth on Schedule 1.1(a) (as revised pursuant to Section 3 hereof);
(b)    Borrower has the corporate or limited liability company (as applicable) power and authority (i) to enter into the Loan Agreement as amended by this Amendment and (ii) to do all acts and things as are required or contemplated hereunder to be done, observed and performed by Borrower;
(c)    This Amendment has been duly authorized, validly executed and delivered by one or more Duly Authorized Officers of Borrower, and each of this Amendment, the Loan Agreement as amended hereby, and each of the other Financing Agreements to which Borrower is a party, constitutes the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, subject to bankruptcy, insolvency or other similar laws affecting the enforcement of creditor’s rights and remedies generally;
(d)    The execution and delivery of this Amendment and performance by Borrower under this Amendment, the Loan Agreement and each of the other Financing Agreements to which Borrower is a party do not and will not require the consent or approval of any regulatory authority or governmental authority or agency having jurisdiction over Borrower that has not already been obtained, nor be in contravention of or in conflict with the organizational documents of Borrower, or any provision of any statute, judgment, order, indenture, instrument, agreement, or undertaking, to which Borrower is party or by which Borrower’s respective assets or properties are bound; and
(e)    No Default or Event of Default will result after giving effect to this Amendment, and no event has occurred that has had or could reasonably be expected to have a Material Adverse Effect after giving effect to this Amendment.
(f)    Borrower has delivered true, correct and complete copies of the fully-signed Selma Acquisition Documents to the Administrative Agent on or prior to the Second Amendment Effective Date. On the Second Amendment Effective Date and concurrently with the making of the transactions completed hereunder, the Selma Acquisition will have been consummated in accordance with the terms of the Selma Acquisition Documents and in accordance in all material respects with all applicable laws. As of the Second Amendment Effective Date, to the Borrower’s knowledge, the Seller (as defined in the Selma Acquisition Documents) is not in default or breach of or under the Selma Acquisition Documents to which Seller is a party. All consents and approvals of, and filings and registrations with, and all other actions by, any Governmental Authority and (except where the failure to obtain or make the same could not reasonably be expected to have an adverse effect on the Selma Acquisition or any portion thereof or a Material Adverse Effect) to the best of Borrower’s knowledge each other Person required in order to make or consummate the Selma Acquisition have been obtained, given, filed or taken, or shall be obtained, given, filed or taken as soon as reasonably practicable following the Second Amendment Effective Date, and are or will be in full force and effect.
7.    Conditions Precedent to Effectiveness of this Amendment. The joinder contained in Section 2 and the amendments contained in Sections 3 and 4 of this Amendment shall become effective on the date hereof as long as each of the following conditions precedent is satisfied as determined by Administrative Agent:
(a)    all of the representations and warranties of Borrower under Section 6 hereof, which are made as of the date hereof, are true and correct;
(b)    receipt by Administrative Agent of duly executed signature pages to this Amendment from Borrower and Lenders;
(c)    receipt by Administrative Agent of duly executed signature pages to the modifications to promissory notes dated as of the date hereof by Borrower in favor of each Lender;
(d)    Administrative Agent shall have received a duly executed Reaffirmation of Second Amended and Restated Guaranty in the form attached hereto;
(e)    receipt by Administrative Agent of duly executed signature pages to the First Amendment to and Reaffirmation of Second Amended and Restated Pledge Agreement dated as of the date hereof, among Diversicare Holding Company, LLC, New Opco and Administrative Agent (the “Diversicare Holding Company Pledge Agreement Amendment”), in form and substance reasonably acceptable to Administrative Agent;
(f)    receipt by Administrative Agent of duly executed signature pages to the First Amendment to and Reaffirmation of Second Amended and Restated Pledge Agreement dated as of the date hereof, among Diversicare Property Co., LLC, New Propco and Administrative Agent (the “Diversicare Property Co. Pledge Agreement Amendment”), in form and substance reasonably acceptable to Administrative Agent;
(g)    receipt by Administrative Agent of a duly executed Reaffirmation of Pledge Agreements in the form attached hereto;
(h)    receipt by Administrative Agent of copies of resolutions of the governing body of New Borrower authorizing the execution, delivery and performance by New Borrower of the Loan Agreement, as amended by this Amendment, and each of the other instruments, agreements and documents entered into in connection with this Amendment to which New Borrower is a party (including with respect to the security interest and equity pledge provided in favor of Administrative Agent), certified by a Duly Authorized Officer of New Borrower;
(i)    receipt by Administrative Agent of copies of resolutions of the governing body of Original Borrower authorizing the execution, delivery and performance by Original Borrower of this Amendment and each of the other instruments, agreements and documents entered into in connection with this Amendment to which Original Borrower is a party, certified by a Duly Authorized Officer of Original Borrower;
(j)    receipt by Administrative Agent of UCC tax, lien, pending suit, bankruptcy and judgment searches on New Borrower, each as of a recent date, the results of which must be in form and substance acceptable to Administrative Agent;
(k)    receipt by Administrative Agent of good standing certificates for New Borrower from the Delaware Secretary of State and certificates of authorization for New Borrower from the Secretary of State of the State of Alabama (as of a recent date);
(l)    receipt by Administrative Agent of an opinion of Bass Berry & Sims, PLC, the legal counsel to Borrower and Guarantor, in form and substance reasonably satisfactory to Administrative Agent;
(m)    receipt by Administrative Agent of a certified copy of New Borrower’s certificate of formation, certified by the Delaware Secretary of State (as of a recent date);
(n)    receipt by Administrative Agent of a true, correct and complete copy of the operating agreement of New Borrower, certified by a Duly Authorized Officer of New Borrower;
(o)    UCC Financing Statements, as requested by Administrative Agent, naming New Borrower as debtor and Administrative Agent as secured party with respect to the Collateral, together with such UCC termination statements necessary to release all Liens (other than Permitted Liens) in any of the Collateral except Administrative Agent, and other documents as Administrative Agent deems necessary or appropriate, shall have been filed in all jurisdictions that Administrative Agent deems necessary or advisable;
(p)    receipt of a duly executed Second Amendment to the Blocked Account Agreement, in form and substance reasonably acceptable to Administrative Agent;
(q)    receipt by Administrative Agent of duly executed signature pages to that certain fee letter dated as of the date hereof, by Borrower in favor of Administrative Agent, and receipt by Administrative Agent in immediately available funds of all fees payable thereunder;
(r)    receipt of certificates from Borrower’s insurance carriers evidencing Administrative Agent as additional insured with respect to New Borrower’s general liability insurance;
(s)    receipt by Administrative Agent of a true, correct and complete copy of the Management Agreement between New Opco and Manager available as of the date hereof, certified by a Duly Authorized Officer of New Borrower;
(t)    receipt by Administrative Agent of duly executed signature pages to the First Amendment to Amended and Restated Assignment and Subordination of Management Agreements dated as of the date hereof, among Manager, New Opco and Administrative Agent, in form and substance reasonably acceptable to Administrative Agent;
(u)    receipt by Administrative Agent of a true, correct and complete copy of the Lease for the Property between New Opco and New Propco available as of the date hereof, and certified by a Duly Authorized Officer of New Borrower;
(v)    receipt by Administrative Agent of a true, correct and complete copy of the fully executed Selma Acquisition Documents, together with all applicable amendments thereto;
(w)    the closing of the transaction contemplated by the Selma Acquisition Documents (including all material conditions precedent thereto, including, without limitation, the obtaining of any and all consents and approvals) shall occur in accordance with its terms concurrently with the transactions contemplated by this Amendment;
(x)    receipt by Administrative Agent of a duly signed and completed perfection certificate with respect to New Borrower;
(y)    UCC Financing Statement naming Diversicare Holding Company, LLC as debtor and Administrative Agent as secured party with respect to the equity of New Opco pledged pursuant to the Diversicare Holding Company Pledge Agreement Amendment shall have been filed in all jurisdictions that Administrative Agent deems necessary or advisable (including the Delaware Secretary of State);
(z)    UCC Financing Statement naming Diversicare Property Co., LLC as debtor and Administrative Agent as secured party with respect to the equity of New Propco pledged pursuant to the Diversicare Property Co. Pledge Agreement Amendment shall have been filed in all jurisdictions that Administrative Agent deems necessary or advisable (including the Delaware Secretary of State);
(aa)    receipt by Administrative Agent of copies of resolutions of the governing body of Diversicare Holding Company, LLC authorizing the execution, delivery and performance by Diversicare Holding Company, LLC of the Diversicare Holding Company Pledge Agreement Amendment, certified by a Duly Authorized Officer of Diversicare Holding Company, LLC;
(bb)    receipt by Administrative Agent of copies of resolutions of the governing body of Diversicare Property Co., LLC authorizing the execution, delivery and performance by Diversicare Property Co., LLC of the Diversicare Property Co. Pledge Agreement Amendment, certified by a Duly Authorized Officer of Diversicare Property Co., LLC;
(cc)    receipt by Administrative Agent of copies of resolutions of the governing body of Guarantor authorizing the execution, delivery and performance by Guarantor of the Guaranty Reaffirmation, certified by a Duly Authorized Officer of Guarantor;
(dd)    receipt by Administrative Agent of copies of the supplemented Schedule 1.1(a) (Borrowers), Schedule 1.1(b) (Propco Borrowers), Schedule 1.1(c) (Affiliated Revolving Borrowers), Schedule 1.1(d) (Facilities, Locations, Real Property, Operators, Owners, Leases), Schedule 7.8 (Names), Schedule 7.12 (Organizational Chart), and Schedule 7.33 (Capitalization) of the Loan Agreement;
(ee)    receipt by Administrative Agent of duly executed amendments to the Mortgages of each Original Borrower, as applicable;
(ff)    receipt by Administrative Agent of duly executed Mortgage by New Propco;
(gg)    receipt by Administrative Agent of duly executed amendments to those Assignments of Rents and Leases by each Original Borrower, as applicable;
(hh)    receipt by Administrative Agent of a duly executed Assignment of Rents and Leases by New Propco;
(ii)    receipt by Administrative Agent of a duly executed Second Amendment and Joinder to Environmental Indemnity Agreement by New Borrower;
(jj)    receipt by Administrative Agent of tract searches for the Property of each Original Borrower, the form and results of which shall be satisfactory to the Administrative Agent in its sole and absolute determination;
(kk)    receipt by Administrative Agent of a title insurance policy in the form of ALTA Form Mortgagee Title Insurance Policy which shall be issued by an insurer (reasonably acceptable to the Administrative Agent) in favor of the Administrative Agent for the Property of New Propco. Each title insurance policy shall contain such endorsements as deemed appropriate by the Administrative Agent that are available in the applicable state. Copies of all documents of record concerning the Property of New Propco as identified on the commitment for the ALTA Policy referred to above;
(ll)    receipt by Administrative Agent of a Phase I environmental report of the Property of New Propco addressed to Administrative Agent prepared by an environmental audit firm reasonably acceptable to the Administrative Agent, the form and results of which shall be satisfactory to the Administrative Agent in its sole and absolute determination;
(mm)    receipt by Administrative Agent of an ALTA plat of survey which shall be prepared on the Property of New Propco;
(nn)    receipt by Administrative Agent of a flood insurance policy, if applicable, concerning the Property of New Propco, reasonably satisfactory to the Administrative Agent, if required by the Flood Disaster Protection Act of 1973;
(oo)    receipt by Administrative Agent of an Appraisal prepared by an independent appraiser of the Property of New Propco engaged by Administrative Agent, which appraisal shall satisfy the requirements of the FIRREA, if applicable, and shall evidence compliance with the supervisory loan-to-value limits set forth in the Federal Deposit Insurance Corporation Improvement Act of 1991 (including a combined loan-to-value ratio on a “stabilized value” not to exceed 75%). Such appraisal (and the results thereof) shall be satisfactory to the Administrative Agent in its sole and absolute determination;
(pp)    receipt by Administrative Agent of a Property Condition Report for the parcel of Property related to New Propco, the form, substance and results of which shall be satisfactory to the Administrative Agent in its sole and absolute determination; and
(qq)    receipt by Administrative Agent of such other certificates, schedules, exhibits, documents, opinions, affidavits, instruments, reaffirmations, amendments, or consents Administrative Agent may reasonably require, if any.
1.    Reaffirmation; References to Loan Agreement; Additional Agreements and Covenants; Etc.
(a)    Borrower acknowledges and agrees that all of Borrower’s obligations and Liabilities under the Loan Agreement and the other Financing Agreements, as amended hereby, are and shall be valid and enforceable and shall not be impaired or limited by the execution or effectiveness of this Amendment. The first priority perfected security interests and Liens and rights in the Collateral securing payment of the Liabilities are hereby ratified and confirmed by Borrower in all respects.
(b)    Upon the effectiveness of this Amendment, each reference in the Loan Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Loan Agreement, as amended by this Amendment.
(c)    The failure by Administrative Agent, at any time or times hereafter, to require strict performance by any Borrower of any provision or term of the Loan Agreement, this Amendment or any of the Financing Agreements shall not waive, affect or diminish any right of Administrative Agent hereafter to demand strict compliance and performance herewith or therewith. Any suspension or waiver by Administrative Agent of a breach of this Amendment or any Event of Default under or pursuant to the Loan Agreement shall not, except as expressly set forth in a writing signed by Administrative Agent, suspend, waive or affect any other breach of this Amendment or any Event of Default under or pursuant to the Loan Agreement, whether the same is prior or subsequent thereto and whether of the same or of a different kind or character. None of the undertakings, agreements, warranties, covenants and representations of any Borrower contained in this Amendment, shall be deemed to have been suspended or waived by Administrative Agent unless such suspension or waiver is (i) in writing and signed by Administrative Agent (and, if applicable, the Required Lenders) and (ii) delivered to Borrower by Administrative Agent or its counsel.
(d)    In no event shall Administrative Agent’s execution and delivery of this Amendment establish a course of dealing among Administrative Agent, any Borrower, pledgor or Guarantor or any other obligor, or in any other way obligate Administrative Agent to hereafter provide any amendments or modifications or, if at any time applicable, consents or waivers with respect to the Loan Agreement or any other Financing Agreement. The terms and provisions of this Amendment shall be limited precisely as written and shall not be deemed (x) to be a consent to any amendment or modification of any other term or condition of the Loan Agreement or of any of the Financing Agreements (except as expressly provided herein or in any of the other instruments, agreements, certificates and documents required to be executed and delivered in connection herewith, including those identified in Sections 7(c), (d), (e), (f), (g), (p), (q), (t), (ee), (ff), (gg), (hh) and (ii); or (y) to prejudice any right or remedy which Administrative Agent may now have under or in connection with the Loan Agreement or any of the other Financing Agreements. In the event an ambiguity or question of intent or interpretation arises, this Amendment shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Amendment.
(e)    Except as expressly provided herein (or in any of the other instruments, agreements, certificates and documents required to be executed and delivered in connection herewith, including those identified in Sections 7(c), (d), (e), (f), (g), (p), (q), (t), (ee), (ff), (gg), (hh) and (ii), the Loan Agreement and all of the other Financing Agreements shall remain unaltered, and the Loan Agreement and all of the other Financing Agreements shall remain in full force and effect and are hereby ratified and confirmed in all respects.
2.    Release.
(a)    In consideration of, among other things, the consent and amendments provided for herein, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, Borrower and Guarantor (on behalf of themselves and their respective subsidiaries, Affiliates, successors and assigns), and, to the extent permitted by applicable law and the same is claimed by right of, through or under the above, for their past, present and future employees, directors, members, managers, partners, agents, representatives, officers, directors, and equity holders (all collectively, with Borrower and Guarantor, the “Releasing Parties”), do hereby unconditionally, irrevocably, fully, and forever remise, satisfy, acquit, release and discharge Administrative Agent and Lenders and each of Administrative Agent’s and Lender’s past, present and future officers, directors, agents, employees, attorneys, parent, shareholders, successors, assigns, subsidiaries and Affiliates and all other persons and entities to whom Administrative Agent or Lenders would be liable if such persons or entities were found in any way to be liable to any of the Releasing Parties (collectively, the “Lender Parties”), of and from any and all manner of action and actions, cause and causes of action, claims, cross-claims, charges, demands, counterclaims, suits, proceedings, disputes, debts, dues, sums of money, accounts, bonds, covenants, contracts, controversies, damages, judgments, liabilities, damages, costs, expenses, executions, liens, claims of liens, claims of costs, penalties, attorneys’ fees, or any other compensation, recovery or relief on account of any liability, obligation, demand, proceedings or cause of action of whatever nature, whether in law, equity or otherwise (including, without limitation, those arising under 11 U.S.C. §§ 541-550 and interest or other carrying costs, penalties, legal, accounting and other professional fees and expenses, and incidental, consequential and punitive damages payable to third parties), whether known or unknown, fixed or contingent, joint and/or several, secured or unsecured, due or not due, primary or secondary, liquidated or unliquidated, contractual or tortious, direct, indirect, or derivative, asserted or unasserted, foreseen or unforeseen, suspected or unsuspected, now existing, heretofore existing or which may have heretofore accrued against any or all of Lender Parties, whether held in a personal or representative capacity, that the Releasing Parties (or any of them) have or may have against the Lender Parties or any of them (whether directly or indirectly) and which are based on any act, fact, event, action or omission or any other matter, condition, cause or thing occurring at or from any time prior to and including the date hereof in any way, directly or indirectly arising out of, connected with or relating to this Amendment, the Loan Agreement or any other Financing Agreement and the transactions contemplated hereby and thereby, the Collateral or the Liabilities, and all other agreements, certificates, instruments and other documents and statements (whether written or oral) related to any of the foregoing, other than any applicable good faith claim as to which a final determination is made in a judicial proceeding (in which Administrative Agent and any of the Released Parties have had an opportunity to be heard) which determination includes a specific finding that Administrative Agent acted in a grossly negligent manner or with actual willful misconduct or illegal activity. Borrower and Guarantor each acknowledges that Administrative Agent and Lenders are specifically relying upon the representations, warranties and agreements contained herein and that such representations, warranties and agreements constitute a material inducement to Administrative Agent and Lenders in entering into this Amendment.
(b)    Borrower and Guarantor each understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.
(c)    To the furthest extent permitted by law, Borrower and Guarantor each hereby knowingly, voluntarily, intentionally and expressly waives and relinquishes any and all rights and benefits that it respectively may have as against Lender Parties under any law, rule or regulation of any jurisdiction that would or could have the effect of limiting the extent to which a general release extends to claims which a Lender Party or Releasing Party does not know or suspect to exist as of the date hereof. Borrower and Guarantor each hereby acknowledges that the waiver set forth in the prior sentence was separately bargained for and that such waiver is an essential term and condition of this Amendment (and without which the joinder in Section 2 and the amendments in Sections 3 and 4 hereof would not have been agreed to by Administrative Agent and Lenders).
3.    Costs and Expenses. Without limiting the obligation of Borrower to reimburse Administrative Agent for all costs, fees, disbursements and expenses incurred by Administrative Agent as specified in the Loan Agreement, Borrower agrees to and shall pay on demand all reasonable costs, fees, disbursements and expenses of Administrative Agent in connection with the preparation, negotiation, revision, execution and delivery of this Amendment and the other agreements, amendments, modifications, reaffirmations, instruments and documents contemplated hereby, including, without limitation, reasonable attorneys’ fees and out-of-pocket expenses. All obligations provided herein shall survive any termination of this Amendment and the Loan Agreement as amended hereby.
4.    Financing Agreement. This Amendment shall constitute a Financing Agreement.
5.    Titles. Titles and section headings herein shall be without substantive meaning and are provided solely for the convenience of the parties.
6.    Severability; Etc. Whenever possible, each provision of this Amendment shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Amendment shall be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Amendment. The parties hereto have participated jointly in the negotiation and drafting of this Amendment. In the event an ambiguity or question of intent or interpretation arises, this Amendment shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Amendment.
7.    Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns; provided, however, no Borrower may assign any of its respective rights or obligations under this Amendment without the prior written consent of Administrative Agent.
8.    Further Assurances. Borrower shall, at its own cost and expense, cause to be promptly and duly taken, executed, acknowledged and delivered all such further acts, certificates, instruments, reaffirmations, amendments, documents and assurances as may from time to time be necessary or as Administrative Agent may from time to time reasonably request in order to more fully carry out the intent and purposes of this Amendment or any of the other instruments, agreements, certificates and documents required to be executed and delivered in connection herewith, including those identified in Sections 7(c), (d), (e), (f), (g), (p), (q), (t), (ee), (ff), (gg), (hh) and (ii).
9.    Counterparts; Faxes. This Amendment may be executed in multiple counterparts, each of which shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes.
10.    Governing Law. This Amendment shall be governed by and construed and enforced in accordance with the internal laws of the State of Illinois, without regard to conflict of law principles that would require the application of any other laws.
[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Second Amendment to Second Amended and Restated Term Loan and Security Agreement as of the day and year first above written.
BORROWER:
ORIGINAL BORROWER:
DIVERSICARE AFTON OAKS, LLC
DIVERSICARE BRIARCLIFF, LLC
DIVERSICARE CHISOLM, LLC
DIVERSICARE HARTFORD, LLC
DIVERSICARE WINDSOR HOUSE, LLC
DIVERSICARE HILLCREST, LLC
DIVERSICARE LAMPASAS, LLC
DIVERSICARE YORKTOWN, LLC
DIVERSICARE CLINTON, LLC
 
BY:
Diversicare Leasing Corp., its sole member
 
By:
/s/ James R. McKnight, Jr.
 
Name: James R. McKnight, Jr.
 
Its: Executive Vice President &
Chief Financial Officer
DIVERSICARE OF CHANUTE, LLC
DIVERSICARE OF COUNCIL GROVE, LLC
DIVERSICARE OF HAYSVILLE, LLC
DIVERSICARE OF SEDGWICK, LLC
DIVERSICARE OF HUTCHINSON, LLC
DIVERSICARE OF LARNED, LLC
BY:

Diversicare Kansas, LLC,
its sole member

 
By:
/s/ James R. McKnight, Jr.
 
Name: James R. McKnight, Jr.
 
Its: Executive Vice President &  
Chief Financial Officer



DIVERSICARE PROPERTY CO., LLC
 
 
 
By:
/s/ James R. McKnight, Jr.
 
Name: James R. McKnight, Jr.
 
Its: Executive Vice President &
Chief Financial Officer

DIVERSICARE AFTON OAKS PROPERTY, LLC
DIVERSICARE BRIARCLIFF PROPERTY, LLC
DIVERSICARE CHANUTE PROPERTY, LLC
DIVERSICARE CHISOLM PROPERTY, LLC
DIVERSICARE COUNCIL GROVE PROPERTY, LLC
DIVERSICARE HAYSVILLE PROPERTY, LLC
DIVERSICARE HARTFORD PROPERTY, LLC
DIVERSICARE HILLCREST PROPERTY, LLC
DIVERSICARE LAMPASAS PROPERTY, LLC
DIVERSICARE LARNED PROPERTY, LLC
DIVERSICARE SEDGWICK PROPERTY, LLC
DIVERSICARE WINDSOR HOUSE PROPERTY, LLC
DIVERSICARE YORKTOWN PROPERTY, LLC
DIVERSICARE GLASGOW PROPERTY, LLC
DIVERSICARE HUTCHINSON PROPERTY, LLC
DIVERSICARE CLINTON PROPERTY, LLC
DIVERSICARE FULTON PROPERTY, LLC
BY:
Diversicare Property Co., LLC, its sole member
 
By:
/s/ James R. McKnight, Jr.
 
Name: James R. McKnight, Jr.
 
Its: Executive Vice President &
Chief Financial Officer


DIVERSICARE OF GLASGOW, LLC
DIVERSICARE OF FULTON, LLC
BY:
Diversicare Holding Company, LLC, its sole member
 
By:
/s/ James R. McKnight, Jr.
 
Name: James R. McKnight, Jr.
 
Its: Executive Vice President &
Chief Financial Officer



NEW BORROWER:

DIVERSICARE OF SELMA, LLC

By:
DIVERSICARE HOLDING COMPANY, LLC, its sole member


By:_ /s/ James R. McKnight, Jr._______________    
Name: James R. McKnight, Jr.
Its:
Executive Vice President & Chief
Financial Officer


DIVERSICARE SELMA PROPERTY, LLC

By:
DIVERSICARE PROPERTY CO., LLC, its sole member


By:_ /s/ James R. McKnight, Jr._______________    
Name: James R. McKnight, Jr.
Its:
Executive Vice President & Chief
Financial Officer






Acknowledged and Agreed:
DIVERSICARE HEALTHCARE SERVICES, INC.
/s/ Kelly J. Gill
 
Name:
Kelly J. Gill
 
Its:
President and Chief Executive Officer
 

ADMINISTRATIVE AGENT:

THE PRIVATEBANK AND TRUST COMPANY, in its capacity as administrative agent

By:_/s/ Adam D. Panos______________________
Name: Adam D. Panos
Its: Managing Director

LENDER:

THE PRIVATEBANK AND TRUST COMPANY

By:_/s/ Adam D. Panos_____________________
Name: Adam D. Panos
Its: Managing Director

LENDER:

BANKERS TRUST COMPANY

By:_/s/ Jon M. Doll______________________
Name: Jon M. Doll
Its: Vice President


LENDER:

BOKF, NA D/B/A BANK OF OKLAHOMA

By:_/s/ Ky Chaffin________________________
Name: Ky Chaffin
Its: Senior Vice President


LENDER:

CIT BANK, N.A.


By:_/s/ Edward Shuster____________________
Name: Edward Shuster
Its: Director



LENDER:
OPUS BANK,  
a California commercial bank
By:
/s/ Randy Boba
 
Name: Randy Boba
 
Its: SVP, Healthcare Banking


LENDER:
FRANKLIN SYNERGY BANK
By:
/s/ Lisa Fletcher
 
Name: Lisa Fletcher
 
Its: Senior Vice President
 
 

REAFFIRMATION OF SECOND AMENDED AND RESTATED GUARANTY

Dated as of June 30, 2017
The undersigned (“Guarantor”) hereby (i) confirms and agrees with The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as administrative agent (together with its successors and assigns, “Administrative Agent”) that Guarantor’s Second Amended and Restated Guaranty dated as of February 26, 2016 made in favor of Administrative Agent (as amended or modified, “Guaranty”), remains in full force and effect and is hereby ratified and confirmed in all respects, including with regard to the Second Amended and Restated Term Loan and Security Agreement dated as of February 26, 2016, as amended prior to the date hereof and as further amended by the foregoing Second Amendment to Second Amended and Restated Term Loan and Security Agreement (“Amendment”), and each reference to the term “Borrower” in the Guaranty shall also include New Borrower (as defined in the Amendment) and each reference to the “Loan Agreement” shall refer to the Loan Agreement as amended by the Amendment; (ii) represents and warrants to Administrative Agent, which representations and warranties shall survive the execution and delivery hereof, that Guarantor’s representations and warranties contained in the Guaranty are true and correct as of the date hereof, with the same effect as though made on the date hereof, except to the extent that such representations expressly related solely to an earlier date, in which case such representations were true and correct on and as of such earlier date (and except for the representations in Section 10(b) thereof which were true and correct on and as of the date when made); (iii) agrees and acknowledges that such ratification and confirmation is not a condition to the continued effectiveness of the Amendment or the Guaranty; and (iv) agrees that neither such ratification and confirmation, nor Administrative Agent’s solicitation of such ratification and confirmation, constitutes a course of dealing giving rise to any obligation or condition requiring a similar or any other ratification or confirmation from the undersigned with respect to subsequent amendments or modifications, if any, to the Loan Agreement, as amended by the Amendment or any other Financing Agreement (as defined in the Loan Agreement, as amended by the Amendment). The execution, delivery and effectiveness of this instrument shall not operate as a waiver of any right, power or remedy of Administrative Agent under or pursuant to the Guaranty. Guarantor acknowledges and agrees that Guarantor has received and reviewed a fully-executed copy of the Amendment (and any other instrument, document or agreement executed or delivered in connection therewith) and understands the contents thereof. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes. This instrument shall be governed by and construed and enforced in accordance with the internal laws of the State of Illinois, without regard to conflict of law principles that would require the application of any other laws.
[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned has duly executed this Reaffirmation of Second Amended and Restated Guaranty on and as of the date above.


DIVERSICARE HEALTHCARE SERVICES, INC. (F/K/A ADVOCAT INC.)

By:    /s/ Kelly J. Gill            
Name:    Kelly J. Gill
Its:    President and Chief Executive Officer    


REAFFIRMATION OF PLEDGE AGREEMENTS

Dated as of June 30, 2017
For good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the undersigned, respectively and as applicable hereby (a) confirms and agrees with The PrivateBank and Trust Company, an Illinois banking corporation in its capacity as administrative agent (together with its successors and assigns, “Administrative Agent”), that (i) Second Amended and Restated Pledge Agreement by and between Diversicare Management Services Co. and Administrative Agent dated as of February 26, 2016, (ii) Second Amended and Restated Pledge Agreement by and between Advocat Finance, Inc. and Administrative Agent dated as of February 26, 2016, (iii) Second Amended and Restated Pledge Agreement by and between Diversicare Leasing Corp. and Administrative Agent dated as of February 26, 2016, (iv) Second Amended and Restated Pledge Agreement by and between Senior Care Florida Leasing Corp. and Administrative Agent dated as of February 26, 2016, (v) Amended and Restated Pledge Agreement by and between Diversicare Leasing Company II, LLC and Administrative Agent dated as of February 26, 2016, (vi) Amended and Restated Pledge Agreement by and between Diversicare Kansas, LLC and Administrative Agent dated as of February 26, 2016, (vii) Second Amended and Restated Pledge Agreement by and between Diversicare Healthcare Services, Inc. (f/k/a Advocat Inc.) and Administrative Agent dated as of February 26, 2016 and (viii) Pledge Agreement by and between Diversicare Leasing Company III, LLC and Administrative Agent dated as of October 1, 2016 and effective as of October 3, 2016 (the foregoing, as the same may be amended, restated, supplemented or otherwise modified from time to time, individually, “Pledge Agreement” and, collectively, “Pledge Agreements”), each remains in full force and effect and is hereby ratified and confirmed in all respects, including with regard to the Second Amended and Restated Term Loan and Security Agreement dated as of February 26, 2016 by and among those certain affiliates of Diversicare Healthcare Services, Inc. that are signatories thereto as borrowers, Administrative Agent and the Lenders, as the same has been amended prior to the date hereof and as amended by the foregoing Second Amendment to Third Amended and Restated Term Loan and Security Agreement dated of even date herewith (“Amendment”), and each reference to the term “Borrower” in each Pledge Agreement shall also include New Borrower (as defined in the Amendment) and each reference to the “Loan Agreement” shall refer to the Loan Agreement as amended by the Amendment, and all of the undersigned’s respective liabilities and obligations under and pursuant to the respective Pledge Agreement, as modified by the Amendment (if and as applicable), are and shall be valid and enforceable and shall not be impaired or limited in any way by the execution, delivery or effectiveness of the Amendment; (b) acknowledges and agrees that each Pledge Agreement is hereby amended to include Diversicare of Selma, LLC, a Delaware limited liability company, and Diversicare Selma Property, LLC, a Delaware limited liability company, as an additional “Borrower” thereunder for all purposes; (c) represents and warrants to Administrative Agent and Lenders, which representations and warranties shall survive the execution and delivery hereof, that each of the undersigned’s representations and warranties contained in the Pledge Agreement are true and correct as of the date hereof, with the same effect as though made on the date hereof, except to the extent that such representations expressly related solely to an earlier date, in which case such representations were true and correct on and as of such earlier date, each of the undersigned has the full right, authority and power to enter into this Reaffirmation and this Reaffirmation constitutes the legal, valid and binding obligation of each of the undersigned, enforceable against each of the undersigned in accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency, reorganization or similar law affecting creditor’s rights generally and general principles of equity; (d) agrees and acknowledges that such ratification and confirmation is not a condition to the continued effectiveness of the Amendment or the Pledge Agreement; and (e) agrees that neither such ratification and confirmation, nor the solicitation of such ratification and confirmation by Administrative Agent and Lenders, constitutes a course of dealing giving rise to any obligation or condition requiring a similar or any other ratification or confirmation from the undersigned with respect to subsequent amendments or modifications, if any, to the Loan Agreement, as amended by the Amendment or any other Financing Agreement (as defined in the Loan Agreement). The execution, delivery and effectiveness of this instrument shall not operate as a waiver of any right, power or remedy of Administrative Agent or Lenders under the Pledge Agreements. Each of the undersigned acknowledges and agrees that it has received and reviewed a fully-executed copy of the Amendment and understands the contents thereof. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes. Illinois law shall govern the construction, interpretation and enforcement of this instrument.
[Signature Pages Follows]

IN WITNESS WHEREOF, each of the undersigned has duly executed this Reaffirmation of Pledge Agreements on and as of the date above.
DIVERSICARE MANAGEMENT SERVICES CO., a Tennessee corporation


By: _/s/ James R. McKnight, Jr. __________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer


ADVOCAT FINANCE INC., a Delaware corporation


By: _/s/ James R. McKnight, Jr.__________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer


DIVERSICARE LEASING CORP.,
a Tennessee corporation


By: _/s/ James R. McKnight, Jr.__________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer



SENIOR CARE FLORIDA LEASING, LLC, a Delaware limited liability company

By: Diversicare Leasing Corp., its sole member


By:_ /s/ James R. McKnight, Jr.__________
James R. McKnight, Jr.,
Executive Vice President & Chief Financial Officer



DIVERSICARE LEASING COMPANY II, LLC, a Delaware limited liability company


By:_ /s/ James R. McKnight, Jr.____________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer



DIVERSICARE KANSAS, LLC, a Delaware limited liability company

By:    DIVERSICARE HOLDING COMPANY, LLC, its sole member

By:_ /s/ James R. McKnight, Jr.___________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer


DIVERSICARE LEASING COMPANY III, LLC,
a Delaware limited liability company


By:_ /s/ James R. McKnight, Jr.___________
James R. McKnight, Jr., Executive Vice President & Chief Financial Officer


DIVERSICARE HEALTHCARE SERVICES, INC., a Delaware limited liability company

By:_/s/ Kelly J. Gill_____________________
Kelly J. Gill, President & Chief Executive Officer
SUPPLEMENTAL SCHEDULE 1.1(a)
to Second Amended and Restated Term Loan and Security Agreement
(Second Amendment)

BORROWERS

Name
State of Formation
Principal Place of Business and
Chief Executive Office
Organizational Number
Diversicare of Selma, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323833
Diversicare Selma Property, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323836


SUPPLEMENTAL SCHEDULE 1.1(b)
to Second Amended and Restated Term Loan and Security Agreement
(Second Amendment)

PROPCO BORROWERS

Name
State of Formation
Principal Place of Business and
Chief Executive Office
Organizational Number
Diversicare Selma Property, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323836



SUPPLEMENTAL SCHEDULE 1.1(c)
to Second Amended and Restated Term Loan and Security Agreement
(Second Amendment)

AFFILIATED REVOLVING BORROWERS

Name
State of Formation
Principal Place of Business and
Chief Executive Office
Organizational Number
Diversicare of Selma, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323833
Diversicare Selma Property, LLC
Delaware
1621 Galleria Boulevard
Brentwood, TN 37027
6323836

SUPPLEMENTAL SCHEDULE 1.1(d)
to Second Amended and Restated Term Loan and Security Agreement
(Second Amendment)

FACILITIES; LOCATIONS; REAL PROPERTY; OPERATORS; OWNERS; LEASES


Facility Name
Real Property/ Location Address
Owner / Lessor
Operator / Lessee
Lease Expiration Date and Options to Extend
Park Place
100 Park Place
Selma, AL 36701
Diversicare Selma Property, LLC
Diversicare of Selma, LLC
June 30, 2027; two 5-year renewals

SUPPLEMENTAL SCHEDULE 7.8
to Second Amended and Restated Term Loan and Security Agreement
(Second Amendment)

OTHER NAMES


Diversicare of Selma, LLC does business in the State of Alabama as “Park Place.”

SUPPLEMENTAL SCHEDULE 7.12
to Second Amended and Restated Term Loan and Security Agreement
(Second Amendment)

ORGANIZATIONAL CHART

See attached.


SUPPLEMENTAL SCHEDULE 7.33
to Second Amended and Restated Term Loan and Security Agreement
(Second Amendment)

CAPITALIZATION

Borrower
Number of Authorized Stock/LLC Interests
Holder of Equity Securities
Ownership Percentage
Diversicare of Selma, LLC
N/A
Diversicare Holding Company, LLC
100%
Diversicare Selma Property, LLC
N/A
Diversicare Property Co., LLC
100%

ANNEX A
LENDERS, PRO RATA SHARES/DOLLAR ALLOCATIONS, AND NOTICE INFORMATION
Lender
Contact Information
Pro Rata Shares
The PrivateBank and
Trust Company
120 South LaSalle Street
Chicago, IL 60603
Attn.: Adam D. Panos
Managing Director
Tel.: (312) 564-1278
Fax: (312) 683-0446
Dollar Allocations:
Term Loan Commitment: $22,914,498.60
Acquisition Loan Commitment: $4,375,000.00
Term Loan Commitment: 35.000000000%
Acquisition Loan Commitment: 35.000000000%
CIT Bank, N.A.
11 West 42nd Street
New York, NY 10036
Attn.: Ed Shuster, Director
Tel.: (212) 771-9303

Dollar Allocations:
Term Loan Commitment: $13,093.999.20
Acquisition Loan Commitment: $2,500,000
Term Loan Commitment: 20.000000000%
Acquisition Loan Commitment: 20.000000000%
Bankers Trust Company
453 7th Street
Des Moines, IA 50304-0897
Attn.: Jon M. Doll
Vice President
Tel.: (515) 245-2837
Fax: (515) 245-5216
Dollar Allocations:
Term Loan Commitment: $9,820,499.40
Acquisition Loan Commitment: $1,875,000
Term Loan Commitment: 15.000000000%
Acquisition Loan Commitment: 15.000000000%

BOKF, NA d/b/a Bank of Oklahoma
One Williams Center, Suite 8NE
Tulsa, OK 74172
Attn.: Ky Chaffin
Senior Vice President
Tel.: (918) 588-6866
Fax: (918) 280-3368

Dollar Allocations:
Term Loan Commitment: $6,546,996.60
Acquisition Loan Commitment: $1,250,000
Term Loan Commitment: 10.000000000%
Acquisition Loan Commitment: 10.000000000%
Opus Bank
19900 MacArthur Blvd.
12th Floor
Irvine, CA 92612
Attn.: Randy Boba,
SVP, Healthcare Banking
Tel.: (949) 251-8123
Fax: (949) 250-9988

Dollar Allocations:
Term Loan Commitment: $6,546,996.60
Acquisition Loan Commitment: $1,250,000
Term Loan Commitment: 10.000000000%
Acquisition Loan Commitment: 10.000000000%
Franklin Synergy Bank
722 Columbia Ave.
Franklin, TN 37064
Attn.: Lisa Fletcher, Senior Vice President
Tel.: (615) 564-6374
Fax: (615) 564-7375

Dollar Allocations:
Term Loan Commitment: $6,546,996.60
Acquisition Loan Commitment: $1,250,000
Term Loan Commitment: 10.000000000%
Acquisition Loan Commitment: 10.000000000%


DM3\4647768.4
 EX-31.1 4 dvcr-ex311x63017certificat.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(i) CERTIFICATION
I, Kelly J. Gill, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 3, 2017
 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer



 EX-31.2 5 dvcr-ex312x63017certificat.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(ii) CERTIFICATION
I, James R. McKnight, Jr., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:  August 3, 2017
 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
Executive Vice President and Chief Financial Officer



 EX-32 6 dvcr-ex32x63017certificati.htm EXHIBIT 32 Exhibit


Exhibit 32
CERTIFICATION OF QUARTERLY REPORT ON FORM 10-Q
OF DIVERSICARE HEALTHCARE SERVICES, INC.
FOR THE QUARTER ENDED JUNE 30, 2017
The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned’s best knowledge and belief, the Quarterly Report on Form 10-Q for Diversicare Healthcare Services, Inc. (the “Company”) for the period ending June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”):
(a)
fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(b)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is executed as of August 3, 2017.

 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer
 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 7 avca-20170630.xml XBRL INSTANCE DOCUMENT 0000919956 2017-01-01 2017-06-30 0000919956 2017-07-28 0000919956 2017-06-30 0000919956 2016-12-31 0000919956 2016-04-01 2016-06-30 0000919956 2017-04-01 2017-06-30 0000919956 2016-01-01 2016-06-30 0000919956 2015-12-31 0000919956 2016-06-30 0000919956 us-gaap:MaximumMember 2017-06-30 0000919956 us-gaap:MinimumMember 2017-06-30 0000919956 2016-10-01 2016-12-31 0000919956 avca:UnnamedPharmacyJointVentureMember 2016-10-01 2016-12-31 0000919956 us-gaap:AccountingStandardsUpdate201517Member 2017-01-01 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-06-30 0000919956 us-gaap:LineOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2016-12-31 0000919956 us-gaap:LineOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-12-28 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2017-06-30 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2017-06-30 0000919956 us-gaap:InterestRateSwapMember 2017-06-30 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-12-29 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember 2017-06-30 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-12-29 2016-12-29 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember avca:MortgageTermLoanMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember us-gaap:ScenarioForecastMember 2017-08-01 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2016-10-03 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember avca:OmegaHealthcareInvestorsIncMember 2017-06-30 0000919956 avca:AmendedandRestatedCreditAgreementMember 2017-06-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember us-gaap:InterestRateSwapMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 avca:TrialOrArbitrationScheduleTimeframeMember 2017-06-30 0000919956 avca:PrefundedDeductiblePolicyMember 2017-06-30 0000919956 avca:UnaffiliatedEntitiesMember us-gaap:ProfessionalMalpracticeLiabilityMember 2017-01-01 2017-06-30 0000919956 us-gaap:ProfessionalMalpracticeLiabilityMember 2017-06-30 0000919956 avca:SHCRiskCarriersIncMember us-gaap:ProfessionalMalpracticeLiabilityMember 2017-01-01 2017-06-30 0000919956 avca:PotentialViolationsofFalseClaimsActMember us-gaap:UnfavorableRegulatoryActionMember 2014-10-31 0000919956 avca:PrefundedDeductiblePolicyMember 2017-01-01 2017-06-30 0000919956 avca:UnaffiliatedEntitiesMember us-gaap:ProfessionalMalpracticeLiabilityMember 2017-06-30 0000919956 avca:PotentialViolationsofFalseClaimsActMember us-gaap:UnfavorableRegulatoryActionMember 2017-06-30 0000919956 us-gaap:EmployeeStockMember 2017-01-01 2017-06-30 0000919956 us-gaap:EmployeeStockMember 2017-06-30 0000919956 us-gaap:EmployeeStockMember 2016-12-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2017-01-01 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2016-12-31 0000919956 us-gaap:RestrictedStockMember 2016-01-01 2016-06-30 0000919956 avca:TwoThousandAndFiveLongTermIncentivePlanMember 2017-06-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2017-01-01 2017-06-30 0000919956 avca:TwoThousandAndTenLongTermIncentivePlanMember 2017-06-30 0000919956 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2016-06-30 0000919956 avca:TwoThousandAndTenLongTermIncentivePlanMember 2017-05-31 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2016-06-29 0000919956 avca:TwoThousandAndFiveLongTermIncentivePlanMember 2017-01-01 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2017-01-01 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2017-01-01 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-01-01 2017-06-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2016-01-01 2016-12-31 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-01-01 2017-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-06-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-06-30 0000919956 avca:ClintonPlaceMember avca:ClintonKentuckyMember 2016-02-26 0000919956 avca:DiversicareofHutchinsonMember avca:HutchinsonKansasMember 2016-02-26 0000919956 avca:ClintonPlaceMember avca:ClintonKentuckyMember 2016-02-26 2016-02-26 0000919956 avca:DiversicareofHutchinsonMember avca:HutchinsonKansasMember 2016-02-26 2016-02-26 0000919956 avca:GoldenLivingMember avca:RiverchaseALMember 2016-11-01 0000919956 avca:GoldenLivingMember avca:EasonBlvdMember 2016-10-01 0000919956 avca:SelmaALMember us-gaap:SubsequentEventMember 2017-07-01 0000919956 avca:GoldenLivingMember avca:WinfieldALMember 2016-11-01 0000919956 avca:LeakeCountyNursingHomeMember 2016-10-01 0000919956 avca:GoldenLivingMember avca:HueytownALMember 2016-11-01 0000919956 avca:GoldenLivingMember avca:FoleyALMember 2016-11-01 0000919956 avca:GoldenLivingMember avca:TylertownMSMember 2016-10-01 0000919956 avca:GoldenLivingMember us-gaap:PropertySubjectToOperatingLeaseMember 2016-10-01 0000919956 avca:BroadmoorManorMember 2016-10-01 0000919956 avca:GoldenLivingMember avca:AmendedLeaseMember 2016-11-01 2016-11-01 0000919956 avca:GoldenLivingMember avca:BoazALMember 2016-11-01 0000919956 avca:GoldenLivingMember avca:BrookManorMississippiMember 2016-10-01 0000919956 avca:GoldenLivingMember avca:BatesvilleMississippiMember 2016-10-01 0000919956 avca:GoldenLivingMember avca:RipleyMSMember 2016-10-01 0000919956 avca:GoldenLivingMember avca:MeadowoodALMember 2016-11-01 0000919956 avca:GoldenLivingMember avca:LanettMSMember 2016-11-01 0000919956 avca:GoldenLivingMember avca:ArmoryMississippiMember 2016-10-01 0000919956 avca:GoldenLivingMember avca:OneontaALMember 2016-11-01 0000919956 avca:SelmaALMember us-gaap:SubsequentEventMember 2017-07-01 2017-07-01 0000919956 avca:GoldenLivingMember 2016-08-15 0000919956 avca:GoldenLivingMember avca:TylertownMSMember 2016-10-01 2016-10-01 0000919956 avca:GoldenLivingMember avca:MontgomeryALMember 2016-11-01 0000919956 avca:AvonOhioLLCMember 2016-05-31 2016-05-31 0000919956 avca:GoldenLivingMember us-gaap:PropertySubjectToOperatingLeaseMember 2016-11-01 0000919956 avca:LeakeCountyNursingHomeMember 2016-10-01 2016-10-01 0000919956 avca:GoldenLivingMember avca:PellCityALMember 2016-11-01 0000919956 avca:GoldenLivingMember avca:SouthavenMSMember 2016-10-01 0000919956 avca:GoldenLivingMember avca:AmendedLeaseMember 2016-11-01 0000919956 avca:GoldenLivingMember avca:EuporaMississippiMember 2016-10-01 0000919956 avca:GoldenLivingMember avca:OxfordALMember 2016-11-01 0000919956 avca:AvonOhioLLCMember 2016-04-01 2016-06-30 0000919956 avca:GoldenLivingMember avca:ArabALMember 2016-11-01 0000919956 avca:BroadmoorManorMember 2016-10-01 2016-10-01 iso4217:USD avca:state avca:lawsuit avca:facility avca:option xbrli:pure avca:center iso4217:USD xbrli:shares avca:bed avca:letter_of_credit xbrli:shares avca:policy avca:investment 7075000 6883000 8000000 17 0 600000 175000 -1958000 0 61000 0 300000 0.03 P25Y 7500000 6 2 3000000 1000000 3000000 1542000 4338000 2 24000 8453 88 85 87 100 154 50 85 180 138 120 173 94 132 123 120 152 130 58 120 119 140 140 60 99 103 76 22 59 17 74 17 7 1 11 496 320 48 0.02 0.02 -96000 -94000 1093000 304000 24675000 540000 300000 780000 0 630000 6.55 11.29 0 630000 231000 214000 6.97 6.64 10.63 5.55 11.10 9.47 9.58 9.93 209000 17000 0.00 0.00 P10Y 209000 41000 168000 214000 46000 168000 0 9.85 9.85 0 0 0 P2Y 1628000 false --12-31 Q2 2017 2017-06-30 10-Q 0000919956 6458836 Smaller Reporting Company Diversicare Healthcare Services, Inc. 28985000 30000000 12972000 10859000 62152000 64633000 3114000 2508000 69022000 73790000 195000 362000 -38000 21935000 22270000 486000 504000 10326000 12066000 62000 46000 163051000 173080000 71690000 82216000 31561000 30852000 28000 42000 34000 43000 3334000 4293000 2898000 3443000 169000 485000 267000 365000 3334000 4293000 0 7000 4585000 3061000 4263000 3900000 -1524000 -363000 0 0 0 0 -2879000 -329000 700000 680000 380000 0.055 0.11 0.055 0.11 0.01 0.01 20000000 20000000 6592000 6691000 6361000 6459000 66000 67000 -2088000 -2032000 383000 1853000 78385000 157003000 113166000 223833000 98122000 194795000 140494000 279034000 0.0475 0.04 0.04 0.060 0.053 0.0579 P5Y P5Y 193000 167000 2162000 21185000 20757000 7644000 -1689000 403000 -7644000 2060000 4063000 2620000 5107000 62000 0 -21000 18000 27000 -0.35 -0.37 0.06 0.27 -0.35 -0.37 0.06 0.26 20108000 18857000 0 1366000 733000 0 8673000 -2008000 -2008000 0 0 -351000 0 6881000 13615000 8221000 17194000 95805000 193750000 142550000 284050000 -2150000 -2224000 381000 1729000 -3447000 -3563000 515000 2725000 -0.35 -0.36 0.06 0.28 -0.35 -0.36 0.06 0.27 0 -37000 -28000 -43000 0.00 -0.01 0.00 -0.01 0.00 -0.01 0.00 -0.01 28000 61000 0 0 -1297000 -1339000 134000 996000 332000 625000 431000 490000 1688000 -2647000 384000 -620000 710000 7313000 -1658000 0 1595000 -309000 1158000 2228000 1541000 3024000 1904000 2563000 P5Y P10Y P10Y P10Y P2Y 13408000 163051000 173080000 58169000 58532000 93462000 101655000 427000 440000 1272000 842000 40751000 100000000 72500000 12500000 60000000 27500000 10000000 15000000 52250000 42250000 67970000 2500000 65470000 15000000 24500000 72145000 81449000 7715000 10373000 0.0579 5000000 500000 1000000 500000 19384000 1934000 4000000 2724000 5394000 1753000 10569000 1753000 10569000 -8397000 -12694000 -8397000 -12694000 5120000 1762000 7999000 2091000 -2150000 -2261000 353000 1686000 -2150000 -2261000 353000 1686000 -1130000 -2518000 -1541000 -2291000 12 8 10 -2317000 -1045000 2056000 5016000 6854000 14106000 13763000 27506000 3108000 3045000 62000 229000 30000 167000 119000 263000 116000 233000 181000 492000 146000 400000 4432000 5299000 9551000 8789000 -358000 -247000 683000 692000 1795000 226000 317000 327000 3300000 4250000 0 8673000 8750000 10055000 5121000 3623000 2959000 71066000 26074000 0 1100000 128822000 133802000 59800000 60012000 3661000 4187000 1193000 1519000 66422000 14166000 2008000 -8276000 -7306000 9401000 10196000 11766000 11417000 486000 504000 0 0 0.00 0.00 83000 26000 88000 88000 9.98 9.98 54000 153000 44000 169000 1000 2000 37000 74000 12.11 9.03 350000 150000 10.21 2.37 10.88 6.21 0.33 0.33 0.33 0.33 0.33 0.33 P10Y 0.85 11420000 12893000 232000 232000 2500000 2500000 6211000 6185000 6472000 6458000 6211000 6185000 6294000 6263000 957000 351000 0 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">LONG-TERM DEBT AND INTEREST RATE SWAP</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company&#8217;s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increases the Company's borrowing capacity to </font><font style="font-family:inherit;font-size:10pt;">$100,000,000</font><font style="font-family:inherit;font-size:10pt;"> allocated between a </font><font style="font-family:inherit;font-size:10pt;">$72,500,000</font><font style="font-family:inherit;font-size:10pt;"> Mortgage Loan ("Amended Mortgage Loan") and a </font><font style="font-family:inherit;font-size:10pt;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;"> Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a </font><font style="font-family:inherit;font-size:10pt;">$60,000,000</font><font style="font-family:inherit;font-size:10pt;"> term loan facility and a </font><font style="font-family:inherit;font-size:10pt;">$12,500,000</font><font style="font-family:inherit;font-size:10pt;"> acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of </font><font style="font-family:inherit;font-size:10pt;">$2,162,000</font><font style="font-family:inherit;font-size:10pt;"> and are being amortized over the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of </font><font style="font-family:inherit;font-size:10pt;">$72,500,000</font><font style="font-family:inherit;font-size:10pt;"> with a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year maturity through February 26, 2021, and a </font><font style="font-family:inherit;font-size:10pt;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;"> Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, with principal and interest payable monthly based on a </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;">-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4.75%</font><font style="font-family:inherit;font-size:10pt;">, respectively. A portion of the Amended Mortgage Loan is effectively fixed at </font><font style="font-family:inherit;font-size:10pt;">5.79%</font><font style="font-family:inherit;font-size:10pt;"> pursuant to an interest rate swap with an initial notional amount of </font><font style="font-family:inherit;font-size:10pt;">$30,000,000</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan balance was </font><font style="font-family:inherit;font-size:10pt;">$67,970,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;">$65,470,000</font><font style="font-family:inherit;font-size:10pt;"> on the term loan facility with an interest rate of </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,500,000</font><font style="font-family:inherit;font-size:10pt;"> on the acquisition loan facility with an interest rate of </font><font style="font-family:inherit;font-size:10pt;">6.0%</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan is secured by </font><font style="font-family:inherit;font-size:10pt;">seventeen</font><font style="font-family:inherit;font-size:10pt;"> owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company&#8217;s Amended Revolver has an interest rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the&#160;</font><font style="font-family:inherit;font-size:10pt;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;">&#160;in the Amended Revolver to&#160;</font><font style="font-family:inherit;font-size:10pt;">$52,250,000</font><font style="font-family:inherit;font-size:10pt;">; provided that the maximum revolving facility be reduced to </font><font style="font-family:inherit;font-size:10pt;">$42,250,000</font><font style="font-family:inherit;font-size:10pt;"> on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at </font><font style="font-family:inherit;font-size:10pt;">$52,250,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modifies the terms of the Amended Mortgage Loan Agreement by increasing the Company&#8217;s letter of credit sublimit from&#160;</font><font style="font-family:inherit;font-size:10pt;">$10,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;to&#160;</font><font style="font-family:inherit;font-size:10pt;">$15,000,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective June 30, 2017, the Company entered into a Second Amendment to the Second Amended (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amends the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by </font><font style="font-family:inherit;font-size:10pt;">$7,500,000</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$24,500,000</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the Amended Revolver compared to </font><font style="font-family:inherit;font-size:10pt;">$15,000,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). Annual fees for letters of credit issued under the Amended Revolver are </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the amount outstanding. The Company has </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> letters of credit with a total value of </font><font style="font-family:inherit;font-size:10pt;">$13,408,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of </font><font style="font-family:inherit;font-size:10pt;">$40,751,000</font><font style="font-family:inherit;font-size:10pt;">, the balance available for borrowing under the Amended Revolver was </font><font style="font-family:inherit;font-size:10pt;">$842,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Swap Transaction</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was </font><font style="font-family:inherit;font-size:10pt;">$28,985,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of </font><font style="font-family:inherit;font-size:10pt;">5.79%</font><font style="font-family:inherit;font-size:10pt;"> while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net liability of </font><font style="font-family:inherit;font-size:10pt;">$62,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the interest rate swap is included in &#8220;other noncurrent liabilities&#8221; on the Company&#8217;s interim consolidated balance sheet. The liability related to the change in the interest rate swap included in accumulated other comprehensive income at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$38,000</font><font style="font-family:inherit;font-size:10pt;">, net of the income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$24,000</font><font style="font-family:inherit;font-size:10pt;">. As the Company&#8217;s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the six month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a </font><font style="font-family:inherit;font-size:10pt;">103</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$8,750,000</font><font style="font-family:inherit;font-size:10pt;">. In connection with the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by </font><font style="font-family:inherit;font-size:10pt;">$7,500,000</font><font style="font-family:inherit;font-size:10pt;">, which is described in Note 4 to the interim consolidated financial statements herein. The acquisition transaction closed subsequent to June 30, 2017, on July 1, 2017. Therefore, at June 30, 2017, the Company maintained the funds in escrow to finance the acquisition, which are presented in the Company's interim consolidated balance sheet. Refer to to Note 10 to the interim consolidated financial statements for further discussion on this acquisition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Golden Living Transaction</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 15, 2016, the Company entered into an Operation Transfer Agreement with Golden Living (the "Lessor") to assume the operations of&#160;</font><font style="font-family:inherit;font-size:10pt;">22</font><font style="font-family:inherit;font-size:10pt;">&#160;centers in Alabama and Mississippi.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2016, the Company entered into a Master Lease Agreement (the "Lease") with Golden Living to directly lease&#160;</font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;">&#160;centers located in Mississippi from the Lessor, which include: (i) a&#160;</font><font style="font-family:inherit;font-size:10pt;">152</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Amory; (ii) a&#160;</font><font style="font-family:inherit;font-size:10pt;">130</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Batesville; (iii) a&#160;</font><font style="font-family:inherit;font-size:10pt;">58</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Brook Manor; (iv) a&#160;</font><font style="font-family:inherit;font-size:10pt;">119</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Eupora; (v) a&#160;</font><font style="font-family:inherit;font-size:10pt;">140</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Ripley; (vi) a&#160;</font><font style="font-family:inherit;font-size:10pt;">140</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Southaven; (vii) a&#160;</font><font style="font-family:inherit;font-size:10pt;">120</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Eason Blvd; (viii) a&#160;</font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Tylertown. The Lease is triple net and has an initial term of&#160;</font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">&#160;with two separate five year options to extend the term. The Company also assumed the individual leases of a&#160;</font><font style="font-family:inherit;font-size:10pt;">120</font><font style="font-family:inherit;font-size:10pt;">-bed center known as Broadmoor Nursing Home, with an initial lease term of&#160;</font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">&#160;with first year rent of&#160;</font><font style="font-family:inherit;font-size:10pt;">$540,000</font><font style="font-family:inherit;font-size:10pt;">, escalating to&#160;</font><font style="font-family:inherit;font-size:10pt;">$780,000</font><font style="font-family:inherit;font-size:10pt;">&#160;in the second year, and&#160;</font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">&#160;annually thereafter, and a&#160;</font><font style="font-family:inherit;font-size:10pt;">99</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Leake County Nursing Home, with a lease term of&#160;</font><font style="font-family:inherit;font-size:10pt;">two years</font><font style="font-family:inherit;font-size:10pt;">&#160;with annual rent of&#160;</font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November, 1 2016, the Company amended and restated the Lease ("Amended Lease") with the Lessor to directly lease an additional&#160;</font><font style="font-family:inherit;font-size:10pt;">twelve</font><font style="font-family:inherit;font-size:10pt;">&#160;centers located in Alabama from the Lessor, which include: (i) a&#160;</font><font style="font-family:inherit;font-size:10pt;">87</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Arab; (ii) a&#160;</font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Meadowood; (iii) a&#160;</font><font style="font-family:inherit;font-size:10pt;">132</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Riverchase; (iv) a&#160;</font><font style="font-family:inherit;font-size:10pt;">100</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Boaz; (v) a&#160;</font><font style="font-family:inherit;font-size:10pt;">154</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Foley; (vi) a&#160;</font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Hueytown; (vii) a&#160;</font><font style="font-family:inherit;font-size:10pt;">85</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Lanett; (viii) a&#160;</font><font style="font-family:inherit;font-size:10pt;">138</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Montgomery; (ix) a&#160;</font><font style="font-family:inherit;font-size:10pt;">120</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Oneonta; (x) a&#160;</font><font style="font-family:inherit;font-size:10pt;">173</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Oxford; (xi) a&#160;</font><font style="font-family:inherit;font-size:10pt;">94</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Pell City; (xii) a&#160;</font><font style="font-family:inherit;font-size:10pt;">123</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center known as Golden Living Center - Winfield. The Amended Lease is triple net and has an initial term of&#160;</font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">&#160;with&#160;</font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#160;separate&#160;</font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;"> options to extend the term. Base rent for the amended lease is&#160;</font><font style="font-family:inherit;font-size:10pt;">$24,675,000</font><font style="font-family:inherit;font-size:10pt;">&#160;for the first year and escalates&#160;</font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">&#160;annually thereafter.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Acquisitions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 26, 2016, the Company exercised its purchase options to acquire the real estate assets for Diversicare of Hutchinson in Hutchinson, Kansas and Clinton Place in Clinton, Kentucky for </font><font style="font-family:inherit;font-size:10pt;">$4,250,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3,300,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company has operated these facilities since February 2015 and April 2012, respectively. Hutchinson is an </font><font style="font-family:inherit;font-size:10pt;">85</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility, and Clinton is an </font><font style="font-family:inherit;font-size:10pt;">88</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility. As a result of the consummation of the Agreements, the Company allocated the purchase price and acquisition costs between the assets acquired. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the assets acquired is as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hutchinson</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinton Place</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition Costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,293,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,443,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,898,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures and Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,293,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Lease Termination</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2016, the Company entered into an Agreement with Avon Ohio, LLC to amend the original lease agreement, thus terminating the Company's right of possession of the facility. As a result, the Company incurred lease termination costs of </font><font style="font-family:inherit;font-size:10pt;">$2,008,000</font><font style="font-family:inherit;font-size:10pt;"> in the second quarter of 2016. Under the amended agreement, the Company is required to pay </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> per year through the term of the original lease agreement, July 31, 2024. For accounting purposes, this transaction was not reported as a discontinued operation, which is in accordance with the modified authoritative guidance for reporting discontinued operations, effective January 1, 2015. A disposal is now required to be reported in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Sale of Investment in Unconsolidated Affiliate</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,366,000</font><font style="font-family:inherit;font-size:10pt;">&#160;gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of </font><font style="font-family:inherit;font-size:10pt;">$733,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;">-month period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, related to the final liquidation of remaining net assets affiliated with the partnership.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the profits and losses from this investment are reported as equity in earnings of investment in an unconsolidated affiliate and the proceeds received from the sale are reported under the heading "Gain on sale of investment in unconsolidated affiliate" in the accompanying interim consolidated statements of operations. The sale resulted in a&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,366,000</font><font style="font-family:inherit;font-size:10pt;">&#160;gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of </font><font style="font-family:inherit;font-size:10pt;">$733,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;">-month period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, related to the liquidation of remaining assets affiliated with the partnership. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the six month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the profits and losses from this investment are reported as equity in earnings of investment in an unconsolidated affiliate and the proceeds received from the sale are reported under the heading "Gain on sale of investment in unconsolidated affiliate" in the accompanying interim consolidated statements of operations. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview of Plans</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (&#8220;2005 Plan&#8221;). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, </font><font style="font-family:inherit;font-size:10pt;">700,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. This plan has expired and no new grants may be made under the 2005 Plan. All grants under this plan expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the date the grants were authorized by the Board of Directors.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (&#8220;Stock Purchase Plan&#8221;). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers . The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (&#8220;RSU's&#8221;) at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">350,000</font><font style="font-family:inherit;font-size:10pt;"> shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (&#8220;2010 Plan&#8221;), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from </font><font style="font-family:inherit;font-size:10pt;">380,000</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">680,000</font><font style="font-family:inherit;font-size:10pt;"> shares. No grants can be made under the Long-Term Incentive Plan after May 31, 2027.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Grants and Valuations</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors approved grants totaling approximately </font><font style="font-family:inherit;font-size:10pt;">88,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">83,000</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (&#8220;SOSARs&#8221;) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date, and expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the grant date. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:240px;" rowspan="1" colspan="1"></td><td style="width:108px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:99px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:240px;" rowspan="1" colspan="1"></td><td style="width:108px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:99px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> SOSARs or Options were granted during </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, previously granted SOSARs and Options remain outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.28125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$10.21 to $10.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.55</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$504,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$486,000</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:240px;" rowspan="1" colspan="1"></td><td style="width:108px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:99px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EARNINGS (LOSS) PER COMMON SHARE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effects of </font><font style="font-family:inherit;font-size:10pt;">46,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">62,000</font><font style="font-family:inherit;font-size:10pt;"> SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, because these securities would have been anti-dilutive.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EQUITY METHOD INVESTMENT</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the net profits and losses of the unconsolidated affiliate are reported as equity in net earnings or losses of unconsolidated affiliate in our statement of operations. For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;">-month period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the equity in the net income of an unconsolidated affiliate was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> compared to </font><font style="font-family:inherit;font-size:10pt;">$61,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;">-month period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The proceeds received from the sale are considered in the calculation of the gain on sale of investment in unconsolidated affiliate in our statement of operations. For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;">-month period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the gain on the sale of investment in unconsolidated affiliate was </font><font style="font-family:inherit;font-size:10pt;">$733,000</font><font style="font-family:inherit;font-size:10pt;">, related to the liquidation of remaining assets affiliated with the partnership.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional Liability and Other Liability Insurance</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (&#8220;SHC&#8221;), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, and Texas. The SHC policy provides coverage limits of either </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> per medical incident with a sublimit per center of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> and total annual aggregate policy limits of </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;">. The remaining nursing centers are covered by one of </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> per claim and have sublimits of </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;"> per center, with varying self-insured retention levels per claim and varying aggregate policy limits.&#160; </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reserve for Estimated Self-Insured Professional Liability Claims</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company&#8217;s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company&#8217;s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of </font><font style="font-family:inherit;font-size:10pt;">$19,384,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos &amp; Associates, Inc. (&#8220;Merlinos&#8221;) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company&#8217;s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator&#8217;s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company&#8217;s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company is engaged in </font><font style="font-family:inherit;font-size:10pt;">74</font><font style="font-family:inherit;font-size:10pt;"> professional liability lawsuits. </font><font style="font-family:inherit;font-size:10pt;">Seventeen</font><font style="font-family:inherit;font-size:10pt;"> lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company&#8217;s cash expenditures for self-insured professional liability costs from continuing operations were </font><font style="font-family:inherit;font-size:10pt;">$4,338,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,542,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company&#8217;s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company&#8217;s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company&#8217;s reported earnings and financial position for the period in which the change in accrual is made.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Civil Investigative Demand ("CID") </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee (DOJ) had commenced a civil investigation of potential violations of the False Claims Act (FCA).</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of its centers. In response to civil investigative demands (&#8220;CIDs&#8221;) and informal requests, the Company has provided to the DOJ documents and information relating to the Company&#8217;s practices and policies for rehabilitation and other services, relating to the preadmission evaluation forms ("PAEs") required by TennCare, and relating to the Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. The DOJ has also issued CID&#8217;s for testimony from current and former employees of the Company. The DOJ&#8217;s civil investigation has been focused on </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> of our centers, but the DOJ has indicated that all of the Company&#8217;s centers are the subject of the investigation related to rehabilitation therapy.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs. The Company has responded to this subpoena and provided additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Insurance</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to workers&#8217; compensation insurance, substantially all of the Company&#8217;s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers&#8217; compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers&#8217; compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June&#160;30, 2003 until June&#160;30, 2007, the Company&#8217;s workers&#8217; compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely self-insured for workers' compensation exposure. From July&#160;1, 2008 through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> per claim, subject to an aggregate maximum of </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;">. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers&#8217; compensation claims is </font><font style="font-family:inherit;font-size:10pt;">$957,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The Company has a non-current receivable for workers&#8217; compensation policies covering previous years of </font><font style="font-family:inherit;font-size:10pt;">$1,628,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The non-current receivable is a function of payments paid to the Company&#8217;s insurance carrier in excess of the estimated level of claims expected to be incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to </font><font style="font-family:inherit;font-size:10pt;">$175,000</font><font style="font-family:inherit;font-size:10pt;"> per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is </font><font style="font-family:inherit;font-size:10pt;">$1,272,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The differences between actual settlements and reserves are included in expense in the period finalized.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diversicare Healthcare Services, Inc. (together with its subsidiaries, &#8220;Diversicare&#8221; or the &#8220;Company&#8221;) provides long-term care services to nursing center patients in </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> states, primarily in the Southeast, Midwest, and Southwest. The Company&#8217;s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company&#8217;s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s continuing operations consist of </font><font style="font-family:inherit;font-size:10pt;">76</font><font style="font-family:inherit;font-size:10pt;"> nursing centers with </font><font style="font-family:inherit;font-size:10pt;">8,453</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The Company owns </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;"> and leases </font><font style="font-family:inherit;font-size:10pt;">59</font><font style="font-family:inherit;font-size:10pt;"> of its nursing centers. Our nursing centers range in size from </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">320</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The licensed nursing bed count does not include </font><font style="font-family:inherit;font-size:10pt;">496</font><font style="font-family:inherit;font-size:10pt;"> licensed assisted and residential living beds.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">RECENT ACCOUNTING GUIDANCE</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.&#160;2014-09,&#160;Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. The ASU will be effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016. The Company will adopt the requirements of this standard effective January 1, 2018. The new standard may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). The Company plans to elect to apply the modified retrospective approach upon adoption. Additionally, the new guidance requires enhanced disclosures, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The Company is developing a plan for adoption and determining the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operation and cash flows. The Company is in the process of reviewing revenue sources and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectibility, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. We expect to complete this process in 2017. The Company is also in the process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration, including settlements with government payors, state Medicaid programs and bundled payment of care programs. Due to the many forms of calculation and reimbursement that these programs take that vary from state to state, the application of the new standard could have an impact on the revenue recognized for variable consideration. Industry guidance is continuing to develop, and any conclusions in the final industry guidance that is inconsistent with the Company's application could result in changes to the Company's expectations regarding the impact of the new standard on the Company's financial statements. Additionally, the adoption of the new standard will impact the presentation on the Company's statement of operations. After the adoption, the majority of what is currently classified as bad debt expense will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenues. The ASU will have a material impact on the amounts presented in certain categories on our consolidated statement of operations, but we do not expect it to have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17,&#160;Balance Sheet Classification of Deferred Taxes, which changes how deferred taxes are classified on the Company's balance sheets. The Company adopted ASU No. 2015-17 as of January 1, 2017, and the new standard was applied on a retrospective basis. The adoption of this guidance resulted in a </font><font style="font-family:inherit;font-size:10pt;">$7,644,000</font><font style="font-family:inherit;font-size:10pt;"> reclassification between current deferred income taxes and non-current deferred income taxes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for building and equipment operating leases and will result in a significant increase in the assets and liabilities on the consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for shared-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15,&#160;Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which will require the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this standard will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017. The Company plans to adopt this standard on January 1, 2018, and is currently evaluating the impact this standard will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017, with early adoption permitted in certain circumstances.&#160;&#160;The Company is still evaluating the effect, if any, the standard will have on the Company&#8217;s consolidated financial condition and results of operations.&#160;&#160;The Company does not expect the adoption of this standard to have a material impact on its consolidated financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#160;The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. Early adoption is permitted. The Company does not presently believe adoption of this new standard will be material to its consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.&#160;2014-09,&#160;Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. The ASU will be effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016. The Company will adopt the requirements of this standard effective January 1, 2018. The new standard may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). The Company plans to elect to apply the modified retrospective approach upon adoption. Additionally, the new guidance requires enhanced disclosures, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The Company is developing a plan for adoption and determining the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operation and cash flows. The Company is in the process of reviewing revenue sources and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectibility, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. We expect to complete this process in 2017. The Company is also in the process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration, including settlements with government payors, state Medicaid programs and bundled payment of care programs. Due to the many forms of calculation and reimbursement that these programs take that vary from state to state, the application of the new standard could have an impact on the revenue recognized for variable consideration. Industry guidance is continuing to develop, and any conclusions in the final industry guidance that is inconsistent with the Company's application could result in changes to the Company's expectations regarding the impact of the new standard on the Company's financial statements. Additionally, the adoption of the new standard will impact the presentation on the Company's statement of operations. After the adoption, the majority of what is currently classified as bad debt expense will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenues. The ASU will have a material impact on the amounts presented in certain categories on our consolidated statement of operations, but we do not expect it to have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17,&#160;Balance Sheet Classification of Deferred Taxes, which changes how deferred taxes are classified on the Company's balance sheets. The Company adopted ASU No. 2015-17 as of January 1, 2017, and the new standard was applied on a retrospective basis. The adoption of this guidance resulted in a </font><font style="font-family:inherit;font-size:10pt;">$7,644,000</font><font style="font-family:inherit;font-size:10pt;"> reclassification between current deferred income taxes and non-current deferred income taxes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for building and equipment operating leases and will result in a significant increase in the assets and liabilities on the consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for shared-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15,&#160;Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which will require the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this standard will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017. The Company plans to adopt this standard on January 1, 2018, and is currently evaluating the impact this standard will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017, with early adoption permitted in certain circumstances.&#160;&#160;The Company is still evaluating the effect, if any, the standard will have on the Company&#8217;s consolidated financial condition and results of operations.&#160;&#160;The Company does not expect the adoption of this standard to have a material impact on its consolidated financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#160;The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. Early adoption is permitted. The Company does not presently believe adoption of this new standard will be material to its consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allocation for the assets acquired is as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hutchinson</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinton Place</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition Costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,293,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,443,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,898,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures and Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,293,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.28125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$10.21 to $10.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.55</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:240px;" rowspan="1" colspan="1"></td><td style="width:108px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:99px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 1, 2017 the Company acquired a </font><font style="font-family:inherit;font-size:10pt;">103</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Selma, Alabama, including certain land, improvements, furniture, fixtures and equipment, personal property and intangible property from Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$8,750,000</font><font style="font-family:inherit;font-size:10pt;">. This facility is expected to contribute in excess of </font><font style="font-family:inherit;font-size:10pt;">$8,000,000</font><font style="font-family:inherit;font-size:10pt;"> in annual revenues.</font></div></div> EX-101.SCH 8 avca-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Business Developments and Other Significant Transactions link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Business Developments and Other Significant Transactions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Business Developments and Other Significant Transactions (Schedule of Assets Acquired) (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Business Developments and Other Significant Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Business (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Consolidated and Basis of Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Consolidation and Basis of Presentation of Financial Statements link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Consolidation and Basis of Presentation of Financial Statements (Policies) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Earnings (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Earnings (Loss) Per Common Share (Basic and Diluted Net Income (Loss) Per Common Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Earnings (Loss) Per Common Share (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Earnings (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Equity Method Investment link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Equity Method Investment (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Interim Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Interim Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Interim Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Interim Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Interim Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Long-Term Debt and Interest Rate Swap link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Long-Term Debt and Interest Rate Swap (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Recent Accounting Guidance link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Recent Accounting Guidance (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Awards, Vested and Expected to Vest, Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Stock-Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Stock-Based Compensation (Schedule of Awards Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Subsequent Events Subsequent Events link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 avca-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 avca-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 avca-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Disclosure [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Forecast Scenario, Forecast [Member] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Omega Healthcare Investors Inc Omega Healthcare Investors Inc [Member] Omega Healthcare Investors Inc [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Mortgage term loan Mortgage Term Loan [Member] Mortgage Term Loan [Member] Acquisition loan facility Mortgage Revolving Credit Facility [Member] Mortgage Revolving Credit Facility [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Credit agreement Line of Credit [Member] Mortgage loan Mortgages [Member] Amended revolver Revolving Credit Facility [Member] Letter of credit Letter of Credit [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Amended and restated credit agreement Amended and Restated Credit Agreement [Member] Amended and Restated Credit Agreement [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Interest rate swap Interest Rate Swap [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instrument Designated as Hedging Instrument [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Loan acquisition costs Debt Issuance Costs, Gross Term of agreements Debt Instrument, Term Period of amortization Line of Credit Facility, Terms, Duration of Amortization Period for Principal and Interest Payments Line of Credit Facility, Terms, Duration of Amortization Period for Principal and Interest Payments Interest rate percentage Debt Instrument, Basis Spread on Variable Rate Debt interest rate at period end Debt Instrument, Interest Rate, Effective Percentage Notional amount of interest rate derivatives Derivative, Notional Amount Amended mortgage loan balance Loans Payable Number of owned nursing centers to secure Amended Mortgage Loan Debt Instrument, Collateral, Number Of Owned Nursing Centers Debt Instrument, Collateral, Number Of Owned Nursing Centers Increase to credit facility limit Line of Credit Facility, Terms, Maximum Increase in Capacity Line of Credit Facility, Terms, Maximum Increase in Capacity Borrowings outstanding Long-term Debt Annual fees for letters of credit issued under Revolver (as a percentage) Line of Credit Facility, Fee Percentage on Amount Outstanding Line of Credit Facility, Fee Percentage on Amount Outstanding Number of letters of credit Number of Letters of Credit Number of Letters of Credit Letters of credit security deposit for a lease Letters of Credit Outstanding, Amount Balance available for borrowing under revolving credit center Line of Credit Facility, Current Borrowing Capacity Annual fixed rate percentage Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Net liability based on interest rate swap valuation model Derivative Liability Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Income tax benefit, interest rate swap Net Income Tax Benefit Net income tax benefit. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Summarized activity of equity compensation plans Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of summarized activity of Restricted Share Units Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of summarized information regarding stock options and SOSAR grants outstanding Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Earnings Per Share [Abstract] Antidilutive shares excluded from computation of diluted earnings per share (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Financial Position [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Receivables, less allowance for doubtful accounts of $12,066 and $10,326, respectively Accounts Receivable, Net, Current Other receivables Receivables, Net, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Deposit in escrow Escrow Deposit Income tax refundable Income Taxes Receivable, Current Current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current PROPERTY AND EQUIPMENT, at cost Property, Plant and Equipment, Gross Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Assets, Noncurrent [Abstract] Deferred income taxes, net Deferred Income Tax Assets, Net Deferred lease and other costs, net Deferred Costs Acquired leasehold interest, net Acquired Leasehold Interest, Net Noncurrent Acquired leasehold interest, net. Other noncurrent assets Other Assets, Noncurrent Total other assets Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment Total assets Assets CURRENT LIABILITIES: Liabilities, Current [Abstract] Current portion of long-term debt and capitalized lease obligations Long-term Debt and Capital Lease Obligations, Current Trade accounts payable Accounts Payable, Trade, Current Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Accrued expenses: Accrued Liabilities, Current [Abstract] Payroll and employee benefits Employee-related Liabilities, Current Self-insurance reserves, current portion Self Insurance Reserve, Current Provider taxes Accrual for Taxes Other than Income Taxes, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net Long-term Debt and Capital Lease Obligations Self-insurance reserves, less current portion Self Insurance Reserve, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Total noncurrent liabilities Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES Commitments and Contingencies SHAREHOLDERS’ EQUITY: Stockholders' Equity Attributable to Parent [Abstract] Common stock, authorized 20,000,000 shares, $.01 par value, 6,691,000 and 6,592,000 shares issued, and 6,459,000 and 6,361,000 shares outstanding, respectively Common Stock, Value, Issued Treasury stock at cost, 232,000 shares of common stock Treasury Stock, Value Paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income Total shareholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and shareholder's equity Liabilities and Equity Organization, Consolidation and Presentation of Financial Statements [Abstract] CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] Per common share – basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Net income (loss) Income Amounts Attributable to Parent, Disclosures [Abstract] Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Loss from discontinued operations, net of income taxes Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Per common share – basic Earnings Per Share, Basic [Abstract] Income (loss) from continuing operations (dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Loss from discontinued operations (dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net income (loss) per common share – basic (dollars per share) Earnings Per Share, Basic Per common share – diluted Earnings Per Share, Diluted [Abstract] Income (loss) from continuing operations (dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Loss from discontinued operations (dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net income (loss) per common share – diluted (dollars per share) Earnings Per Share, Diluted Weighted Average Common Shares Outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Basic and diluted net income (loss) per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Unnamed pharmacy joint venture Unnamed Pharmacy Joint Venture [Member] Unnamed Pharmacy Joint Venture [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Number of equity method investments sold Number of Equity Method Investments Sold Number of Equity Method Investments Sold Gain on sale of investment in unconsolidated affiliate Equity Method Investment, Realized Gain (Loss) on Disposal Equity Method Investments and Joint Ventures [Abstract] EQUITY METHOD INVESTMENT Equity Method Investments and Joint Ventures Disclosure [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Amended lease Amended Lease [Member] Amended Lease [Member] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Domain] Property Subject to or Available for Operating Lease [Domain] Property subject to operating lease Property Subject to Operating Lease [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Selma, AL Selma, AL [Member] Selma, AL [Member] Armory, MS Armory, Mississippi [Member] Armory, Mississippi [Member] Batesville, MS Batesville, Mississippi [Member] Batesville, Mississippi [Member] Brook Manor, MS Brook Manor, Mississippi [Member] Brook Manor, Mississippi [Member] Eupora, MS Eupora, Mississippi [Member] Eupora, Mississippi [Member] Ripley, MS Ripley, MS [Member] Ripley, MS [Member] Southaven, MS Southaven, MS [Member] Southaven, MS [Member] Eason Blvd Eason Blvd [Member] Eason Blvd [Member] Tylertown, MS Tylertown, MS [Member] Tylertown, MS [Member] Arab, AL Arab, AL [Member] Arab, AL [Member] Meadowood, AL Meadowood, AL [Member] Meadowood, AL [Member] Riverchase, AL Riverchase, AL [Member] Riverchase, AL [Member] Boaz, AL Boaz, AL [Member] Boaz, AL [Member] Foley, AL Foley, AL [Member] Foley, AL [Member] Hueytown, AL Hueytown, AL [Member] Hueytown, AL [Member] Lanett, MS Lanett, MS [Member] Lanett, MS [Member] Montgomery, AL Montgomery, AL [Member] Montgomery, AL [Member] Oneonta, AL Oneonta, AL [Member] Oneonta, AL [Member] Oxford, AL Oxford, AL [Member] Oxford, AL [Member] Pell City, AL Pell City, AL [Member] Pell City, AL [Member] Winfield, AL Winfield, AL [Member] Winfield, AL [Member] Hutchinson, Kansas Hutchinson, Kansas [Member] Hutchinson, Kansas [Member] Clinton, Kentucky Clinton, Kentucky [Member] Clinton, Kentucky [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Golden Living Golden Living [Member] Golden Living [Member] Broadmoor Manor Broadmoor Manor [Member] Broadmoor Manor [Member] Leake County Nursing Home Leake County Nursing Home [Member] Leake County Nursing Home [Member] Diversicare of Hutchinson Diversicare of Hutchinson [Member] Diversicare of Hutchinson [Member] Clinton Place Clinton Place [Member] Clinton Place [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Avon Ohio, LLC Avon Ohio, LLC [Member] Avon Ohio, LLC [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent event Subsequent Event [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Number of licensed nursing beds Number of Licensed Nursing Beds Number of licensed nursing beds. Payments to acquire nursing center Payments to Acquire Productive Assets Deposit in escrow Payments to Acquire Businesses, Gross Number of nursing centers Number Of Nursing Center Facilities Number Of Nursing Center Facilities Number of center locations Number of Real Estate Properties Term of contract Lessee Leasing Arrangements, Operating Leases, Term of Contract Rent expense, base year rent Rent Expense, Base Year Rent Rent Expense, Base Year Rent Rent expense, increase during year two Rent Expense, Increase During Year Two Rent Expense, Increase During Year Two Annual rent increase, percentage Operating Leases, Annual Rent, Annual Increase, Percentage Operating Leases, Annual Rent, Annual Increase, Percentage Maximum number of lease renewal periods Maximum Number Of Lease Renewal Periods Maximum Number Of Lease Renewal Periods Operating leases, renewal term Lessee Leasing Arrangements, Operating Leases, Renewal Term Lease termination costs Restructuring Charges Lease termination fees, future annual payment amounts Lease Termination Fees, Future Annual Payment Amounts Due Under Amendment Lease Termination Fees, Future Annual Payment Amount Due Under Amendment Income Statement [Abstract] PATIENT REVENUES, net Health Care Organization, Revenue Net of Patient Service Revenue Provisions EXPENSES: Costs and Expenses [Abstract] Operating Cost of Services Lease and rent expense Operating Leases, Rent Expense, Net Professional liability Malpractice Loss Contingency, Premium Costs General and administrative General and Administrative Expense Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Lease termination costs Gain (Loss) on Contract Termination Total expenses Costs and Expenses OPERATING INCOME (LOSS) Operating Income (Loss) OTHER INCOME (EXPENSE): Nonoperating Income (Expense) [Abstract] Equity in net income of unconsolidated affiliate Income (Loss) from Equity Method Investments Interest expense, net Interest Expense Debt retirement costs Write off of Deferred Debt Issuance Cost Total other expense Nonoperating Income (Expense) INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest BENEFIT (PROVISION) FOR INCOME TAXES Income Tax Expense (Benefit) INCOME (LOSS) FROM CONTINUING OPERATIONS LOSS FROM DISCONTINUED OPERATIONS: Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract] Operating loss, net of tax expense of ($18) and $0, respectively NET INCOME (LOSS) Net Income (Loss) Attributable to Parent NET INCOME (LOSS) PER COMMON SHARE: Per common share – basic, Continuing operations (dollars per share) Per common share – basic, Discontinued operations (dollars per share) Per common share – diluted, Continuing operations (dollars per share) Per common share – diluted, Discontinued operations (dollars per share) COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share) Common Stock, Dividends, Per Share, Declared WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Statement of Comprehensive Income [Abstract] NET INCOME (LOSS) OTHER COMPREHENSIVE INCOME: Other Comprehensive Income (Loss), Net of Tax [Abstract] Change in fair value of cash flow hedge, net of tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Less: reclassification adjustment for amounts recognized in net income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Accounting Policies [Line Items] Accounting Policies [Line Items] [Line Items] for Accounting Policies [Table] Number of states in which entity operates Number of States in which Entity Operates Number of nursing center facilities owned Number Of Nursing Center Facilities Owned Number Of Nursing Center Facilities Owned Number of nursing center facilities leased Number Of Nursing Center Facilities Leased Number Of Nursing Center Facilities Leased Number of licensed nursing beds per center Number of Licensed Nursing Beds per Nursing Center Number of Licensed Nursing Beds per Nursing Center Number of licensed assisted and residential living beds Number of Licensed Assisted Living Beds Number of Licensed Assisted Living Beds Purchase Price Acquisition Costs Business Combination, Acquisition Related Costs Consideration transferred Business Combination, Consideration Transferred Buildings Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Furniture, Fixtures, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Health Care Organizations [Abstract] COMMITMENTS AND CONTINGENCIES Malpractice Loss Contingency Disclosure [Text Block] STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Tax effect on operating income Discontinued Operation, Tax Effect of Discontinued Operation Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Options and Stock Appreciation Rights (SARs) Stock Options and Stock Appreciation Rights (SARs) [Member] Stock Options and Stock Appreciation Rights (SARs) [Member] Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $10.21 to $10.88 Stock Options Exercise Price Range One [Member] Stock Options Exercise Price Range One [Member] $2.37 to $6.21 Stock Options Exercise Price Range Two [Member] Stock Options Exercise Price Range Two [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Range of exercise prices, minimum (dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of exercise prices, maximum (dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Weighted average exercise prices (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Grants outstanding (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Intrinsic value - grants outstanding Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Grants exercisable (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Intrinsic value - grants exercisable Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value LONG-TERM DEBT AND INTEREST RATE SWAP Long Term Debt And Derivative Instruments [Text Block] Long Term Debt And Derivative Instruments [Text Block] BUSINESS Nature of Operations [Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Expected annual revenue of acquired Asset Acquisition, Expected Annual Revenue of Acquired Asset Acquisition, Expected Annual Revenue of Acquired Consolidation Consolidation, Policy [Policy Text Block] Basis of Accounting Basis of Accounting, Policy [Policy Text Block] Recent Accounting Guidance New Accounting Pronouncements, Policy [Policy Text Block] EARNINGS (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Accounting Policies [Abstract] RECENT ACCOUNTING GUIDANCE New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Schedule of Malpractice Insurance [Table] Schedule of Malpractice Insurance [Table] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months Scheduled for trial or arbitration over next 12 months Trial Or Arbitration Schedule Timeframe [Member] Trial Or Arbitration Schedule Timeframe [Member] SHC Risk Carriers, Inc SHC Risk Carriers, Inc [Member] SHC Risk Carriers, Inc [Member] Unaffiliated entities Unaffiliated Entities [Member] Unaffiliated Entities [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Professional malpractice liability insurance Professional Malpractice Liability Insurance [Member] Prefunded deductible policy Prefunded Deductible Policy [Member] Prefunded deductible policy. Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Unfavorable regulatory action Unfavorable Regulatory Action [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Potential violations of false claims act Potential Violations of False Claims Act [Member] Potential Violations of False Claims Act [Member] Malpractice Insurance [Line Items] Malpractice Insurance [Line Items] Insurance policy coverage limits per claim Malpractice Insurance, Maximum Coverage Per Incident Malpractice insurance annual sublimit per center Malpractice Insurance, Annual Sublimit Per Center Malpractice Insurance, Annual Sublimit Per Center Aggregate policy limit Malpractice Insurance, Annual Coverage Limit Number of types of professional liability insurance policies Number Of Types Of Professional Liability Insurance Policies Number Of Types Of Professional Liability Insurance Policies Liability for reported and estimated future claims Malpractice Loss Contingency, Accrual, Undiscounted Number of professional liability lawsuits Number Of Professional Liability Lawsuits Number Of Professional Liability Lawsuits Cash expenditures for self-insured professional liability costs Malpractice Insurance Self Insured Costs Paid During Period Malpractice Insurance Self Insured Costs Paid During Period Number of facilities Loss Contingency, Number of Facilities Loss Contingency, Number of Facilities Other Insurance Other Insurance Industry Disclosures [Abstract] Insurance policy coverage limits per claim Professional liability insurance, annual coverage limit per facility Malpractice Insurance Annual Coverage Limit Per Facility Malpractice Insurance Annual Coverage Limit Per Facility Liability for workers compensation claims Workers' Compensation Liability Workers compensation insurance, non current receivable for excess premiums paid Workers Compensation Receivable For Excess Premiums Paid Workers Compensation Receivable For Excess Premiums Paid Health insurance, maximum self-insured annual amount per individual Employee Health Insurance Maximum Payable Per Individual Annually Employee Health Insurance Maximum Payable Per Individual Annually Liability for reported claims and estimates for incurred but unreported claims Liability for Future Policy Benefits Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable, Current Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Treasury stock, shares (shares) Treasury Stock, Shares BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Business Combination Disclosure [Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2015-17 Accounting Standards Update 2015-17 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Reclassification of current deferred income tax assets Deferred Tax Assets, Net, Current Subsequent Events Subsequent Events [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, December 31, 2015 (shares) Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement By Share Based Payment Award, Exercises In Period Share-based Compensation Arrangement By Share Based Payment Award, Exercises In Period Expired or cancelled (shares) Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Outstanding, June 30, 2016 (shares) Exercisable (shares) Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, December 31, 2016 (dollars per share) Granted (dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Exercised (dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Expired or cancelled (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Outstanding, March 31, 2017 (dollars per share) Exercisable, weighted average exercise price (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Employee Stock Employee Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding, December 31, 2016 (share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Dividend equivalents (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding, March 31, 2017 (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Outstanding, December 31, 2016 (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Granted (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Dividend equivalents (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Vested (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cancelled (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Outstanding, March 31, 2017 (dollars per share) Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Discontinued operations Income (loss) from continuing operations Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Provision for doubtful accounts Provision for Doubtful Accounts Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit) Provision for self-insured professional liability, net of cash payments Increase (Decrease) in Self Insurance Reserve Stock-based compensation Share-based Compensation Equity in net income of unconsolidated affiliate, net of investment Income (Loss) from Equity Method Investments, Net of Contributions Paid Income (Loss) from Equity Method Investments, Net of Contributions Paid Gain on sale of unconsolidated affiliate Debt retirement costs Gain (Loss) on Extinguishment of Debt Provision for leases in excess of cash payments Provision For Leases In Excess Of Cash Payments Provision For Leases In Excess Of Cash Payments Lease termination costs, net of cash payments Gain (Loss) on Contract Termination, Net of Cash Payments Gain (Loss) on Contract Termination, Net of Cash Payments Deferred bonus Deferred Compensation, Bonus Deferred Compensation, Bonus Other Other Noncash Income (Expense) Changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] Receivables, net Increase (Decrease) in Receivables Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Trade accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash provided by continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of unconsolidated affiliate Proceeds from Sale of Equity Method Investments Change in restricted cash Increase (Decrease) in Restricted Cash Net cash used in continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of debt obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt and Capital Securities, Net Financing costs Payments of Financing Costs Issuance and redemption of employee equity awards Proceeds (Payments) for Issuance (Redemption) of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Proceeds (Payments) for Issuance (Redemption) of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payment of common stock dividends Payments of Ordinary Dividends, Common Stock Payment for preferred stock restructuring Payments of Stock Issuance Costs Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Financing Activities, Discontinued Operations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Cash payments of interest Interest Paid, Net Cash payments of income taxes Income Taxes Paid, Net SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Acquisition of equipment through capital lease Capital Lease Obligations Incurred Schedule of allocation for net assets acquired Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2005 Long Term Incentive Plan Two Thousand And Five Long Term Incentive Plan [Member] Two Thousand And Five Long Term Incentive Plan [Member] 2008 Stock Purchase Plan Two Thousand And Eight Stock Purchase Plan [Member] Two Thousand And Eight Stock Purchase Plan [Member] 2010 Long Term Incentive Plan Two Thousand And Ten Long Term Incentive Plan [Member] Two Thousand And Ten Long Term Incentive Plan [Member] Restricted Stock Restricted Stock [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] First anniversary of grant date Share-based Compensation Award, Tranche One [Member] Second anniversary of grant date Share-based Compensation Award, Tranche Two [Member] Third anniversary of grant date Share-based Compensation Award, Tranche Three [Member] Shares reserved for future issuance (shares) Common Stock, Capital Shares Reserved for Future Issuance Expiration period Share Based Compensation Arrangements By Share Based Payment Award Option Expiration Period Share Based Compensation Arrangements By Share Based Payment Award Option Expiration Period Percentage of quoted market price offering rate Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Restriction period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Shares authorized under the plan (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Grant of restricted common stock (shares) Vesting percentage of awards Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Payment award, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period SOSARs granted in period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options and SOSARs, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options and SOSARs, Grants in Period, Gross Share-based compensation expense Allocated Share-based Compensation Expense EX-101.PRE 12 avca-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 medicaidrateperdaygrapha06.jpg begin 644 medicaidrateperdaygrapha06.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# (! 0(! 0(" @(" @(" P4# P,# M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_ MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# S_P 1" $A >$# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]_**** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** /DO_@J]^Q+X>_;+^'GA_1)-'TE?&&I75U9 M:5K+6D?VVW>/2]0N88?.(WB%IXT+)N"GD]>:\=_X)=?M,7'[3_\ P3QT'X3Z ME([>,='U)O NNP3 K+#I<0:61W"_,@-BCVRN#] M4\/^*O"VB:7X8O3?S6>H^&Y]1N+R1H9[=PLR7T"QJ8;A\ Q.0X5B6&4/G'PO M_P"">.G_ #^/OQB^)G@;5]-T[Q5\5&MWMUU+1S>6.B,OS7'[J.>%YA/(3(< M21X.WD@'/L4<93^HSPM1[I2BM=)J5M=-I1D[Z[+O9'EXC#5)8B->DK-.S?>$ MHZ_.,DFKK?NCX2_X(V?%OP?^QG_P3;^-GQKU'POI>H:UX7\375A#/%!'#?7< M3Q6(ALA<[&=(6G=21RJY+;217TW\'_\ @IUXVT_1-4U[Q]X0U#5_!]OX ?QH MOB'1_ NN>'[&RNHHC+)I;/?ATN-Z%3%=1NB-C&SY@0[]FO\ X(X-\'/V6/B+ M\&?$_P 0+'Q=X%^(DTNH7#6OAM],U.QO6%N$ECF:\FC*1FW1@C0Y+&/V:U^$/Q"^)5CX[\#0^'9O#:1V?AG^R;^XMWC,2^?.UU=:JGS2?*H[K10L[76C4]>B>FK7,CGP>'Q%-PBH\L M>:;>W6::O9[.#:ZM:Z7Y6OA3XK_$?Q=^T5^TC^PO\6/&6E^ ['4/'WB1[BT& MA:=+!>6MFMU;&&VN9Y)9#<;5?>&'EJK2R 1C[Q]6^%/[;>F_LR_'+]N#QMXA M\*Z"USX!OM,\ZYTB2^@N/$DK-<06D:6:X1BC1HI*Q*&C M 5&S(=C1_P#@DG;ZMXU_:$N/&/C.V\0>'/V@_+>_TZRT-]/N='DAE:2VDAN& MNI58Q[\D-%AW53\JY1M*V.P'LI48R]VU1))26CK0E&.JWY(O?3FLV[ZF%'"8 MJ\:E1>]>ES-VWC&:D_2\E;9VNDDM#KOV)K/5?#.;.XL]1D7S/[+,4UW,UR2C+MG58D)Z@9P/'/A/\ \%7/'&J_M7_" M/P3XLT7PUIL?Q76_6]\+'3[C3_$_@&:,EK:.^$MR_FK+& RLUO;&1&$BH -I M]Y_9Q_91^)'P8^!EG\/=:^+T&NZ/HNA2Z)I-[IWAC^R]3@!C,<,LTS74XD," M%0GEI"L=)+DVUV=IZ;7;NDN6WG7AW]O"/]E#XK?MP>-K[PCX;FUKP7J> MDVT=SIS:A$_B"XE>XMK3[2D]U/%&(QY88P)$" _&2H6IX"M/$US_ ,%R?@?K MWC*U\$P^)O%GPVEUC4)O#6F26$,\DEM>#$JR2RO))&%$7FF0[TC3Y4 VCVO6 M?^".,?CO6_VA6\4>/;74M*^/DD-W);6?AY[2?0;JVF:6TECE:[D$JH6.]61? M,(&#&,@]3\+/^":&N:%^U-X!^+'C#XJ7'B+7/AWX63PO86^E^'HM+@NXE$B& M2?S);EFWQROO"%#O.Y61?DK:CCL%"/-S>^Z:A>TO^?')9::6J;]+NON)VOKS7ONCYS_X+\?#_P )6'QS_9OUZ^\,Z3=7 M.L>+UMM:GBT9;N\U:TCDM,6\BHC2W*A6<+%A\[B%4DX-C]DS1_"?QC_X*TKX MR_9D72_"?PK\+Z#]@^(%I9P?V-;ZK>D3I#"NE.(YE92T9\TPI&'@E^8OD2?1 MG[>O_!/+Q1^VO\4?A_KT'Q$T'PKI_P -=536M)LW\)RZA--*/^"7VM:;^UUI/QR^'OQ&TOX?^/+BQ^S^+K>'PO)=:'XL MF(4/(UI]M1X5&#A0G4M*U5=7%7\KNP+>4 ML/[6G[0/Q0\3?\%,/V;?!_A'Q3H_AWPSXLTR\\16UK>Z/+>1M,+"XYO$CNH6 MG"J6V(DD:HQ#MYA"@7/VAO\ @C5XB_:"USXQ37OQE2.S^+UQI\\R77A0WEUH MZV4OFQ6T$[7B_P"C;BW[L(I&V/#?*WF>H?$3_@G;J7CGXT_ _P"(EOX^ATGQ M=\(=-?2;B:'0/-M=8MY(3#(8XGN";:3:TA5F:=5++E7"X:,+6R^E&DVUS+FO MHVM:-E>ZUM4UZVN[>[9*L53QE1UHP3Y6M-5NJB>FNEZ>G2_VM7=^3>/_ /@K M'XVU;XO_ !1TWX;^$)/%EE\)=6M=&FT2S\':UK&H>*IA*RWACOK,-;::$"N( MQ/',9#$S9 ( ]0_X*F?MK^,_V-?V0M/^)G@BQT"2[DU"SMY]/\2:9Y =9%#2.2'&U4\H_X.+M5M=%_X)R1:==ZG$U]=^(= M/2 7$D:7%Z8]Y=E4!0Q ^9MB@#T K+#QPE7$X2E32: M_162Z'[>$<1.;T2J./:R3<'O>Z5D]-6KN[U?;^#/^"C?B+X"+K4/!OQ):^2632O!6N0Q^"2CM]D:XU2939Z@CA3'(\*P M!'.>@(KMO@1^P7HOC?XD>,OBWXJ\<6'Q+F^*7A&+PM;2Z58I8Z?'HSPHK!62 M:7SI90BLTRLB$EML:J0J['[$?[#WCC]BKP19^!['XKVNO_#S2;^YN]-LKGPL M(]6MXI79UM7O/M31/$&8LQ%LKL6;:T8PH*DL!&,DTN=**ZI7]]22TNFKP=[+ M6+L[-\W+0^N3A"2;Y6V^C?PP:>^JYN?2^TE=:*WE/[(G[=W[0G[3_B[Q)I]C MX6^&NH6/P_\ B6?"OB.^ACN+%I=*5BDEQ;PR74F)DVL[;G889%5)#N*]M_P7 M \$:+XI_X)K?$:^U/1]+U&^T*TBNM-N+JU2:73YC<0H9(68$QN49E+*02&(Z M&NF_8%_83UK]BS7OB3=ZAXWTOQ=#\1]>E\23Q6_AZ33&LKJ5F+JK-=SAHL' M4J&&.6;I76?MW_LQ:U^V-^SKK/PZTSQ3I?A*Q\2*L.I7=UHDFJ2F%760"$+< MP"-]Z+EFWC&1M!.1RXBO0^LTW0LHKD;:36MH\WW-.UEU._"4ZJC-UKMMR23L MU;FDX_?%I.[Z(_.7XH? #P]\(/\ @BC\+OCOX!M(? /Q8\&:;IU_%XD\/PK8 MWNI"YF2WGBNGCV_:%=7!/F[ONE?NNX;ZR\2?\%!?'8^!?P:UZUT?2O"MMX^\ M(#Q'KOC;7]+EN_#.@SK:HZ6L^RYMO)-S,X6.228#)15CE+GRX6_X)/\ B#QY M^SQX'^#?CWXL0:M\*/!B1++I7A_PPVC7VO\ DD-"MW=R7ER/+5ADK%%&6)SD M%5*]Q^TA_P $]]2^,'QO^&/BSPQX\A\'Z3\,M-GTRR\.7&@_VGIV)87MQ/$G MVB(0SQPOM1RKX*1\%0RMZ6-Q^%K2E&<^:]2I*+:?NQ<7RQU5]9VE:SBGO=.2 M/.P.#KT84VH\O+3A&2NO>DI1N]';2/,N9M/735)GA.I_\%1_C-XZ_P""6FC? MM#>"/#O@-;[1YYK?Q=H]_I]Y=HT<\):M\-;KPYIU]"]KHL]OJ#WUS$)60RM=R(JK&4D,9AW* M+F-=[%68^$_"OX;^#?\ @DU^RCX?^#?Q,\23>,O"OQ$UR\T&VU*#0?L$%LMW M!(\D5XS7,@PV'12F&8NH$9PS#WO]@G]E^R_8\_92\)^!+/S&DTZ!KB\DE4"6 M6XF7O:>'OVZ_%">*/@[INL^!-#>U^*^F7UW#J.B M^)CJ""2ULVNPUO&ML/.@FC\K8Q='#.ZF,A%>3W/XP>%-<\:^ +[3O#NL6.AZ MI<+MCGOM-&HVXU_PE;:_I\=M:B%( MK![.X?:\?EQ/\ZNC!YY9%*,U=I^S#^SQI?[,GPM7PYI<.DP">]N-3NDTFP.G M:0V%NTT\L<,*6>@9G_ FNC_\ 06TS_P "D_QH_P"$UT?_ *"VF?\ M@4G^-:=% &9_PFNC_P#06TS_ ,"D_P :/^$UT?\ Z"VF?^!2?XUIT4 9G_": MZ/\ ]!;3/_ I/\:/^$UT?_H+:9_X%)_C6G10!F?\)KH__06TS_P*3_&C_A-= M'_Z"VF?^!2?XUIT4 9G_ FNC_\ 06TS_P "D_QH_P"$UT?_ *"VF?\ @4G^ M-:=% &9_PFNC_P#06TS_ ,"D_P :/^$UT?\ Z"VF?^!2?XUIT4 9G_":Z/\ M]!;3/_ I/\:/^$UT?_H+:9_X%)_C6G10!F?\)KH__06TS_P*3_&C_A-='_Z" MVF?^!2?XUIT4 9G_ FNC_\ 06TS_P "D_QH_P"$UT?_ *"VF?\ @4G^-:=% M &9_PFNC_P#06TS_ ,"D_P :/^$UT?\ Z"VF?^!2?XUIT4 9G_":Z/\ ]!;3 M/_ I/\:/^$UT?_H+:9_X%)_C6G10!F?\)KH__06TS_P*3_&C_A-='_Z"VF?^ M!2?XUIT4 9G_ FNC_\ 06TS_P "D_QH_P"$UT?_ *"VF?\ @4G^-:=% &9_ MPFNC_P#06TS_ ,"D_P :/^$UT?\ Z"VF?^!2?XUIT4 9G_":Z/\ ]!;3/_ I M/\:/^$UT?_H+:9_X%)_C6G10!F?\)KH__06TS_P*3_&C_A-='_Z"VF?^!2?X MUIT4 9G_ FNC_\ 06TS_P "D_QH_P"$UT?_ *"VF?\ @4G^-:=% &9_PFNC M_P#06TS_ ,"D_P :/^$UT?\ Z"VF?^!2?XUI,P12S$*JC))[5S7PK^,OA7XX M:!/JGA'7M-\0Z?:W4EG+/93"1$E3&5/U4JZGHZ.CJ2K*Q/(#3_X371_^@MIG M_@4G^-'_ FNC_\ 06TS_P "D_QK3HH S/\ A-='_P"@MIG_ (%)_C1_PFNC M_P#06TS_ ,"D_P :TZ* ,S_A-='_ .@MIG_@4G^-'_":Z/\ ]!;3/_ I/\:T MZ* ,S_A-='_Z"VF?^!2?XT?\)KH__06TS_P*3_&I_$'B"Q\)Z%>:IJEY:Z=I MNG0/M4C&=1M0BVDY M-*[44W>5EJ[7LMS2%&I.,IPBVH[M+17T5WTN]%<];_X371_^@MIG_@4G^-'_ M FNC_\ 06TS_P "D_QK3HKL,S,_X371_P#H+:9_X%)_C5VPU*WU6#S;6XAN M8\[=\3AUSZ9%344 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M7D_[5O[61"]K9,_G:AJ&.,0VZ9DDYX+!=JD_, M5'-53IRG+E@KOR)E.,5S2=D=Y\2?B3HGPB\$ZAXB\1:A%IND::@>:9P6))(5 M415!9Y'8JB(@+.S*J@D@'+^"'QR\/_M!>!TUWP_/,8UE-M=VEU'Y-YIMPH!: M">,\I( RGN&5E=2R,K'\QXOV^_B)_P %+/CK;^,/"/P3\?S? GP98SF/4KMD M^2Y#$-J$5N !/,(R8S%$]Q(B;C'M+R)+W4/_ 3FU+_@HGIL/B.S\9>(_ACX M3PJV^L:)+)%>^+47)1@HD5#:1EF,+S[.17EZ5'#X2KE,L?3K)U%*RIV:;7>[^]/X=+ M-W=E^D&O^)]-\*6+76J:A8Z;;*"3+=3K#& !D_,Q X )^E>7^,O^"@/P*^'I M9=:^,GPOTV6,X,,OB>R$V* M+QL>8;S6+:.-P#P/DM@_3 ^^>G&.E>G>#O\ @WM_9-\(HID^&DVL3*H7S=0\ M0:C(3Q@DHLZQY/7[O!/&*_1/98".]24O2*7YL\'VF+>T(KU;?Y(W?&/_ 78 M_90\$*WVKXP:3=.O1-/TV^OMYP2 ## R\XZD@=,D5Y1XS_X.=?V9?"^[["?B M%XDVGC^SM"6/=R.GVB:+U)YQT/MGZ5\&_P#!+G]G+P$Z-IWP1^&7F1G2(TP$=H2EZM+\DPY<6]Y17HF_S9^>(_X.,IO'+[?A[^S'\:O&32'$0^R& M(R._VZOC/IMU'\9OA-X= M\+_"_P II-8L/"5]!+J5W .=LL8N[B6:$@YDAAV/(L97:P+0RNT_PC\7/C#> MWLW[,7BC2_"OBV.T@CU'Q)8J^^()'OB1V8R1I*%F_ M3:L_PUX2TKP7I\EIH^EZ?I-K+<2W;PV=LD$;S2NTDLA50 7=V9V;JS,2BBFU#]J+X=VURJ[6CL]+C2,R1@9..5ACW''J-IF)O!\N20 'U!R,9_O>M#?\ !NMJVKA9=9_:F^-&IWH& MTS&=Q\O88>=SQ_O5^F5%']L8OI+\(_Y!_9N'_E_%_P"9^;?A?_@W1T?P=X@L M_$:?&KXB>(/$VDR"XLO[?C@OM->1.8Q- P+,@;GY9%8=596 ([KX9_LI^,OC MGXX&C>*M#U+P7HWA>^AFU:^$A66]N8766*/3)P 2A(20W:A6C4A%"S[_ +/] MU45\'Q-P7E.?YK@\ZS6GSU\*[TW>R[I22TDHRM))[279M/W,MS+$8#"U<'A' MRPJ_$M_+1O9M:/R\[-%%%%?5'"%%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%>;?M,_M??#7]COP0WB#XD>+](\+V)5C ES+NNKUEY*00+F29O9%..IP M.:J$)3ERP5WY$RDHKFD[(])KR_\ :C_;0^&'[&/@TZY\2?&&D^&K=U9K:WED M\R\OB/X8+=,RRGM\JD#/) YKX#UK_@JU^T5_P4LUNZ\-_LC_ UN?#/A?>UO M<_$+Q3&L<< S@M&"&A1A_='VB7!SY:D<>B_LL?\ !O\ >"O"_C+_ (3[X]^) M-4^/?Q&NV6:XFUN2232X7ZX\IV9[C'*_OF*$8Q$M>G]0IT=<9*S_ )5K+Y]% M\]?(X?KDZNF&C?S>B_S?R^\\WU+_ (*@?M+_ /!3W5KC0?V4OAS/X'\%-(T% MQ\0O%,:KM7.TF+(>%&'=(Q<2C@X3MZ?^R;_P0 ^'_P //%__ G?QKUS4_CS M\2+QQ<7-WX@=Y=-27CGR9&9IR.F9V92,$1H:^^-(TBT\/Z7;V-A:V]C96<:P MP6]O&(XH448"JJ@!5 X P*L5%3,I*/L\,N2/EN_66_W614<"F^>N^=^>R]% ML0Z?I]OI%A#:VD$-K:VR+%##$@2.)%& JJ. . !P*FHHKS3N"BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH \M_;,^+WB;X%_L]:UXF\)Z'=:]JU@T(,=OI[:D]G TJK-=?94DB>X$49 M9S&DBEMO4 $UX7\,_P!N+QUXH\0? -;'7/AOX[T'XK:?JHGN]'TZXMYYKFSL MWN496>Z*6[EBD4EO(C&-XY#Y@W!(_J3XI^ 9?B5X+N=*M]>USPS=2E7AU+29 M(UN;9@>H65)(I%(R"DL;J0>F0"/!_A__ ,$P] ^'GC#P/X@L_'WCU-5\$ZA= M:Q^ZBTF.WU:^NU"7D\Z?82?WT06(K&R!412NV0M*WIX&>&5*<<1N]G:^\9+M MHDVGWOT>CCPXR-;GA*CLMU>W5/ON]O2]FM>?S4_M>?M*_"/Q=KFC_$FU^!CS M#^P]+TR3PQ:ZK.EKJ6L:BMI;?:3/*F^.*-9YGC3:SCR@)$WY'T?^Q]\>[W]H M'X8ZG>:M'9KKGAGQ#J?AG4WLH'@M;F>RN7A,T4;O(T:2*$?8TCE"Q7 M+_V4O#OC3PAXLTNZNM86?Q;KL/B274HY(OMEA?V_V1V. M$1$48"JJ@ .MB,/4H?"E/396Z1_)\Z\[Q?314Z%:%5>\W'S?^)?C[C6FEI+2 M]GU=W>0V%NTT\L<,*6=YF?\ M":Z/_P!!;3/_ *3_&C_ (371_\ H+:9_P"!2?XUIT4 9G_":Z/_ -!;3/\ MP*3_ !H_X371_P#H+:9_X%)_C6G10!F?\)KH_P#T%M,_\"D_QH_X371_^@MI MG_@4G^-:=% &9_PFNC_]!;3/_ I/\:/^$UT?_H+:9_X%)_C6G10!F?\ ":Z/ M_P!!;3/_ *3_&C_ (371_\ H+:9_P"!2?XUIT4 9G_":Z/_ -!;3/\ P*3_ M !H_X371_P#H+:9_X%)_C6G10!F?\)KH_P#T%M,_\"D_QH_X371_^@MIG_@4 MG^-:=% &9_PFNC_]!;3/_ I/\:/^$UT?_H+:9_X%)_C5W4=2M]'LI+F[N(;6 MWA&Z269PB(/4D\"O$_BA_P %,_V?/@T)%\0_&3X>6LT.[?;0:S#>728ZYAA+ MR?AMY/2M*=*#U.9EZ=3U'='*<6U=PLO. MR_.QR2S'#IV4K^FOY7/T,\=?'#P?\,_"EYKFN^)-'T_2[!0TTSW*MU(5555R MSNS$*J*"S,P !) KD_C'^W)\(?@#\,8O&/BSXB>%=,\/W4 N;2X%^D[:BA4, M/L\<99YR5(($:L2#GI7PP?BE^T-\6=4L/$_[2'PQ'P[T6VN$M_"\=E>PS:7; M7,@9"]S<LL=T^[RXY9MJ8/EH(WE/GVOV:?^"1OPU_:M_: F^,'C'PJVJ>" MUL_)TC3KRYE6RUFZ\W>U]' I %KRX .4N'=I FS#S?G>$XPG+C&KPMB,'55. MG353VZLX-OHG>UG\*E=OG4DX)1/_%IB@AM1T+QHY,*,.H# M&:0J?]4I%=E^S'_P0S^'UGXV_P"%@?M%?$)OCU\1+HK+,-5U$MI-NPY"['4*_13PSX7TSP5X?M-)T;3K'2=+T^,0VMG96Z6]O;(.BI&@"JH M] *O5^BSS)QCR86/(O+XGZO?[K'@1P*D^;$/F?X+T7^9@Z#JWA?PKHMKINE MW.@Z;I]C&(;>UM9(H8;=!P%1%PJJ.P Q5O\ X371_P#H+:9_X%)_C6G17F'< M9G_":Z/_ -!;3/\ P*3_ !H_X371_P#H+:9_X%)_C6G10!F?\)KH_P#T%M,_ M\"D_QH_X371_^@MIG_@4G^-:=% &9_PFNC_]!;3/_ I/\:/^$UT?_H+:9_X% M)_C6G10!F?\ ":Z/_P!!;3/_ *3_&C_ (371_\ H+:9_P"!2?XUIT4 9G_" M:Z/_ -!;3/\ P*3_ !H_X371_P#H+:9_X%)_C6G10!F?\)KH_P#T%M,_\"D_ MQH_X371_^@MIG_@4G^-:=% &9_PFNC_]!;3/_ I/\:/^$UT?_H+:9_X%)_C6 MG10!F?\ ":Z/_P!!;3/_ *3_&C_ (371_\ H+:9_P"!2?XUIT4 9G_":Z/_ M -!;3/\ P*3_ !H_X371_P#H+:9_X%)_C6G10!F?\)KH_P#T%M,_\"D_QH_X M371_^@MIG_@4G^-:=% &9_PFNC_]!;3/_ I/\:/^$UT?_H+:9_X%)_C6G10! MF?\ ":Z/_P!!;3/_ *3_&KMAJ5OJL'FVMQ#*!X7\%:7I_ MBCQ39-'<:LEU=-;V6EPD!Q#)*JL?M,RD;$ /EJXE<;?+2;BO&W_!;W]FWX6Z M<@\6>.YO#NN+&#=:%<:/>3:E8RXR8I$AB=0>P<,8V&&5V4ACYN!SC XS,*N4 MX2K&>(I)2G3B[RBI;-I:K]+J]KJ^U?#U*-".*K1<:S_ *Z]F?6= M%?G!XL_X.=?@:FHG3O!WA/XI>.M3DR(([#2(H8YCQ@?/-YO)('$1_EG*_P"' MS7[37QB^3X9_L7^-HX9>(-0\0RW,5O+GA3\UO"F >N)C]17TBRC%;RCR^K2_ M-GEO,L/M&5_1-_DC]-**_,O_ (2C_@I_\P/\ AU7^VA\:.?B-^V5J6@K-S/%X2M9XT;/+*/)-F,=ONXP3 MQV+_ +/A'^)6@O1N7Y)_F'UR3^"G)^ME^;/TLU75[30=/DN[ZZM[.UA&9)IY M!'&@]V8@#\:\:^)'_!2?]G_X2>8NO_&3X<6<\/W[:/7;>YN5YQS#$S2=?]GL M?0U\@Z3_ ,&RWPW\4:A'?_$GXL?%[X@Z@AW,\^HPPQR,?O$^9'+)R>>) ?4F MO9?AO_P0+_93^&WER)\+X=;NH^L^L:K>7F_C',;2^5ZGA!R?887L<#'XJDI> MD;?F_P! ]IBY;04?5W_)?J8?CS_@I_X9_:^L;WP[\#/%S7.EV>U/$'B6UCDM M;JV#;MMK:),JR*[A26N2FU5XB+2$O!Q/CS_@KO\ %SX&SZ?X'TSX%Z_\_! T?1Q-<7%Q)]IU+4KDAKO5KD@!IYF +$ *%4!$151%5551^(: M?&%7,JF*C/+'32C0<6I*?>ZMJG>3G?WDU#D7*I+Z"I6P<\ICAU3<<3S-N:>E MNUG]UK:6OS:M'P ?VIO^"D7QY!'A?X$_#_X:Z;-REWKETC747;!62YS_ .2_ M;\T_X=Z?M]?';_DH'[5VD^#+6;.8O"-JZ2P*>HS!#9G<.W[PG_:[U^FU%?H_ M]I./\*G"/_;MW][N?/\ U%/^).3^=ORL?F?IW_!M'X0\=WD=Y\6?C=\7_B5? MH=[227L=NDC],GSAL3R>3^2#.:^Q**BIFF+FK.H[>6GY6*CE^'B[J"^>OYG#_##]F3X;_!) M8QX-\ >"_"OE+M5M(T2VLV ZGF- >3R3W/-=Q117#*4I.\G%.B*OS?Q,SNS.WT517S>7\(9/@,WKY]@Z$88JLDIS6[2W M\DY:Z7\1O%7BK0?$4&OZ?XGT;5M#LK/4%NM.T]KGR+D"!94O(Y& M",8W2-U2(A#N:23[6^)_POT?XP>#[C0]%DE MB'_P#@G3\*?#FL^$]2ATSQ,VJ>"Y'GTRZ?Q;JQ?SI#^^FF M47(2>24?)(TJMYD86-LQJJ#TL%B*%.C4A56KO9V3WC)=7LFTTE9IZW>RXL51 MJSJ0G3>BW5VKZI].O2^NFENI\L?#?_@H3\3_ (D_ GQ[K]T_Q'M/B%KF@Z;K MWAGPQX<\$66L0:1I-_/Y$%]8Q+(]Q?3(L7$K,Q9WEGF9Y99&8EF>1 MF9B222:VQF,PDZHCC:1OP502?P%4/^$MM?^>.I_P#@MN/_ (BM M.BO'/3,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+; M7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C M_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_Y MXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ MB*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+; M7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C M_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_Y MXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ MB*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+; M7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C M_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_Y MXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ MB*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+; M7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C M_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_Y MXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ MB*TZ* ,S_A+;7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+; M7_GCJ?\ X+;C_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C M_P"(H_X2VU_YXZG_ ."VX_\ B*TZ* ,S_A+;7_GCJ?\ X+;C_P"(J[87\>HP M>9&LRKG&)87B;\F /XU-10 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110!Y7^VAJOQ T3]G;7+KX9VDU[XHMS"XBMIX(+PVHE4W!MFN M(Y(/M AW[/-1ESV)P#\N_"7]LKQ'J/B;]GV]TOXC>*O%6@^(H-?T_P 3Z-JV MAV5GJ"W6G:>USY%R! LJ7DN17; MVS6-U;R*I0Z9X MF;5/!H:WJWB'PUXQ\>W/AJ30]'CT33DTGP]HNLZE'917]I*3//=7"J)&9KL MI'YLL>+;RP"WUI^PS\8]:^,7PGUL^(+B?4-3\*^*]8\,-J,T444FJ1V=Y)%% M<.L2)&':,*'\M%0NK$*H(46O#O["OPK\)^&?$&CZ?X8DAT_Q+'##=(=5O7:V MBAE::"*T=IB]E'#*[21);&)8G.Y I ([[X:?#/1?A!X-M= \/VCV>F6C22*L MEQ+HCC M:1OP502?P%4/^$MM?^>.I_\ @MN/_B*TZ*\<](S/^$MM?^>.I_\ @MN/_B*/ M^$MM?^>.I_\ @MN/_B*TZ* ,S_A+;7_GCJ?_ (+;C_XBC_A+;7_GCJ?_ (+; MC_XBM.B@#,_X2VU_YXZG_P""VX_^(H_X2VU_YXZG_P""VX_^(K3HH S/^$MM M?^>.I_\ @MN/_B*/^$MM?^>.I_\ @MN/_B*TZ* ,S_A+;7_GCJ?_ (+;C_XB MC_A+;7_GCJ?_ (+;C_XBM.B@#,_X2VU_YXZG_P""VX_^(H_X2VU_YXZG_P"" MVX_^(K3HH S/^$MM?^>.I_\ @MN/_B*/^$MM?^>.I_\ @MN/_B*TZ* ,S_A+ M;7_GCJ?_ (+;C_XBC_A+;7_GCJ?_ (+;C_XBM.B@#,_X2VU_YXZG_P""VX_^ M(H_X2VU_YXZG_P""VX_^(K3HH S/^$MM?^>.I_\ @MN/_B*/^$MM?^>.I_\ M@MN/_B*TZ* ,S_A+;7_GCJ?_ (+;C_XBC_A+;7_GCJ?_ (+;C_XBM.B@#,_X M2VU_YXZG_P""VX_^(H_X2VU_YXZG_P""VX_^(K3HH S/^$MM?^>.I_\ @MN/ M_B*/^$MM?^>.I_\ @MN/_B*TZ* ,S_A+;7_GCJ?_ (+;C_XBC_A+;7_GCJ?_ M (+;C_XBM.B@#,_X2VU_YXZG_P""VX_^(H_X2VU_YXZG_P""VX_^(K3HH S/ M^$MM?^>.I_\ @MN/_B*/^$MM?^>.I_\ @MN/_B*TZ* ,S_A+;7_GCJ?_ (+; MC_XBC_A+;7_GCJ?_ (+;C_XBM.B@#,_X2VU_YXZG_P""VX_^(H_X2VU_YXZG M_P""VX_^(K3HH S/^$MM?^>.I_\ @MN/_B*/^$MM?^>.I_\ @MN/_B*TZ* , MS_A+;7_GCJ?_ (+;C_XBC_A+;7_GCJ?_ (+;C_XBM.B@#,_X2VU_YXZG_P"" MVX_^(H_X2VU_YXZG_P""VX_^(K3HH S/^$MM?^>.I_\ @MN/_B*/^$MM?^>. MI_\ @MN/_B*TZ* ,S_A+;7_GCJ?_ (+;C_XBC_A+;7_GCJ?_ (+;C_XBM.B@ M#,_X2VU_YXZG_P""VX_^(J[87\>HP>9&LRKG&)87B;\F /XU-10 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y#^W-H7BKQ3^SEJV MF^"]>TO0?$5Y-;K;?;K^?3TU-5D5Y+);F!TFA>:-70/$=XSQCDCY%^"'QMN& M^(?[-MUIM]\3=#^SMXDT+Q/XZ5N[35VI<6+PTJM2$X]-[]5=/]-_))W] MUQ^!OAM\1?B9I/P*^)EUJ"_&C_A//B%;:=/HZWOQFT:ZT.2TOKWRQ)HNIJ!; M6%Q(QG2*+;*P5(O+,G./M'_@G*+VU_9CLK'5O^%G#7-)U"[L=57QYK4>MZK' M>1RD31K>Q@1W%NCY2.1 H*IRJG('::=^R/\ "G2/ FH>%K3X8_#VU\,:M.ES M?:1#X$_".D^ O#=GHVAZ7I^BZ/IL0@ MM+&PMDM[:UC'1(XT 55'H !6V,S&E5IRA"%KM6WT2226[\]-;MWNOA,U[[;N]^BWTMM9*S4G[QD<94,WTW$#\S5#^WKK_H" MZG_WW;__ !VM.BO'/3,S^WKK_H"ZG_WW;_\ QVC^WKK_ * NI_\ ?=O_ /': MPOBI^T)X!^!;6*^-O''@_P &MJ6_[&-9 M(>R+DGTI)/BOX6A^(J^#V\2>'U\6R6GV]=$.H0C46MLD><+?=YGEY!&_;MR# MS4\DFKI::_AO]W4'.*T;[?CHOO>Q=_MZZ_Z NI_]]V__ ,=H_MZZ_P"@+J?_ M 'W;_P#QVJ7PW^+?A7XR:)-J?@_Q-X?\5:;;SM:RW>CZC#?01S* 6C9XF90X M#*2I.0&'K4_@?XB^'_B=I,NH>&]>T;Q#8P7$EI)QW<,@M:G#I\$DI!81J\K*I8JK':#G"D]JJZC\?O >CZ%X?U2\\ M;>$;73/%LL<&AWWJ3* MI%.S?2_R[^AM_P!O77_0%U/_ +[M_P#X[1_;UU_T!=3_ .^[?_X[5;XA_$[P MW\(O#,FM>+/$.A^%]&A=8Y+_ %:_BLK5&8X53)(RJ"3P!GDU#K7Q>\)^&O$V MAZ+J7BCP[I^L^* QT:PN=2ABNM6V@%OL\;,&FP""=@. 14QIRE\*\OU_+4)3 MC'XGY_+;\]"__;UU_P! 74_^^[?_ ..T?V]=?] 74_\ ONW_ /CM4?!WQ<\* M?$37=:TOP_XG\/:YJ?AN?[+J]II^HPW4^E398>7<(C%HGRCC:X!RK>AJQX:^ M(OA_QIJ^L:?H^O:-JU_X?N!::I;6=['/-ILQ&1'.BL3$Y'.UP#BCDDMUTO\ M)VU]-5]Z#FCWZV^?;UT?W$W]O77_ $!=3_[[M_\ X[1_;UU_T!=3_P"^[?\ M^.UIT5)1F?V]=?\ 0%U/_ONW_P#CM']O77_0%U/_ +[M_P#X[47CWXA^'_A7 MX6N=<\4:YH_AO1+/:+C4-4O8[.U@W,%7?+(55_?Y>W[3O\ *SO^3&[.[CKQ5QISDN:* M=KV^?;U)E.*=F_,Z'^WKK_H"ZG_WW;__ !VC^WKK_H"ZG_WW;_\ QVH]9^(& M@^'/!4OB74-;TBQ\.0VPO9-5N+R.*RC@(#"4S,0@C((.XG&#UK(U;X_^ ]!\ M,:%K=]XV\(V>B^*)8H-&OY]8MX[75Y)!F-+>1G"S,X&5"$EATS35.;=DGO;; MKV]1>TBE=M;7^7?T-O\ MZZ_Z NI_P#?=O\ _':/[>NO^@+J?_?=O_\ ':HZ M=\7/"FK_ !%O_!]IXG\/77BW2X%NKW1(=1A?4;.%@I622W#>8B$.A#,H!WKZ MBK%E\1?#^I>-[WPS;Z]HUQXDTVW2[N])CO8VOK6%^$EDA#;U1NS$ 'L:GV:KJU] M9Z7I>FPO>YT35(-0AAEP&V,\+,%;:0<$YP0>]4H2:5 M_P )!_;EM_9>_?Y>W[3O\K._Y,;L[N.O%"IR>R[+YO;[^@.26[[_ (;_ '=3 MH?[>NO\ H"ZG_P!]V_\ \=H_MZZ_Z NI_P#?=O\ _':S)?C3X.A\<:7X8?Q9 MX97Q)KEK]OTW26U2 7VH6^&/G0P[M\D>$<[U!&$;G@U=O?B+X?TSQO8^&;G7 MM&M_$FI6[W=GI,E[&E]=PI]^2.$MO=%[LH('>G[.:T:?7\+W^ZSOZ,/:1:O? MM^-K??=6]43?V]=?] 74_P#ONW_^.T?V]=?] 74_^^[?_P".UIT5!1F?V]=? M] 74_P#ONW_^.T?V]=?] 74_^^[?_P".U/XB\1Z?X0T&\U75KZSTO2]-A>YN M[R[F6"WM8D!9I)'8A550"2Q( KC](_:H^&'B#X?:EXML/B/X#OO"NBRK!J& MLV_B"TDT^QD8J%26=9#'&Q+H &8$[U]151IRDKQ7]/;[R7))I-[G4_V]=?\ M0%U/_ONW_P#CM']O77_0%U/_ +[M_P#X[4FG>*M+U?PQ#K=IJ5A=:+<6PO8K M^&X1[66 KO$JR [3&5^8,#C'.<5S7_#27PZ_X5=_PG'_ GW@O\ X0KS/*_X M2#^W+;^R]^_R]OVG?Y6=_P F-V=W'7BG[.=[6>]OF]EZL.>-D[[_ *:G0_V] M=?\ 0%U/_ONW_P#CM']O77_0%U/_ +[M_P#X[69+\:?!T/CC2_##^+/#*^)- MH(PC<\&LW1?VG?AKXD^),G@W3OB%X' MU#QA#-+;R:%;:]:RZE'+$&,J&W5S(&0*VX%U]NBW?HB?:P M2O==.O?;[^ATO]O77_0%U/\ [[M__CM']O77_0%U/_ONW_\ CM:=%9FAF?V] M=?\ 0%U/_ONW_P#CM']O77_0%U/_ +[M_P#X[6C)(L,;,S*JJ,LQ. !ZFN+^ M'7[2OPY^+ZZFWA+Q_P""?%"Z+&)M1.D:Y:WWV!#NPTOE.WEJ=KHG))I/KMYG1_P!O77_0%U/_ +[M_P#X[1_;UU_T!=3_ .^[?_X[ M4'P^^)/AWXM>%X=<\*Z_HOB;1;EF2'4-)OHKVUE*L58++&S*2&!!P>""*R]* M^/W@/7?#.O:U8^-O"-YHWA:66'6K^#6+>2UTB2(9D2XD#E860HE4BTFGOL;?]O77_ $!=3_[[M_\ X[1_;UU_T!=3_P"^[?\ ^.U@ M3?M%?#^WM_#$TGCKP;'#XV8)X==M:M@NO,2HQ:'?_I!RZ#$>[EE]14.M_M._ M#7PS\28_!NI?$+P/I_C":6*WCT*YUZUBU)Y)0IB06[.)"SAE*C;E@PQG(JE0 MJMV47?7H^FC^[KV)]M"W-=6]>^WWG2_V]=?] 74_^^[?_P".U=L+J2\@W26T MUJV<;)2A;Z_*S#]:FHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X MA\+_ !(\*?LX?\%%_P!H35_C7K&B^&H?%>E:2/".J>(KB."TU#1X;=A=V5H\ MI"L4N)EF9U8AL@UX;^RAXQA^&_CW]D/1_%VL6/A^9M=\67>A:1JU[';W MUAH][%+'I2/$[!U64G9"&5$?%BZC#;+=1 M:A8W^FW/V:_TF\B),5S;RX.R5,G!((P2""#BNN^'WA:\\%>$K73=0\1:UXLN MK;=OU35DM4N[G+$C>+6&&'Y00HVQJ2%&J>JO&VR7]U:*"YOD/_ (+#Z]^SS:>$ M=#T7XR:AHNE:YXGEBM-.U.6RFO\ 4=#LXIQ//<6R0H\L!?R_)\R-1O=XPY9$ M(7S=CJ5S^WW#I:R26_BBZ^,%CXL@M9W"WB>&QX7,+W)')%NN'MV?.P2YCSN. M#^CU%883,O84N1)OXMWIK*$M%;O!G_$+]DC]IZT\)^++6XTO5/C&S^(K_0;^*XGL/#EW/9QW-Z" MA<"!H$G!D*M&427(*JV/L3_@F=XLUKQ5^R]#'JES8ZEINBZUJ6C>'M4LK*UL M[?5](MKIX;.XCBM52W$9B4*IA1494#*,')^@:*5;,8SH.@H?RZMW?NPC'LOY M;]O>>CT8XX.2K>V*=+^"G_!6G M0_&WQ.U*PT+P'-\/)=*\*ZYK-PEOI.F:L;O?=0^=(5CAN9;91@DAI$0J"<%: M^0O'FM_ *X\*_$Z;XG7FDZ+X.^)WQ#FF^'>IRZ?->7.F:6DD0;RC$9# M*RL.5=6565AR&4&JOP ^#+/&EMIJ)!9W?B)[22\MX$C2-( M?,M[>'S F=\H>0ECESP![F"S.%&$9._-%**L[7CS\]T[.TKZ:IIIOJSR\5@ M95)M*W+)\SNKV:@H*^JNK7?=24>B/#O^"H'C/X*Z%^RJEY\7H]#CM=8MWTW0 M8];M7O'LKJZC$7VI+= [F2W1C(9(U,D:JX1@7PWRA\5K&SCU?2](\&:E>WEE MXL\(_#JR^%\]Z&BO-9AL-:+RRP(X#[DCV7,@P&CCD5W"CI^JU%8X'-%AK-1; MM-2MS::;*UM[[N^J;5MFJQ6 =>#@VE>#CMW:;>^UDO=Z/5/=/\]/&GQIDNOC MQ^W!'\-?$&GZIX\C\):4=)M=(ODGU#SK:RGAN#"D;;S+!(ZJ=O*2%%(W$ ^G M_P#!(/6I(OA?XN\,Z+K%KXH^&OA/4K2V\(ZY!:V<(O(IK&"XN8F:UCCCFDBN M)'#RE/,:1W$A+AL?7E%3+,8NC*ER?%&"O?K"ROMV32[FBL%%%%>6=Q\A?M^7$?@O]L_]G'QIXQD2W^$OAF^U4ZK?7;! M=+T759;94T^[NF;"1@.72.5SA'?JI8$^"^,OB#\./B;^U!\>I8_B)H_@?X>? M%#2K?0?#WC1;>&?2;GQ&EA*E[+:W4B-;JYM)/(E=75Y@Y1) X4K^E'BKPOI_ MC?PQJ6BZM:0ZAI6KVLEE>6LPS'<0R*4=&'HRD@_6O//V5?V5[/\ 9'\#'PMH M?BSQCKGA>U^32=+UR>UN(]"B\R1_)@EC@CG:/Y]H$\DI540*0 <^MAL=3CA_ M9U$[QBXJVS4I.3OH]4WI=6:2O9Q7-Y^(PU1UE4IO=Q;ONG%)1MJM'U7=RM=S M;CX[::SX,^#7_!*SP3>?M!^'_#UMH_A3P[9+=Z#?VI-K=3PP^7;0&TD!\R5@ M$80R*=DGS%08P5^//&,'@KPQ^R_X'_X0S6VUKX;7WPN\;^&M U">WGMX-4U^ M[G@D-I:Q7"K+YDDGFQ0QLHD<6[!0V"3^N]%53S6U2=22?OR7^[S6-_P1:\4>((- M:U[06UF7Q)I5YX?LO$?B:>ZM+:._T;Q9<7-RFH65U+%&DLDW[H$KVMQ?_#WP[\0])U7QU;QQF6$:3$SL MTUQ&/OVT4GER2 Y4!0Q!"\>9?$CXL7WQ>_X*(KXK^ <,GQ&T6T\#'1?&VI>$ M-1L9(9#->*;=([B6XAMI+R&/SG3,Q9 W3!*M]_$9%>/?LT_L8:'^R9K>N+X- M\1>++7PGK=Y/J"^$KB6UFT?3+B8H7>U)@^TQC*$B/SS$#(YV9((]3!XRG"DX M36L>=KL^>*BU)+79:-6UM=JR//Q6%G.?-!_%R)]TH2^KG51KEPCV]Q:IJ=P[>:5D?S$8_NV1R3(0 MRE75QN\#^%OC+X2P_#OP)XY^'.J6EC\*X?B[J.O>*C)9R:9HWABXO-'N8[:T MVS*B(D0:WC+*/)\VX4(Q!4#]4J*J69J52M4<7^\=[*6B5[N]T[M]'I9J^JNF M?4;0A337NWZ:ZII6LU:UW=:IKL[-?FO\%_&5E\,O$/[ _AWQAKNE:/XDL=)U M/S=/U"^C@N[6*ZT\Q6*/$Y#IO^2%%(!+KL&6&*U_^"?_ (P\7:?^WWXFM[K5 M)-3UKQEJ/B6?X@:3=V=K]K\.?8KN&/1G\X1BZ6WDM9%6&.21XBKNT8'S8_1& MBMJN<*4I+I]EN_FXQ=U:SRCEKC3C34_A<'M_(K/KU_!76H44 M45X9ZI\G?\%;-&O+OX=_"_4[VUN+_P"'OAWXAZ3JOCJWCC,L(TF)G9IKB,?? MMHI/+DD!RH"AB"%X\6_:D^-?A7XA_M/^/O&W@3Q7X(K'4 M8)-'NKVIA<93C1=.> MZYVNSYXJ$D]'K97B^]KZ+7BK4)NLJL.O(GW2A-S37SLFNS=M3COV;_%_P[\0 M?\$M? NI>+=4\/WWP_L_!.GQZW--=+)8;;>"-)X)BIPV)(VB>(YW$-&RG)4_ M'_PM\9?"6'X=^!/'/PYU2TL?A7#\7=1U[Q49+.33-&\,7%YH]S';6FV941$B M#6\991Y/FW"A&(*@?JE152S).I6J.]N;1)N[3TU>UGI9I/573SIX%QHT MJ-U[B:O;7X7%-:Z;NZU3VT=FOS7^"_C*R^&7B']@?P[XPUW2M'\26.DZGYNG MZA?1P7=K%=:>8K%'BR?HNBC%9HZTW M4BG%OGZZ>_*3>EELI-?<]+!A\O5."IR::7)TU]U+7?JU]UUUN%%%%>2>B?-? M_!73P?XJ\=_\$_\ QYIOA&UU34=0F6U>\L=-#-=W]@MU$UW#&J_,Q: 2 J"" MR[EYS@_/_P"UA\7_ (,_'CXR? BX\%Z[X.UKP9X+L[Z\\:3Z=^'G[%^A?"']H3Q-\0/"?B'Q7X?7QM M="_\0>'+>6UDT75KL(ZFY:.6!YHI6+[F,$T8=D7<" 0?4R_&0I0<)[IRE%]Y M.*C:6_NV6GFVGI)N/!C,+*H^:/5*+7]V][Q[2\^MHO["3\@_X)9ZY\&?%O[- M_P 1-1^&U]'%X-U[Q%J&K:Q#%;3Z38Z ]Q"A:RBWB/RQ!;"$N\6(U9R4; &W MYF7Q'\$O&_@WXO\ B#X%W&GVND6_C3PC>^*=-TC2Y=/TG1M'T[4HT^TL"B0L MLVRXN7:+*B*,,Y5@V?U9HK2GFBAB)5XJ7V+)RO\ XM*7N^\O=5MFNK>MXG@ M'.@J,FOMW:C_ #II\JO[KUOU5TM$E8_+_P 4?$O1/ _[.?PYOM?\3:#I>D:[ M^T=-XET![S488([C11JUP[7D6YAFVRYD\T?)MF1LX=2?K3Q[^SK\/O$?[;'@ M._L?!_A5?$UD+WQIJVNKID3ZG<&-$M+6-[HJ9-C/JG**[+J]4RBBBO+.\* M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9 end GRAPHIC 14 medicarerateperdaygrapha05.jpg begin 644 medicarerateperdaygrapha05.jpg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htm IDEA: XBRL DOCUMENT v3.7.0.1
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2017
Jul. 28, 2017
Document and Entity Information [Abstract]    
Entity Registrant Name Diversicare Healthcare Services, Inc.  
Entity Central Index Key 0000919956  
Document Type 10-Q  
Document Period End Date Jun. 30, 2017  
Amendment Flag false  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q2  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   6,458,836
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interim Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
CURRENT ASSETS:    
Cash and cash equivalents $ 3,900 $ 4,263
Receivables, less allowance for doubtful accounts of $12,066 and $10,326, respectively 64,633 62,152
Other receivables 1,519 1,193
Prepaid expenses and other current assets 2,959 3,623
Deposit in escrow 8,673 0
Income tax refundable 490 431
Current assets of discontinued operations 42 28
Total current assets 82,216 71,690
PROPERTY AND EQUIPMENT, at cost 133,802 128,822
Less accumulated depreciation and amortization (73,790) (69,022)
Property and equipment, net 60,012 59,800
OTHER ASSETS:    
Deferred income taxes, net 20,757 21,185
Deferred lease and other costs, net 167 193
Acquired leasehold interest, net 6,883 7,075
Other noncurrent assets 3,045 3,108
Total other assets 30,852 31,561
Total assets 173,080 163,051
CURRENT LIABILITIES:    
Current portion of long-term debt and capitalized lease obligations 10,373 7,715
Trade accounts payable 10,859 12,972
Current liabilities of discontinued operations 440 427
Accrued expenses:    
Payroll and employee benefits 18,857 20,108
Self-insurance reserves, current portion 10,196 9,401
Provider taxes 2,508 3,114
Other current liabilities 5,299 4,432
Total current liabilities 58,532 58,169
NONCURRENT LIABILITIES:    
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net 81,449 72,145
Self-insurance reserves, less current portion 11,417 11,766
Other noncurrent liabilities 8,789 9,551
Total noncurrent liabilities 101,655 93,462
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:    
Common stock, authorized 20,000,000 shares, $.01 par value, 6,691,000 and 6,592,000 shares issued, and 6,459,000 and 6,361,000 shares outstanding, respectively 67 66
Treasury stock at cost, 232,000 shares of common stock (2,500) (2,500)
Paid-in capital 22,270 21,935
Accumulated deficit (7,306) (8,276)
Accumulated other comprehensive income 362 195
Total shareholders’ equity 12,893 11,420
Total liabilities and shareholder's equity $ 173,080 $ 163,051
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interim Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable $ 12,066 $ 10,326
Common stock, par value (dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (shares) 20,000,000 20,000,000
Common stock, shares issued (shares) 6,691,000 6,592,000
Common stock, shares outstanding (shares) 6,459,000 6,361,000
Treasury stock, shares (shares) 232,000 232,000
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interim Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]        
PATIENT REVENUES, net $ 142,550 $ 95,805 $ 284,050 $ 193,750
EXPENSES:        
Operating 113,166 78,385 223,833 157,003
Lease and rent expense 13,763 6,854 27,506 14,106
Professional liability 2,724 1,934 5,394 4,000
General and administrative 8,221 6,881 17,194 13,615
Depreciation and amortization 2,620 2,060 5,107 4,063
Lease termination costs 0 2,008 0 2,008
Total expenses 140,494 98,122 279,034 194,795
OPERATING INCOME (LOSS) 2,056 (2,317) 5,016 (1,045)
OTHER INCOME (EXPENSE):        
Equity in net income of unconsolidated affiliate 0 28 0 61
Gain on sale of investment in unconsolidated affiliate     733 0
Interest expense, net (1,541) (1,158) (3,024) (2,228)
Debt retirement costs     0 (351)
Total other expense (1,541) (1,130) (2,291) (2,518)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 515 (3,447) 2,725 (3,563)
BENEFIT (PROVISION) FOR INCOME TAXES (134) 1,297 (996) 1,339
INCOME (LOSS) FROM CONTINUING OPERATIONS 381 (2,150) 1,729 (2,224)
LOSS FROM DISCONTINUED OPERATIONS:        
Operating loss, net of tax expense of ($18) and $0, respectively (28) 0 (43) (37)
NET INCOME (LOSS) $ 353 $ (2,150) $ 1,686 $ (2,261)
NET INCOME (LOSS) PER COMMON SHARE:        
Per common share – basic, Continuing operations (dollars per share) $ 0.06 $ (0.35) $ 0.28 $ (0.36)
Per common share – basic, Discontinued operations (dollars per share) 0.00 0.00 (0.01) (0.01)
Net income (loss) per common share – basic (dollars per share) 0.06 (0.35) 0.27 (0.37)
Per common share – diluted        
Per common share – diluted, Continuing operations (dollars per share) 0.06 (0.35) 0.27 (0.36)
Per common share – diluted, Discontinued operations (dollars per share) 0.00 0.00 (0.01) (0.01)
Net income (loss) per common share – diluted (dollars per share) 0.06 (0.35) 0.26 (0.37)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share) $ 0.055 $ 0.055 $ 0.11 $ 0.11
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic (shares) 6,294 6,211 6,263 6,185
Diluted (shares) 6,472 6,211 6,458 6,185
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]        
Tax effect on operating income $ (18) $ 0 $ (27) $ 21
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interim Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Statement of Comprehensive Income [Abstract]        
NET INCOME (LOSS) $ 353 $ (2,150) $ 1,686 $ (2,261)
OTHER COMPREHENSIVE INCOME:        
Change in fair value of cash flow hedge, net of tax 146 181 400 492
Less: reclassification adjustment for amounts recognized in net income (116) (119) (233) (263)
Total other comprehensive income 30 62 167 229
COMPREHENSIVE INCOME (LOSS) $ 383 $ (2,088) $ 1,853 $ (2,032)
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interim Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
NET INCOME (LOSS) $ 1,686 $ (2,261)
Discontinued operations (43) (37)
Income (loss) from continuing operations 1,729 (2,224)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:    
Depreciation and amortization 5,107 4,063
Provision for doubtful accounts 4,187 3,661
Deferred income tax provision (benefit) 403 (1,689)
Provision for self-insured professional liability, net of cash payments (309) 1,595
Stock-based compensation 504 486
Equity in net income of unconsolidated affiliate, net of investment 0 (61)
Gain on sale of unconsolidated affiliate (733) 0
Debt retirement costs 0 351
Provision for leases in excess of cash payments (304) (1,093)
Lease termination costs, net of cash payments 0 1,958
Deferred bonus 600 0
Other 247 358
Changes in assets and liabilities affecting operating activities:    
Receivables, net (7,313) (710)
Prepaid expenses and other assets 620 (384)
Trade accounts payable and accrued expenses (2,647) 1,688
Net cash provided by continuing operations 2,091 7,999
Discontinued operations (329) (2,879)
Net cash provided by operating activities 1,762 5,120
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (5,121) (10,055)
Deposit in escrow 8,673 0
Proceeds from sale of unconsolidated affiliate 1,100 0
Change in restricted cash 0 1,658
Net cash used in continuing operations (12,694) (8,397)
Discontinued operations 0 0
Net cash used in investing activities (12,694) (8,397)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of debt obligations (14,166) (66,422)
Proceeds from issuance of debt 26,074 71,066
Financing costs (226) (1,795)
Issuance and redemption of employee equity awards (94) (96)
Payment of common stock dividends (692) (683)
Payment for preferred stock restructuring (327) (317)
Net cash provided by financing activities 10,569 1,753
Discontinued operations 0 0
Net cash provided by financing activities 10,569 1,753
NET DECREASE IN CASH AND CASH EQUIVALENTS (363) (1,524)
CASH AND CASH EQUIVALENTS, beginning of period 4,263 4,585
CASH AND CASH EQUIVALENTS, end of period 3,900 3,061
SUPPLEMENTAL INFORMATION:    
Cash payments of interest 2,563 1,904
Cash payments of income taxes 625 332
SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:    
Acquisition of equipment through capital lease $ 7 $ 0
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of June 30, 2017, the Company’s continuing operations consist of 76 nursing centers with 8,453 licensed nursing beds. The Company owns 17 and leases 59 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted and residential living beds.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidation and Basis of Presentation of Financial Statements
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the profits and losses from this investment are reported as equity in earnings of investment in an unconsolidated affiliate and the proceeds received from the sale are reported under the heading "Gain on sale of investment in unconsolidated affiliate" in the accompanying interim consolidated statements of operations. The sale resulted in a $1,366,000 gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of $733,000 for the six-month period ended June 30, 2017, related to the liquidation of remaining assets affiliated with the partnership.
The interim consolidated financial statements for the six month periods ended June 30, 2017 and 2016, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at June 30, 2017, and the results of operations for the three and six month periods ended June 30, 2017 and 2016, and cash flows for the six month periods ended June 30, 2017 and 2016. The Company’s balance sheet information at December 31, 2016, was derived from its audited consolidated financial statements as of December 31, 2016.
The results of operations for the periods ended June 30, 2017 and 2016 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Recent Accounting Guidance
 6 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
RECENT ACCOUNTING GUIDANCE
RECENT ACCOUNTING GUIDANCE
In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. The ASU will be effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016. The Company will adopt the requirements of this standard effective January 1, 2018. The new standard may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). The Company plans to elect to apply the modified retrospective approach upon adoption. Additionally, the new guidance requires enhanced disclosures, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The Company is developing a plan for adoption and determining the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operation and cash flows. The Company is in the process of reviewing revenue sources and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectibility, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. We expect to complete this process in 2017. The Company is also in the process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration, including settlements with government payors, state Medicaid programs and bundled payment of care programs. Due to the many forms of calculation and reimbursement that these programs take that vary from state to state, the application of the new standard could have an impact on the revenue recognized for variable consideration. Industry guidance is continuing to develop, and any conclusions in the final industry guidance that is inconsistent with the Company's application could result in changes to the Company's expectations regarding the impact of the new standard on the Company's financial statements. Additionally, the adoption of the new standard will impact the presentation on the Company's statement of operations. After the adoption, the majority of what is currently classified as bad debt expense will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenues. The ASU will have a material impact on the amounts presented in certain categories on our consolidated statement of operations, but we do not expect it to have a material impact on our financial position, results of operations or cash flows.
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which changes how deferred taxes are classified on the Company's balance sheets. The Company adopted ASU No. 2015-17 as of January 1, 2017, and the new standard was applied on a retrospective basis. The adoption of this guidance resulted in a $7,644,000 reclassification between current deferred income taxes and non-current deferred income taxes.
In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for building and equipment operating leases and will result in a significant increase in the assets and liabilities on the consolidated balance sheet.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for shared-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which will require the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this standard will have on our consolidated financial statements.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017. The Company plans to adopt this standard on January 1, 2018, and is currently evaluating the impact this standard will have on our consolidated financial statements.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017, with early adoption permitted in certain circumstances.  The Company is still evaluating the effect, if any, the standard will have on the Company’s consolidated financial condition and results of operations.  The Company does not expect the adoption of this standard to have a material impact on its consolidated financial condition and results of operations.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. Early adoption is permitted. The Company does not presently believe adoption of this new standard will be material to its consolidated financial statements.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Long-Term Debt and Interest Rate Swap
 6 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
LONG-TERM DEBT AND INTEREST RATE SWAP
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increases the Company's borrowing capacity to $100,000,000 allocated between a $72,500,000 Mortgage Loan ("Amended Mortgage Loan") and a $27,500,000 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000,000 term loan facility and a $12,500,000 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162,000 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500,000 with a five-year maturity through February 26, 2021, and a $27,500,000 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000,000. The Amended Mortgage Loan balance was $67,970,000 as of June 30, 2017, consisting of $65,470,000 on the term loan facility with an interest rate of 5.25% and $2,500,000 on the acquisition loan facility with an interest rate of 6.0%. The Amended Mortgage Loan is secured by seventeen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500,000 in the Amended Revolver to $52,250,000; provided that the maximum revolving facility be reduced to $42,250,000 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250,000.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modifies the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10,000,000 to $15,000,000.
Effective June 30, 2017, the Company entered into a Second Amendment to the Second Amended (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amends the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500,000.
As of June 30, 2017, the Company had $24,500,000 borrowings outstanding under the Amended Revolver compared to $15,000,000 outstanding as of December 31, 2016. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,408,000 outstanding as of June 30, 2017. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $40,751,000, the balance available for borrowing under the Amended Revolver was $842,000 at June 30, 2017.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at June 30, 2017.
Interest Rate Swap Transaction
As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $28,985,000 as of June 30, 2017. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at June 30, 2017, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net liability of $62,000 at June 30, 2017. The fair value of the interest rate swap is included in “other noncurrent liabilities” on the Company’s interim consolidated balance sheet. The liability related to the change in the interest rate swap included in accumulated other comprehensive income at June 30, 2017 is $38,000, net of the income tax benefit of $24,000. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2017
Health Care Organizations [Abstract]  
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, and Texas. The SHC policy provides coverage limits of either $500,000 or $1,000,000 per medical incident with a sublimit per center of $1,000,000 and total annual aggregate policy limits of $5,000,000. The remaining nursing centers are covered by one of seven claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of $1,000,000 per claim and have sublimits of $3,000,000 per center, with varying self-insured retention levels per claim and varying aggregate policy limits. 
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $19,384,000 as of June 30, 2017. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of June 30, 2017, the Company is engaged in 74 professional liability lawsuits. Seventeen lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $4,338,000 and $1,542,000 for the six months ended June 30, 2017 and 2016, respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Civil Investigative Demand ("CID")
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee (DOJ) had commenced a civil investigation of potential violations of the False Claims Act (FCA).
In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against two of its centers. In response to civil investigative demands (“CIDs”) and informal requests, the Company has provided to the DOJ documents and information relating to the Company’s practices and policies for rehabilitation and other services, relating to the preadmission evaluation forms ("PAEs") required by TennCare, and relating to the Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. The DOJ has also issued CID’s for testimony from current and former employees of the Company. The DOJ’s civil investigation has been focused on six of our centers, but the DOJ has indicated that all of the Company’s centers are the subject of the investigation related to rehabilitation therapy.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs. The Company has responded to this subpoena and provided additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers’ compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely self-insured for workers' compensation exposure. From July 1, 2008 through June 30, 2017, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500,000 per claim, subject to an aggregate maximum of $3,000,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $957,000 at June 30, 2017. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,628,000 as of June 30, 2017. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of June 30, 2017, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $175,000 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,272,000 at June 30, 2017. The differences between actual settlements and reserves are included in expense in the period finalized.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION

Overview of Plans
In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (“2005 Plan”). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, 700,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. This plan has expired and no new grants may be made under the 2005 Plan. All grants under this plan expire 10 years from the date the grants were authorized by the Board of Directors.
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers . The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150,000 shares to 350,000 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from 380,000 shares to 680,000 shares. No grants can be made under the Long-Term Incentive Plan after May 31, 2027.
Equity Grants and Valuations
During the six months ended June 30, 2017 and 2016, the Compensation Committee of the Board of Directors approved grants totaling approximately 88,000 and 83,000 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.
Prior to 2016, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2016
231,000

 
$
6.97

Granted
—

 
—

Exercised
—

 
—

Expired or cancelled
(17,000
)
 
11.29

Outstanding, June 30, 2017
214,000

 
$
6.64

 
 
 
 
Exercisable, June 30, 2017
209,000

 
$
6.55


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2016
153,000

 
$
9.47

Granted
88,000

 
9.98

Dividend Equivalents
2,000

 
9.85

Vested
(74,000
)
 
9.03

Cancelled
—

 
—

Outstanding, June 30, 2017
169,000

 
$
9.93


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2016
54,000

 
$
11.10

Granted
26,000

 
9.98

Dividend Equivalents
1,000

 
9.85

Vested
(37,000
)
 
12.11

Cancelled
—

 
—

Outstanding, June 30, 2017
44,000

 
$
9.58



The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

While no SOSARs or Options were granted during 2017 and 2016, previously granted SOSARs and Options remain outstanding as of June 30, 2017. The following table summarizes information regarding stock options and SOSAR grants outstanding as of June 30, 2017:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.21 to $10.88
 
$
10.63

 
46,000

 
$
—

 
41,000

 
$
—

$2.37 to $6.21
 
$
5.55

 
168,000

 
$
630,000

 
168,000

 
$
630,000

 
 
 
 
214,000

 
 
 
209,000

 
 

Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $504,000 and $486,000 in the six month periods ended June 30, 2017 and 2016, respectively.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
Earnings (Loss) Per Common Share
 6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER COMMON SHARE
EARNINGS (LOSS) PER COMMON SHARE
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Net income (loss)
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
381

 
$
(2,150
)
 
1,729

 
(2,224
)
Loss from discontinued operations, net of income taxes
(28
)
 
—

 
(43
)
 
(37
)
Net income (loss)
$
353

 
$
(2,150
)
 
$
1,686

 
$
(2,261
)
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.06

 
$
(0.35
)
 
$
0.28

 
$
(0.36
)
Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – basic
$
0.06

 
$
(0.35
)
 
$
0.27

 
$
(0.37
)
Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.06

 
$
(0.35
)
 
$
0.27

 
$
(0.36
)
Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – diluted
$
0.06

 
$
(0.35
)
 
$
0.26

 
$
(0.37
)
Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,294

 
6,211

 
6,263

 
6,185

Diluted
6,472

 
6,211

 
6,458

 
6,185


The effects of 46,000 and 62,000 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the six months ended June 30, 2017 and 2016, respectively, because these securities would have been anti-dilutive.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
Equity Method Investment
 6 Months Ended
Jun. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]  
EQUITY METHOD INVESTMENT
EQUITY METHOD INVESTMENT
The Company had one equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the net profits and losses of the unconsolidated affiliate are reported as equity in net earnings or losses of unconsolidated affiliate in our statement of operations. For the six-month period ended June 30, 2017, the equity in the net income of an unconsolidated affiliate was zero compared to $61,000 for the six-month period ended June 30, 2016. The proceeds received from the sale are considered in the calculation of the gain on sale of investment in unconsolidated affiliate in our statement of operations. For the six-month period ended June 30, 2017, the gain on the sale of investment in unconsolidated affiliate was $733,000, related to the liquidation of remaining assets affiliated with the partnership.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Developments and Other Significant Transactions
 6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
2017 Acquisition
On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750,000. In connection with the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by $7,500,000, which is described in Note 4 to the interim consolidated financial statements herein. The acquisition transaction closed subsequent to June 30, 2017, on July 1, 2017. Therefore, at June 30, 2017, the Company maintained the funds in escrow to finance the acquisition, which are presented in the Company's interim consolidated balance sheet. Refer to to Note 10 to the interim consolidated financial statements for further discussion on this acquisition.
Golden Living Transaction
On August 15, 2016, the Company entered into an Operation Transfer Agreement with Golden Living (the "Lessor") to assume the operations of 22 centers in Alabama and Mississippi.
On October 1, 2016, the Company entered into a Master Lease Agreement (the "Lease") with Golden Living to directly lease eight centers located in Mississippi from the Lessor, which include: (i) a 152-bed skilled nursing center known as Golden Living Center - Amory; (ii) a 130-bed skilled nursing center known as Golden Living Center - Batesville; (iii) a 58-bed skilled nursing center known as Golden Living Center - Brook Manor; (iv) a 119-bed skilled nursing center known as Golden Living Center - Eupora; (v) a 140-bed skilled nursing center known as Golden Living Center - Ripley; (vi) a 140-bed skilled nursing center known as Golden Living Center - Southaven; (vii) a 120-bed skilled nursing center known as Golden Living Center - Eason Blvd; (viii) a 60-bed skilled nursing center known as Golden Living Center - Tylertown. The Lease is triple net and has an initial term of ten years with two separate five year options to extend the term. The Company also assumed the individual leases of a 120-bed center known as Broadmoor Nursing Home, with an initial lease term of ten years with first year rent of $540,000, escalating to $780,000 in the second year, and 2% annually thereafter, and a 99-bed skilled nursing center known as Leake County Nursing Home, with a lease term of two years with annual rent of $300,000.
On November, 1 2016, the Company amended and restated the Lease ("Amended Lease") with the Lessor to directly lease an additional twelve centers located in Alabama from the Lessor, which include: (i) a 87-bed skilled nursing center known as Golden Living Center - Arab; (ii) a 180-bed skilled nursing center known as Golden Living Center - Meadowood; (iii) a 132-bed skilled nursing center known as Golden Living Center - Riverchase; (iv) a 100-bed skilled nursing center known as Golden Living Center - Boaz; (v) a 154-bed skilled nursing center known as Golden Living Center - Foley; (vi) a 50-bed skilled nursing center known as Golden Living Center - Hueytown; (vii) a 85-bed skilled nursing center known as Golden Living Center - Lanett; (viii) a 138-bed skilled nursing center known as Golden Living Center - Montgomery; (ix) a 120-bed skilled nursing center known as Golden Living Center - Oneonta; (x) a 173-bed skilled nursing center known as Golden Living Center - Oxford; (xi) a 94-bed skilled nursing center known as Golden Living Center - Pell City; (xii) a 123-bed skilled nursing center known as Golden Living Center - Winfield. The Amended Lease is triple net and has an initial term of ten years with two separate five years options to extend the term. Base rent for the amended lease is $24,675,000 for the first year and escalates 2% annually thereafter.
2016 Acquisitions
On February 26, 2016, the Company exercised its purchase options to acquire the real estate assets for Diversicare of Hutchinson in Hutchinson, Kansas and Clinton Place in Clinton, Kentucky for $4,250,000 and $3,300,000, respectively. The Company has operated these facilities since February 2015 and April 2012, respectively. Hutchinson is an 85-bed skilled nursing facility, and Clinton is an 88-bed skilled nursing facility. As a result of the consummation of the Agreements, the Company allocated the purchase price and acquisition costs between the assets acquired. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the assets acquired is as follows:
 
 
Hutchinson
Clinton Place
Purchase Price
$
4,250,000

$
3,300,000

Acquisition Costs
43,000

34,000

 
$
4,293,000

$
3,334,000

 
 
 
Allocation:
 
 
Buildings
3,443,000

2,898,000

Land
365,000

267,000

Furniture, Fixtures and Equipment
485,000

169,000

 
$
4,293,000

$
3,334,000



2016 Lease Termination
On May 31, 2016, the Company entered into an Agreement with Avon Ohio, LLC to amend the original lease agreement, thus terminating the Company's right of possession of the facility. As a result, the Company incurred lease termination costs of $2,008,000 in the second quarter of 2016. Under the amended agreement, the Company is required to pay $300,000 per year through the term of the original lease agreement, July 31, 2024. For accounting purposes, this transaction was not reported as a discontinued operation, which is in accordance with the modified authoritative guidance for reporting discontinued operations, effective January 1, 2015. A disposal is now required to be reported in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results.
2016 Sale of Investment in Unconsolidated Affiliate
On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366,000 gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of $733,000 for the six-month period ended June 30, 2017, related to the final liquidation of remaining net assets affiliated with the partnership.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Events Subsequent Events
 6 Months Ended
Jun. 30, 2017
Subsequent Events [Abstract]  
Subsequent Events
SUBSEQUENT EVENTS
On July 1, 2017 the Company acquired a 103-bed skilled nursing center in Selma, Alabama, including certain land, improvements, furniture, fixtures and equipment, personal property and intangible property from Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC for an aggregate purchase price of $8,750,000. This facility is expected to contribute in excess of $8,000,000 in annual revenues.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidation and Basis of Presentation of Financial Statements (Policies)
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Consolidation
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the profits and losses from this investment are reported as equity in earnings of investment in an unconsolidated affiliate and the proceeds received from the sale are reported under the heading "Gain on sale of investment in unconsolidated affiliate" in the accompanying interim consolidated statements of operations.
Basis of Accounting
The interim consolidated financial statements for the six month periods ended June 30, 2017 and 2016, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at June 30, 2017, and the results of operations for the three and six month periods ended June 30, 2017 and 2016, and cash flows for the six month periods ended June 30, 2017 and 2016. The Company’s balance sheet information at December 31, 2016, was derived from its audited consolidated financial statements as of December 31, 2016.
The results of operations for the periods ended June 30, 2017 and 2016 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
Recent Accounting Guidance
In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. The ASU will be effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016. The Company will adopt the requirements of this standard effective January 1, 2018. The new standard may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). The Company plans to elect to apply the modified retrospective approach upon adoption. Additionally, the new guidance requires enhanced disclosures, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The Company is developing a plan for adoption and determining the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operation and cash flows. The Company is in the process of reviewing revenue sources and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectibility, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. We expect to complete this process in 2017. The Company is also in the process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration, including settlements with government payors, state Medicaid programs and bundled payment of care programs. Due to the many forms of calculation and reimbursement that these programs take that vary from state to state, the application of the new standard could have an impact on the revenue recognized for variable consideration. Industry guidance is continuing to develop, and any conclusions in the final industry guidance that is inconsistent with the Company's application could result in changes to the Company's expectations regarding the impact of the new standard on the Company's financial statements. Additionally, the adoption of the new standard will impact the presentation on the Company's statement of operations. After the adoption, the majority of what is currently classified as bad debt expense will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenues. The ASU will have a material impact on the amounts presented in certain categories on our consolidated statement of operations, but we do not expect it to have a material impact on our financial position, results of operations or cash flows.
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which changes how deferred taxes are classified on the Company's balance sheets. The Company adopted ASU No. 2015-17 as of January 1, 2017, and the new standard was applied on a retrospective basis. The adoption of this guidance resulted in a $7,644,000 reclassification between current deferred income taxes and non-current deferred income taxes.
In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for building and equipment operating leases and will result in a significant increase in the assets and liabilities on the consolidated balance sheet.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for shared-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which will require the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this standard will have on our consolidated financial statements.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017. The Company plans to adopt this standard on January 1, 2018, and is currently evaluating the impact this standard will have on our consolidated financial statements.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017, with early adoption permitted in certain circumstances.  The Company is still evaluating the effect, if any, the standard will have on the Company’s consolidated financial condition and results of operations.  The Company does not expect the adoption of this standard to have a material impact on its consolidated financial condition and results of operations.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. Early adoption is permitted. The Company does not presently believe adoption of this new standard will be material to its consolidated financial statements.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summarized activity of equity compensation plans
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2016
231,000

 
$
6.97

Granted
—

 
—

Exercised
—

 
—

Expired or cancelled
(17,000
)
 
11.29

Outstanding, June 30, 2017
214,000

 
$
6.64

 
 
 
 
Exercisable, June 30, 2017
209,000

 
$
6.55
Schedule of summarized activity of Restricted Share Units
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2016
153,000

 
$
9.47

Granted
88,000

 
9.98

Dividend Equivalents
2,000

 
9.85

Vested
(74,000
)
 
9.03

Cancelled
—

 
—

Outstanding, June 30, 2017
169,000

 
$
9.93


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2016
54,000

 
$
11.10

Granted
26,000

 
9.98

Dividend Equivalents
1,000

 
9.85

Vested
(37,000
)
 
12.11

Cancelled
—

 
—

Outstanding, June 30, 2017
44,000

 
$
9.58
Schedule of summarized information regarding stock options and SOSAR grants outstanding
The following table summarizes information regarding stock options and SOSAR grants outstanding as of June 30, 2017:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.21 to $10.88
 
$
10.63

 
46,000

 
$
—

 
41,000

 
$
—

$2.37 to $6.21
 
$
5.55

 
168,000

 
$
630,000

 
168,000

 
$
630,000

 
 
 
 
214,000

 
 
 
209,000

 
 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Earnings (Loss) Per Common Share (Tables)
 6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Basic and diluted net income (loss) per common share
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Net income (loss)
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
381

 
$
(2,150
)
 
1,729

 
(2,224
)
Loss from discontinued operations, net of income taxes
(28
)
 
—

 
(43
)
 
(37
)
Net income (loss)
$
353

 
$
(2,150
)
 
$
1,686

 
$
(2,261
)
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.06

 
$
(0.35
)
 
$
0.28

 
$
(0.36
)
Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – basic
$
0.06

 
$
(0.35
)
 
$
0.27

 
$
(0.37
)
Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.06

 
$
(0.35
)
 
$
0.27

 
$
(0.36
)
Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – diluted
$
0.06

 
$
(0.35
)
 
$
0.26

 
$
(0.37
)
Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,294

 
6,211

 
6,263

 
6,185

Diluted
6,472

 
6,211

 
6,458

 
6,185
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Developments and Other Significant Transactions (Tables)
 6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Schedule of allocation for net assets acquired
The allocation for the assets acquired is as follows:
 
 
Hutchinson
Clinton Place
Purchase Price
$
4,250,000

$
3,300,000

Acquisition Costs
43,000

34,000

 
$
4,293,000

$
3,334,000

 
 
 
Allocation:
 
 
Buildings
3,443,000

2,898,000

Land
365,000

267,000

Furniture, Fixtures and Equipment
485,000

169,000

 
$
4,293,000

$
3,334,000
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business (Narrative) (Details)
Jun. 30, 2017
state
center
bed
Accounting Policies [Line Items]  
Number of states in which entity operates | state 10
Number of nursing centers | center 76
Number of licensed nursing beds 8,453
Number of nursing center facilities owned | center 17
Number of nursing center facilities leased | center 59
Number of licensed assisted and residential living beds 496
Minimum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 48
Maximum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 320
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated and Basis of Presentation of Financial Statements (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Dec. 31, 2016
USD ($)
investment
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Schedule of Equity Method Investments [Line Items]      
Number of equity method investments sold | investment 1    
Gain on sale of investment in unconsolidated affiliate   $ 733 $ 0
Unnamed pharmacy joint venture      
Schedule of Equity Method Investments [Line Items]      
Gain on sale of investment in unconsolidated affiliate $ 1,366    
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Recent Accounting Guidance (Narrative) (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Jan. 01, 2017
Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Deferred income taxes, net $ 20,757   $ 21,185
Accounting Standards Update 2015-17      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Reclassification of current deferred income tax assets   $ 7,644  
Deferred income taxes, net   $ 7,644  
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Long-Term Debt and Interest Rate Swap (Narrative) (Details)
Dec. 29, 2016
USD ($)
Feb. 26, 2016
USD ($)
center
Aug. 01, 2017
USD ($)
Jun. 30, 2017
USD ($)
letter_of_credit
Dec. 31, 2016
USD ($)
Dec. 28, 2016
USD ($)
Oct. 03, 2016
USD ($)
Line of Credit Facility [Line Items]              
Accumulated other comprehensive income (loss)       $ 362,000 $ 195,000    
Interest rate swap              
Line of Credit Facility [Line Items]              
Notional amount of interest rate derivatives       $ 28,985,000      
Annual fixed rate percentage       5.79%      
Net liability based on interest rate swap valuation model       $ (62,000)      
Accumulated other comprehensive income (loss)       (38,000)      
Income tax benefit, interest rate swap       $ (24,000)      
Amended and restated credit agreement              
Line of Credit Facility [Line Items]              
Loan acquisition costs   $ 2,162,000          
Number of letters of credit | letter_of_credit       11      
Credit agreement | Amended and restated credit agreement              
Line of Credit Facility [Line Items]              
Borrowing capacity   $ 100,000,000          
Term of agreements   5 years          
Mortgage loan | Amended and restated credit agreement              
Line of Credit Facility [Line Items]              
Borrowing capacity   $ 72,500,000          
Term of agreements   5 years          
Period of amortization   25 years          
Amended mortgage loan balance       $ 67,970,000      
Number of owned nursing centers to secure Amended Mortgage Loan | center   17          
Mortgage loan | Amended and restated credit agreement | Interest rate swap              
Line of Credit Facility [Line Items]              
Debt interest rate at period end   5.79%          
Amended revolver | Amended and restated credit agreement              
Line of Credit Facility [Line Items]              
Borrowing capacity   $ 27,500,000   40,751,000     $ 52,250,000
Borrowings outstanding       24,500,000 $ 15,000,000    
Balance available for borrowing under revolving credit center       $ 842,000      
Amended revolver | Amended and restated credit agreement | LIBOR              
Line of Credit Facility [Line Items]              
Interest rate percentage   4.00%          
Letter of credit | Amended and restated credit agreement              
Line of Credit Facility [Line Items]              
Borrowing capacity $ 15,000,000         $ 10,000,000  
Annual fees for letters of credit issued under Revolver (as a percentage) 3.00%            
Mortgage term loan | Mortgage loan | Amended and restated credit agreement              
Line of Credit Facility [Line Items]              
Borrowing capacity   $ 60,000,000          
Debt interest rate at period end       5.30%      
Amended mortgage loan balance       $ 65,470,000      
Increase to credit facility limit       $ 7,500,000      
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | Interest rate swap | Designated as hedging instrument              
Line of Credit Facility [Line Items]              
Notional amount of interest rate derivatives   $ 30,000,000          
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | LIBOR              
Line of Credit Facility [Line Items]              
Interest rate percentage   4.00%          
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement              
Line of Credit Facility [Line Items]              
Borrowing capacity   $ 12,500,000          
Debt interest rate at period end       6.00%      
Amended mortgage loan balance       $ 2,500,000      
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement | LIBOR              
Line of Credit Facility [Line Items]              
Interest rate percentage   4.75%          
Omega Healthcare Investors Inc | Amended revolver | Amended and restated credit agreement              
Line of Credit Facility [Line Items]              
Letters of credit security deposit for a lease       $ 13,408,000      
Forecast | Amended revolver | Amended and restated credit agreement              
Line of Credit Facility [Line Items]              
Borrowing capacity     $ 42,250,000        
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies (Narrative) (Details)
 6 Months Ended
Jun. 30, 2017
USD ($)
lawsuit
facility
policy
Jun. 30, 2016
USD ($)
Oct. 31, 2014
facility
Malpractice Insurance [Line Items]      
Number of professional liability lawsuits | lawsuit 74    
Cash expenditures for self-insured professional liability costs $ 4,338,000 $ 1,542,000  
Other Insurance      
Liability for workers compensation claims 957,000    
Workers compensation insurance, non current receivable for excess premiums paid $ 1,628,000    
Unfavorable regulatory action | Potential violations of false claims act      
Malpractice Insurance [Line Items]      
Number of facilities | facility 6   2
Professional malpractice liability insurance      
Malpractice Insurance [Line Items]      
Liability for reported and estimated future claims $ 19,384,000    
Prefunded deductible policy      
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 500,000    
Other Insurance      
Insurance policy coverage limits per claim 500,000    
Professional liability insurance, annual coverage limit per facility 3,000,000    
Health insurance, maximum self-insured annual amount per individual 175,000    
Liability for reported claims and estimates for incurred but unreported claims 1,272,000    
SHC Risk Carriers, Inc | Professional malpractice liability insurance      
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 500,000    
Malpractice insurance annual sublimit per center 1,000,000    
Aggregate policy limit 5,000,000    
Other Insurance      
Insurance policy coverage limits per claim 500,000    
Unaffiliated entities | Professional malpractice liability insurance      
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 1,000,000    
Malpractice insurance annual sublimit per center $ 3,000,000    
Number of types of professional liability insurance policies | policy 7    
Other Insurance      
Insurance policy coverage limits per claim $ 1,000,000    
Scheduled for trial or arbitration over next 12 months      
Malpractice Insurance [Line Items]      
Number of professional liability lawsuits | lawsuit 17    
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Narrative) (Details) - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
May 31, 2017
Jun. 29, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based compensation expense $ 504 $ 486      
Restricted Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Grant of restricted common stock (shares) 88,000 83,000      
Restricted Stock | First anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Restricted Stock | Second anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Restricted Stock | Third anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Stock Options and Stock Appreciation Rights (SARs)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Payment award, expiration period 10 years        
SOSARs granted in period (shares) 0   0    
Stock Options and Stock Appreciation Rights (SARs) | First anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Stock Options and Stock Appreciation Rights (SARs) | Second anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Stock Options and Stock Appreciation Rights (SARs) | Third anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
2005 Long Term Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares reserved for future issuance (shares) 700,000        
Expiration period 10 years        
2008 Stock Purchase Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Percentage of quoted market price offering rate 85.00%        
Restriction period 2 years        
Shares authorized under the plan (shares)   350,000     150,000
2010 Long Term Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares reserved for future issuance (shares) 680,000     380,000  
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Awards, Vested and Expected to Vest, Outstanding and Exercisable) (Details) - Stock Options and Stock Appreciation Rights (SARs)
shares in Thousands
 6 Months Ended
Jun. 30, 2017
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding, December 31, 2015 (shares) | shares 231
Granted (shares) | shares 0
Exercised (shares) | shares 0
Expired or cancelled (shares) | shares (17)
Outstanding, June 30, 2016 (shares) | shares 214
Exercisable (shares) | shares 209
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Outstanding, December 31, 2016 (dollars per share) | $ / shares $ 6.97
Granted (dollars per share) | $ / shares 0.00
Exercised (dollars per share) | $ / shares 0.00
Expired or cancelled (dollars per share) | $ / shares 11.29
Outstanding, March 31, 2017 (dollars per share) | $ / shares 6.64
Exercisable, weighted average exercise price (dollars per share) | $ / shares $ 6.55
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details)
shares in Thousands
 6 Months Ended
Jun. 30, 2017
$ / shares
shares
Restricted Stock Units (RSUs)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, December 31, 2016 (share) | shares 153
Granted (shares) | shares 88
Dividend equivalents (shares) | shares 2
Vested (shares) | shares (74)
Cancelled (shares) | shares 0
Outstanding, March 31, 2017 (shares) | shares 169
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, December 31, 2016 (dollars per share) | $ / shares $ 9.47
Granted (dollars per share) | $ / shares 9.98
Dividend equivalents (dollars per share) | $ / shares 9.85
Vested (dollars per share) | $ / shares 9.03
Cancelled (dollars per share) | $ / shares 0.00
Outstanding, March 31, 2017 (dollars per share) | $ / shares $ 9.93
Employee Stock  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, December 31, 2016 (share) | shares 54
Granted (shares) | shares 26
Dividend equivalents (shares) | shares 1
Vested (shares) | shares (37)
Cancelled (shares) | shares 0
Outstanding, March 31, 2017 (shares) | shares 44
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, December 31, 2016 (dollars per share) | $ / shares $ 11.10
Granted (dollars per share) | $ / shares 9.98
Dividend equivalents (dollars per share) | $ / shares 9.85
Vested (dollars per share) | $ / shares 12.11
Cancelled (dollars per share) | $ / shares 0.00
Outstanding, March 31, 2017 (dollars per share) | $ / shares $ 9.58
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Schedule of Awards Outstanding and Exercisable) (Details) - Stock Options and Stock Appreciation Rights (SARs) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 6 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise prices (dollars per share) $ 6.64 $ 6.97
Grants outstanding (shares) 214  
Grants exercisable (shares) 209  
$10.21 to $10.88    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (dollars per share) $ 10.21  
Range of exercise prices, maximum (dollars per share) 10.88  
Weighted average exercise prices (dollars per share) $ 10.63  
Grants outstanding (shares) 46  
Intrinsic value - grants outstanding $ 0  
Grants exercisable (shares) 41  
Intrinsic value - grants exercisable $ 0  
$2.37 to $6.21    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (dollars per share) $ 2.37  
Range of exercise prices, maximum (dollars per share) 6.21  
Weighted average exercise prices (dollars per share) $ 5.55  
Grants outstanding (shares) 168  
Intrinsic value - grants outstanding $ 630  
Grants exercisable (shares) 168  
Intrinsic value - grants exercisable $ 630  
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
Earnings (Loss) Per Common Share (Basic and Diluted Net Income (Loss) Per Common Share) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Net income (loss)        
Income (loss) from continuing operations $ 381 $ (2,150) $ 1,729 $ (2,224)
Loss from discontinued operations, net of income taxes (28) 0 (43) (37)
Net income (loss) $ 353 $ (2,150) $ 1,686 $ (2,261)
Per common share – basic        
Income (loss) from continuing operations (dollars per share) $ 0.06 $ (0.35) $ 0.28 $ (0.36)
Loss from discontinued operations (dollars per share) 0.00 0.00 (0.01) (0.01)
Net income (loss) per common share – basic (dollars per share) 0.06 (0.35) 0.27 (0.37)
Per common share – diluted        
Income (loss) from continuing operations (dollars per share) 0.06 (0.35) 0.27 (0.36)
Loss from discontinued operations (dollars per share) 0.00 0.00 (0.01) (0.01)
Net income (loss) per common share – diluted (dollars per share) $ 0.06 $ (0.35) $ 0.26 $ (0.37)
Weighted Average Common Shares Outstanding:        
Basic (shares) 6,294 6,211 6,263 6,185
Diluted (shares) 6,472 6,211 6,458 6,185
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
Earnings (Loss) Per Common Share (Narrative) (Details) - shares
shares in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Earnings Per Share [Abstract]    
Antidilutive shares excluded from computation of diluted earnings per share (shares) 46 62
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
Equity Method Investment (Narrative) (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
USD ($)
Dec. 31, 2016
investment
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Equity Method Investments and Joint Ventures [Abstract]          
Number of equity method investments sold | investment   1      
Equity in net income of unconsolidated affiliate $ 0   $ 28 $ 0 $ 61
Gain on sale of investment in unconsolidated affiliate       $ 733 $ 0
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Developments and Other Significant Transactions (Narrative) (Details)
 3 Months Ended 6 Months Ended
Jul. 01, 2017
USD ($)
bed
Nov. 01, 2016
USD ($)
facility
option
bed
Oct. 01, 2016
USD ($)
facility
bed
May 31, 2016
USD ($)
Feb. 26, 2016
USD ($)
bed
Dec. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
center
bed
Jun. 30, 2016
USD ($)
Aug. 15, 2016
facility
Business Acquisition [Line Items]                    
Number of licensed nursing beds               8,453    
Deposit in escrow | $               $ 8,673,000 $ 0  
Number of nursing centers | center               76    
Gain on sale of investment in unconsolidated affiliate | $               $ 733,000 $ 0  
Avon Ohio, LLC                    
Business Acquisition [Line Items]                    
Lease termination costs | $             $ 2,008,000      
Lease termination fees, future annual payment amounts | $       $ 300,000            
Golden Living                    
Business Acquisition [Line Items]                    
Number of nursing centers | facility                   22
Broadmoor Manor                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     120              
Term of contract     10 years              
Rent expense, base year rent | $     $ 540,000              
Rent expense, increase during year two | $     $ 780,000              
Annual rent increase, percentage     2.00%              
Leake County Nursing Home                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     99              
Term of contract     2 years              
Rent expense, base year rent | $     $ 300,000              
Selma, AL | Subsequent event                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds 103                  
Payments to acquire nursing center | $ $ 8,750,000                  
Armory, MS | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     152              
Batesville, MS | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     130              
Brook Manor, MS | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     58              
Eupora, MS | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     119              
Ripley, MS | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     140              
Southaven, MS | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     140              
Eason Blvd | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     120              
Tylertown, MS | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds     60              
Term of contract     10 years              
Arab, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   87                
Meadowood, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   180                
Riverchase, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   132                
Boaz, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   100                
Foley, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   154                
Hueytown, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   50                
Lanett, MS | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   85                
Montgomery, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   138                
Oneonta, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   120                
Oxford, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   173                
Pell City, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   94                
Winfield, AL | Golden Living                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds   123                
Hutchinson, Kansas | Diversicare of Hutchinson                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds         85          
Deposit in escrow | $         $ 4,250,000          
Clinton, Kentucky | Clinton Place                    
Business Acquisition [Line Items]                    
Number of licensed nursing beds         88          
Deposit in escrow | $         $ 3,300,000          
Unnamed pharmacy joint venture                    
Business Acquisition [Line Items]                    
Gain on sale of investment in unconsolidated affiliate | $           $ 1,366,000        
Property subject to operating lease | Golden Living                    
Business Acquisition [Line Items]                    
Number of center locations | facility   12 8              
Amended lease | Golden Living                    
Business Acquisition [Line Items]                    
Term of contract   10 years                
Rent expense, base year rent | $   $ 24,675,000                
Annual rent increase, percentage   2.00%                
Maximum number of lease renewal periods | option   2                
Operating leases, renewal term   5 years                
Mortgage term loan | Amended and restated credit agreement | Mortgage loan                    
Business Acquisition [Line Items]                    
Increase to credit facility limit | $               $ 7,500,000    
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Developments and Other Significant Transactions (Schedule of Assets Acquired) (Details) - USD ($)
$ in Thousands
 6 Months Ended
Feb. 26, 2016
Jun. 30, 2017
Jun. 30, 2016
Business Acquisition [Line Items]      
Purchase Price   $ 8,673 $ 0
Diversicare of Hutchinson | Hutchinson, Kansas      
Business Acquisition [Line Items]      
Purchase Price $ 4,250    
Acquisition Costs 43    
Consideration transferred 4,293    
Buildings 3,443    
Land 365    
Furniture, Fixtures, and Equipment 485    
Total purchase price 4,293    
Clinton Place | Clinton, Kentucky      
Business Acquisition [Line Items]      
Purchase Price 3,300    
Acquisition Costs 34    
Consideration transferred 3,334    
Buildings 2,898    
Land 267    
Furniture, Fixtures, and Equipment 169    
Total purchase price $ 3,334    
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Events (Details)
$ in Thousands
Jul. 01, 2017
USD ($)
bed
Jun. 30, 2017
bed
Subsequent Event [Line Items]    
Number of licensed nursing beds | bed   8,453
Selma, AL | Subsequent event    
Subsequent Event [Line Items]    
Number of licensed nursing beds | bed 103  
Payments to acquire nursing center | $ $ 8,750  
Expected annual revenue of acquired | $ $ 8,000  
EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ɋ\^9LPGG$^?TB:>3_ZOH)LU]+? MM'W&/+%,A!4"*B#(JDZ:V(0?)$LIM-*\;D^/-1 &0;F1@/B'==+YC7RFD<+6PF&.&=8;6P5@67*08HCZOS\)75>]^(Z MF8J/-SH_^F&Z*I<[6;>S02: L!0K+K!!0CF, =E$M'C0W2D$&V"ZT'"8U99( M^C+M5@?T8^&^ ,X:K(?8Z!Z3;F>;S%IIG.362>H@YDP@OS$3#",RA7:#K"TT M".*U+9?S!;@WJ#P4P6F04M&\D_@&(LS""Z@E(-P Z#9!5,4U2MJ0_J]-F.,C MW2T)ZGQT?3P9?" Q;7>[3%%GJ8KG(:2G0F$&@'J8JP[O:S^YX3UJS"YH<)!I MIP-^/G*]G^5WHV)2&Q0/JER5ZYHZ!^\$/ZW#C )HF*1:6,F1H!HHBS?H8)%R M7FF0"_A9Z-B!),['TV?WQ<9DHQ?7!!W%TR8=9HXQY"UP(IHO&&D6%J0:'0/T MA:7RGH6E'><%=@!)+1E@>O-.4]SK>>+NBSGU M>XBG/[GT=J*]V8RVGP/90^*D?C/"28!%"B")Y-PP[6P=Q]#>LI1TH>/KVEW2 M(8H^Q3(\1=R*TLVHA0I[!)2 T$G%C%6U9A2>)46W]]/1V6\)BYFCMS=[J\6V+R3C'$NF964:N.-)$I[938&#C3] MG![OT:WODBC/CSET)86S<5$OYT69QVR0WV;[2Q0<:IIQ:'5P#K%!U 14I0N6 M2#UC@4&O!W#.9BSVPKHTY'L\Y#7.\\GJF/#'T32_NMZ1Y+G_Q%>S/C*JN6>( M4,8MQTI!8.'&K6--LT@T,&B M5EPP1P6AW&&^B8@!+E,BD\V/TUSF4MLR]L-S/=J)1C;L..-:$VM<> \=A8@3 M87Q=DD$3QOX:T<@N>-JK7,X9C=PRHU:BD8W[S:P4RCLGN<;$!<@H\O0!*P.] M[O>6C4M:XOL4R_ 4<2M*-T,*>B\<,9@YK#1'2->G.0PE,H65X%>Z0, MSLS$AY*I[40C]W26">"9=3KNW"(J./"&>XXF#S M7CJO4Q*-7E-$LA6RO+CUKS,YG"-.%*O.QUH(AR<3,&X8-SJJSTP(A11A7$*/ M!!40,EHK".,E37&4!KEWTR-7^Q)*W\'T3?GS\L94\_WQS!U-,LHI<1 #'^O1 M"$&,T76-)*.\Z>=6E,M4D2UAGG+0=47[>AS7U:QF_X=\DM_>17E5U^L:]\LR MR.Q-^%/PL^[S43E9??SY>,%X2)6 MZ*>(>P&LKG,/#.(DY5#:T86&SN:KM\GFX0NQ?[5KBPAW.9DWN^-\?\/,8V@L MC5%EY"7&7EI7A^(,\RSEH&[S$.FEJ^ 6D.^?9ZM1UB]:\R7^9;,,.F*T\.1L[V1[J$._S,D^%]VDV^QY>G=5MU4=3[EG[+,P280!,K FO+; JX%W/ MG7.7LAEY=![2W4H\@0^SQ:4P+@WNRZ*:I59#(I2@UAD*-&6Z3D?E\$2M4[]^=?O9DQKA6 MQCGB@C&*K8]I='"CI:E)*J4V/%^U=2F_R!Q/0;?'8PGK^TGR>1/"/'\X(]!" MI06V0"N)*<8,U"=OK;.BUSR%2^!,(L!]FDYQ\IO2?W469#G9$8295O/E+&^P MU*5VG7$7M+LD!$L/#14"(EPG EM$0$H-^@&&W#HSMGJ407^L727UK&I 7WV> M%C?K:&!XZY91HGM)N;=EAIAB4E@M%#!&*1YPKS=V+.'^PI;._NCQ@I=MBN&1 M=O_^ZPL)O T?K/ZT]2\/_;Q =32YC[(MRO'?@B9?RV-E"!3QBMIY-2TF<;-S M\]+&"N35;>C]2U[.B_O\Y2WMZZ'FWQ9Y.0D4[<%9>50HZ]%$K^OE&)LX+%!AEU&O7[.Q"9X'YEY+9'GM_> >Z9J5LR#+6"7 ML_#O>N(U#"<0_/0OR[@VGFA%@QR9)\IBPV6-JD DQ4T=H"KNDX8-WX#>9'?N M-R).[4,^GH[F\^*Z&*_9LBF*'L\"T2>;Z9N6#!ZH/!<40ZS#8LU-+2C$2N)E QS[I%5 MC#2ZG[";.?Y'L!P77TR@\M7L9E06_UIA_B&_S\OEFD#OPR=A+A_SV7T1SR"M M_K*Y]F]?Q":Y[\P$R B)YT4,\M!@[[VI<8,RJ<#ZT:Y%'[YT,G^J\TJ@OT5I MOIC'6ISKJS::5-78U21CV$F(*$>>6@*%@DC@>H8@!@?_;&WG:9-8A2#IU%A!+-@.&>UG-U,"DC=I JIG7NM EO7U3Z M?32]BY,.;(]NWOJTUTU>CK^_G^6WQ?+VT"G39AUD3E)-73#LD9786 P((O7L M)20IYTT'6?NI=7)U@G-?+/LM+\.K,8VW.4UNB[*(6,18UN%K7P^TS*Q0V%#* M.&$:4J$%Q&;S5F&9LH]UM)O^*GG5+L!]$E,TGA8$S&C$9* *VBPWC ? MNI00T WO=H. *4CVEL-@*JL?AQL?5=O@ZJ\A]IF4GH-=8#/$,4H(M[(S9P% M3"H//4B#N6T>M8UPO\=\(NUC4L'Q%^ T:I\Y)6D04O 7F /(<4J@VAAZ 8_+ MRK)JD0M;CP&UBW9?3-L^V@\OD[^*^5TU'TWWD.[8KC*+J!>L6.17U]=7U_9!-+$,]-/:?7O(<[AQ%O>FK? R6!> Q[*^ MQ-EZUMJKE".)P[R@JS,^M0[VV>WZ4^SYC&DOK+:Q5ID# D/.81U2(X0GU4H: MXCU:G=&I+83/8\=OJ\ZH\^MJEC\Y2/Y[45;AI?E>:V)53MKU!CH=10:PBCM9 MV&GKI4,^>&RPEH,4OI]RR*\V[C%<2?5>X.+AQ=9YF5\7C:I<_-@BDV%)L8P! M ZT7#!*H :KG!R5-*>4YR-!^-UQ,Q74XFC9)06;6.((U9U13J3Q'1+-Z)X,( MAE-RM088]^]?KQT)\'EHM;TZ;9T3KQ:+6?%YN1A]GN:?J@_Y7=Q3+6]<:+#X MWCC3N\7ORK@R4&#M(0@.'):>$UV'G$CX-V4Q'F!IE6Y)V[\\7AW'^^!VIKCF MP6R17%$>Q,>]M73C+H*DU(]!)LV>D85=O0]'RK WE_^TJB'4*^^8YMH"1(-' MJ\W&C 92I&RB#+ H=^L;= E8]K9%,IJ5@;NQ+O/J+B0]FA?C!NOYWG:9-!![ M3QWE4G+ D !.;.;*<5*U&7#YBW.;X ['1PFS64UD-:4DA^6'GC*JH.%*&PT- ML)(Z(XBK\?":IP2T![C3VQ(WCO9A4C ?HK%W&AN/Z#/S&EEF))>*(J.=$T9M M8O\I"G6/I@9G?XGW7!/7:AS82'CEE@J,%.8X&A-&#S_AF3XB@,, .O M&V:U@>RY6&.+Z7*13TXPU)ZUS(+F]LQH+:$DEDE@B=C,5VB09*H-@VXMAC6#KH]E@:K[W?>W/F\&7FLO'>@[GN#YAEC M@B'&:'!Y$%!: 8CJY"-J4=*% W"0RJO]\BRMHWS>6&XY>7@K5D7U'@O@-RD" M=&*/F7://^"9MTSQ@<9)&%?B+ ;0/?6TIS7MQ\B?H^B&)T MD[];WG[.9U?7JYG-KY:+^6)43L)T#\5"CNHG\PH0*CS6S%F.&51L<_J2!A,X M98E]!6Y&ZXQYGOS][$#BIORRX-D1[ M2!4E3F#"#*>NQH=:FY(#UWR)^S$-^-/90KB-R?*\7$P/T/>D,=Y6Y4TL41+/ M(:URY==I\Q\"5!^_CN[.IA'B>(ZZ>&][@PQKI8$R"'*)J%=.4"P(D-800SV3 MC9;-YS,DSL&E:G>C3'IBA>)8&8.0!X!@1>M9 M,FY2[DX;H-Y)%W8#]IR$[&'^[(B17-WF-Z/UG3GC42S<$ LP5+-X!_K.M:A9 MPXPSBI"3AFOEE99(0P7K&7",4ZKTOQ)N'"O*JD-\>],P57FS> B!-%F8MCR> M(440=\ A32W '!&+93TSK'5*%.WXS*K7N"BE@WHNNAQ>C+8VR(C41&-#H-5( M60RD!9O9$9ZT&SM$99,DX -L.0G1DQ>@WZO9XF9TD\>PZ=MJ5.Y?=;8_G7G* MN1'<&:ND1,RY\/O#6!4UJM>;JOJ7_K$"J]H&-%GX'_+[:GI?E#<_:L%F7-C; M.!.&(&4 %-PBH*G "MAZ)DR#E&-60W1P.J!&F_CVEJ?[PU /V" O'X[)3M1J MH0P#5MGPDT&LGA57M-\+>U^A!9(,Z7F(YER4EH]F:G/GE%#@9I7SZ]?#@S"BM"C<< 0NF5PXYLO#OB: I=CB^7_0K]H&1(ST.4=Z/;PY'874TR MQ"VC!AJ,<'BE, \SWLS0$'9A"2PI(M[+EI,1/3D\G,GZ M75 WLWRUJ;4_(->P>:;"F*4G!G-M)0 R[IQNX D"N&1^G"+4JG.,^](R_QC- MBJA/8T+T@<7H^:,9#RXCH(! S@4"S&GFY 8N"E*6HN;U\E_Q4I0(Z#DHOEP!JET""H(*.8,*$\9W[Q5X7VX, /W=*'N8<=)2/:X83RIRM7)BL^C\L^K MZR"/?!*'_?:-OOIPV"MJTCZSQH:W2U )8[41*K2'C_M?"*5<_3=P%ATK_)>; MR:W#VY\-_/+$T8=B_N=!MVEWLPQS":6U88HZ7JRI[:H8TGJFTN-^[^-^A:M6 MB^#V3Z/-E?--$EOV-BPO+LVQ'Z#N9E(QO7TQZ M?G[PX.*VO4$&D)'>QTJ!-E@#EB+(_,/L--.PU_28?DZEMB'J'5>/)F';%W/^ M(Y_<%.6-S>?%3;F6V?Y%;'N##%!-"-=200NX#;.RKG[9-+$N96M[@#?TM+]\ MM0+K^4AS<-':U21C""@ B44"6"0Q)X_)R=H!/!']$<(RT#LYM/6^KU86=OTX7_PO3IVV(SY%V M4VOD^-F;17Z[]UC!OG:9$@)RC $TR .DD)5AT@]S5<"F%$P__DZD5[BJM8GN M.9GT^^A;<;N\U=5L5GV-N\2CN_"7O1?%'=--1H.:9^&U\DY@9BR-0?X-$M1< MV$982ZQHP+66 .]O?5S+R1=E?:O\_+?9_DO<=K;)B(?2Q+HZC@#E$>,<;!P. MPI)*[P\QH;T34K6%[GEVY^-9C<;[\O'A#%H5L^CKUZOH"'[Y_;Y;J2776M;N,%EO]:_?8^GQ75Y+J:O9\5Y;BX M&TU'CZ6HWH^^KPII[=K#[^*[,HHTXC*@PWRP+*FD>A-RT= DF>]'GZ;H.T\Q MG8!#DJ8&,5N+N+3$DD <1.6,$APMAYL5'W!B75 MZWLE^6UM*\;6P#X/W9Y&>=?50XO[/+Q-XRCAFWW5XX[J)Z/4.(<)5I(BYIWA M6.,:"^1XRK[@*\EF:9MX[2)^'/OF^?AO-]7]K\6J2D/D'G[X.;(./V'=^M,G M.Q3OJBB^T31H[V6YK03C@1:99@!3:K5&0B&O'$)4;]!#28OKT3O,KV]Q;1?= M_I)@1N4\+..'"EH^>2S3DD''/38DQJ0I%9S7QZ^TITE+W2O9RFDA&'$ZH"=; M_S]J.5--IT'!S4;3NB#^U=E.-9+&M4E'LBHR?VE#$4YB08#*,2 M6!N!G3+"(2>Y!4J@I%/3 [Q@OD^?L"W0^RP"5)?-WI^ZN7DLHY(#$59F )$0 M2BF&99V@J"F'27F^?YW@^NF(MJIT?/[$4@^R6-E>^Z_M.;FO !;RL4Z)CJJ5 M4DZQV2A70-)NW!C\L=D.54_+P)],L/7"6EVOCVG.ZV'NXM".QS,BG;>(L;@Q MSBW#U''T:/F3I)R#BP^:MXALOZ>KYS4&3XB[TS5OVC1SA@5'DB@4%ESG!#", M\DWDR_*D]-U74D^HA<6J793/F7A@EK.(8VKBP:YN,HRUU)! %C0CMQX(Z!\U MK0))Y<"/CFN_OB6N!\S/85H_KLXZ'\W"V'WQ+?_ADIJ&QO?ACC*/!'56".V% M,5Y18/4F.&)YV@&JHP/_X&8M\7HOK14UU&\3T)2_G MJZ-!\0[!M]5\_BY?7%U_&GW;0ZDC>\J8UE)9)C'Q 6<*H31UV-\HC5(R1.%? M)EK>+>BG^X?Y8OWEX3MU7N;7>WS#EX]F$"CGO#-&>,0@-%30.@G;0(&2#E,U MCXB_6CW4$JZ/TN_T0K\/>5QR Y&C@Q&6W-^6Q21F#/XXF!YO[GLHTS?=>ZMEF]QF#&!GIH*<:T'@F%7&H&:/62>AU MO]>?]&'DMD&DZNQR.+/N&,PMH&WK$@",,@RJF"<="Q@IP1%7P26A'@&O&_E\ MO>N2J]F:8ULI=NC&T*1^,_O_MW=MS6WD.OI]?PUO((F7K0)OIU(U=68JRCY21[,S,_OIERY+C^*(;^T+)KDKEXG0W2> #"( J*.6P:LVHX2+ MO/\YPS?T"B#WNAK]=,I#N@#._KJC<_(/YO-<_>_M\F:UAC1?;-..VPNZ#_I. MPWPVX!AE+F0UFKQ"%&Y#"^1X9N6Z ^'FL3O4(T>&0F?;1^'GW^EJ_K7E\L[: MWN<>;XPQ0IB @J.,UEN1A7^SLK9'^'EAK2>NSSLG](!!G?7Z/[3'-Q>+J^6O M7Z^R%YN?!VYV8FJO]QN+GDFCF!*"R^Q$D'*)M(^6M*)9W^IC364Y5]/M#$E Q9J;(3;2SGBMSW'4@E4Q3Y/C*Z M^;%:J!X!FA]\_W1]95K_17 M-FA6ORU_FRS;ECBSJ_CWU\EEJVCF[8\>)A:U_S=97$Z7[9XT=KPN3)>7U_/E M[:(]CGFPX/>3U1G;JHO!:KV?'JQWGYA>V8<;AHF2],2\2*!TQF0*2$QJDY63 MVB_;J!^*?;C\,KFZO<[+V@F5Y4M8V14#[&R,)OG$G9+9S^,&;!36*-!9NQLK MK?(PS-8[7)//@4 WKX-=@[G7JPGNOGC[A^<:0J4,>*&%CQ"MPN0<850Q)C!< M#GH!6?_0&P$#CWWL NH/A:3C:?-]=;.K7ZXO9GM=)]/'< T2M&F9BGR2 -K3 MJDPS(3,^("^ZQ[5"7!^)JL<:/5/^IKY=#F] MVURFG[_D;>5B\?(=C4=]I_%YT[$:K#0:(/* *"7S*3@6.6?#9@(,H$!'A6)0@)N629*\8"Y=U.H@T>7?9 =4DQ5(61R_'M@\%9 M5CW0US+^P#E_/[^^3O-%^Y]]@'_K@(TFJVP05L3(\VY*I$24)EB2@6$8U>2T"7_CK='RB)4#R9_5TSYHKW2\3A--* @F0!M4AURM!#^J^K9G8?;BX6-W6BO".HS>MA:!G@/VV9]Z=_G@1U5E/^5W[B9CE==RY\ MJ3UNYV,T(?G A-1:B03,@G/!1W1.!:.3T6=V)EL=Q,=A8W_P?HE^ZV.$-I7Y M;MI'@WOO$1IOH:WD$J"( P%'9R(F;45F2O9]2H)Z^SR\C9N?+*)D4%UYI\-&CC>2RG^]YE,B*NB[L MWW3AU>._!MZ^/OL=)#$K=6 L^UH\(G'T2K'H#$?I1(GN/[@!Q)W]'F?]EBF> M!?"[8>?P<'^0)=$3T)^,T"2-%+)/PSA&R'_+TL\0LW.37%8*6')<7F$+Y;. M=RD33S!*^3^3]@1BUX];R0=,+3C!*VCED^['!.H1 ?^*T_<1]>1!1E+KJ2LL*GM:Q&M/C$PE@6X,P8X@EU8-*=&I(0*$R.;#$!2 M3G"'V=T%ST6P14T6*FP"?#:R5P\DWIRQK6I-)XA,,!D$!Q/:^\N5E4*AS50E M6=)R]OQ#WC6+6#\ &$N8'L1 1Q"F/4=OD$P?6:!:D?Y@]5 MRF]C]9^ULQ[J.ZR.!#E"09D%.@0%)(68')9)4.GJN] M:NA'IMA#].[5R[/PRXU3QMMH!3&1K3!RCA(1CX'+UB>215>]U-AW8"B(/6XZ M,"B;1E5+U?3XK%5-,9VL%A 1HW9)L[;!!#'F>-!>)[97-_^WG@&3)N2=68HD MI%-NY44:21LZ6?$'QI&.TO]'Q7^.J\Y!M)1ZRRA(B4OT[U8 M"G-F1?K',?(%-!Q%P:,C'Q__FG_\,K]=9D^79E>IO4-F?3_1NUG;ZSS_H)W8 M]M+Z@S[2**NULI",#A@PRM;4VZQ,1CBSQB3'LG4^$'T[0DYL8P\KP_F7V\7E MEZPH#X7-MB\TS!F!:"7G+*:4*+!T+U1)L)(SS@K3![K'3(?$[0@P'R>S8DVS M_1O9N?0)4_06'?!$1DFQ$80@52@QI"L\&.\>-)V2M^YF6="B&%M%$"@9)[ M;8U3>H7'O'N&G%YG-DV Q@G7_D+NB7.M-NOSG+VV9.(A #<$HX;2>FU'Z+83 M]'8#\<%3C1$*G06FI!0<,]7:G,KU.E#9 L_NO-'G!EB@* MD^EJO05AO+RG0](E^;<5&EI#X>Q8^E:$LSQ<%QKMP7<:H9@B"E_/'?+9RFOW%U^G-Q?5J' ;@UL&]3<^+2;O)\>K_(^<:*M MIUGEJF[$/*^W/1W?98;T,FB#W%B6R,M,;,41T,/&J(O>N)*.F!6:S2/J]6IX M6'9>N?B^-U<0HE4C:IJP1?"8P5VP=AS32NB+E?G#] M^UD*02VLJUX9IG !)GFAD@C!*0'.<])*\/7J5:!05$C*WA#<-T-&[>;R*'&>9E>/?O+K;'JS MI,N;Z;?LH+RU?'F^^T82";0-5DDG 4F[P%3D7*?LF/$8]LJ+[LGJ/*F6+S:+ M!ZD@-3D.RAHG+'&%$;QT*A4%NRL\G!\*=+VU?#F,7757OB(+V8 019E-IN= MTR"9;,O!A8-$):4-%4)O! QLK7P]C/K51(E/H?(U^>2Y!O*H0+-L%COR"9UD MQBO!SKKR=6]4#5+Y>A C1JI\75E[[S_\>F@%[(_O-0J9M8QY9CB!%1)3L(Y) M)SCW(*P\+]"-"Y?ME;!%C!D*A/&/K]?S?R:3_8JOGWFZ"9QGORHA)JV!H2>) M! EU$$Z:@"5]MDXQ-6Y(P)6SHYKM?.0,^PB9.DPQHT,"+QQJ$I8K!2RXS)N2 MK;I&$(]N@@[.LNJ!OO,8^M_SV;>\P4RNWG^_:'64'(?G)M(8DLQZW8:!)7BN M"*,D!]E!CAB]/[..L4/"=[ \AP[X>D92]N*%TX//H9$6T,7$6X(#"+!&)V.S MSI4\@X6]W0BY3Q(J*."10'QPB)FR2= M$)"=Z+>RH[.2QTY0R7+Y-^NO"MM4"CSZY)8-H: M0Z6M >!9N=I@?*3(@N!2ID'/&L_H/*0?>>CDHO$Q\7/ZF_*/D>QCI+^Z.3;> M!Q<@@+,I@+5@':7DR#+-M1& ;QMQ3=)_ZO@9OF+W^07??%]PF'Z;7DUFJP>_ M75RWCY3MZ]7,LH'(C8F1C",)&".*]B)E92VBDXI*6LN_SH.=@7;V4T70Z>_P M/P;CZ]SA#YQCPU,VS[3F)@F"P 11:JMZ>=;3BCB4N-KGU'VO$BUPZO@Y?1VP M/@.XS9"O4P$<,L%&6!&SFR:T0 Y.$ID 3"6B "H"E<3.SZGMX*N1_A[!\Q:L MZS/8PB&;822S*18B@##.M789D+ FAB1*NEF]WD.P5Q.J.PP]H[9S^5Y4M:+# MPW52=E_^GBPNI\NV:.JMD\NS'V[:?D!*.E L. C 26+2)GB3[3?-U5YN_ULG ME]5='HB)2XXVRSL8B\()J[1#,E;!F56 #P6ZWCJY',:NNCNY6$Z9CK:]GY!E MDGKK)69CS!)$J; H^ZQ"Z(V @:V=7 ZC?C4>[PET M1FN<=YFH@1AX"SN7^OOE]+)@M MKS>GL!V?^G\<6![<&>] M9LE:)!:3A]26.FG-(3+M4G9)1$GE=XU&PFF [5CV5!.'&+D%'7,H\[Y$DB0 M\OQ/BV@").-B6\EW9EEOE5J^/;+L) W=G^9_319W?YO^,=UYP7!/PS:2!=)30\<,*.\]3.FCT1LF8 MS5O/N)4.7$3B-F6EH[EEJ)&5W&]2HWDUO$34R\R.!>-(X=Y+Z6PYO>PG MEW7'>(T3(7*1F:925B0BD8P(VCG'G8H\EIRWGE.:>36[0A'[ZMH''F2$CK / M/!F]X9FK0C/%22$DQ9P6FC);#2:?PG[IEUTE:K\V41B9F6/M P_F/<@^\.)X MC929BPFE,MF@E$H[1J2<%=)X'5PJ\9"$*(:#2TM9I>"HZ"[W618+_V9.$'8S41,65UCH: M+1%$EHGL%!@!%$6640TEGEV%0?.A #BOB6F#Q)188Q\)/&HB(,CR_MI.?GS-K\>O[5$&[O@]?%\]K!F7WJE02^LCF2TU<[Z!"P90U9:K6)H;W<= ML4CUQRGOK#=]YO$F,1>9#L8QC(EB!A#H]>J25;Y$!51H,98S^;%PE]-TL$TJ M,VAEDOYK,O^\N/CZ97IY<;VKWN.E=QH;LON=, 8,3N4U&8SK-286H2AV6#]N M#F3S8\QT1-3!@#/Y_'BVNXLA7GJG"4H::=&9_$?P>9E.V\T:I6,EW4%J!$XY MKQ^CIR/*'A\!GES_<4$_[6S5@I_M*)R0=$3*[=Y67 MWFFX(\0L09:4$ &,,>%>FQJI2U+I:]0PI9S>C9RCZ#H2=E[KL\Q/-Z.FJ.H.A)B?MJGP.>%5QK%B1B 9U)%GA@/TM-F MA<$6=6RH,&K6YQ9U+$V/METWZ1,_32\GLV5[9]-B.9U]=I.7"UV'TB&;B/#'.5W^>3M=3'Y9S*]N MVW.*"2V7DYMMRF3GNTVPWL0DO0+0"9V-DEJ1(D7!99U\9F=3G6&I+P(?K6)6 MHZWFL)RV?(A_?YVT1ULTF]U>7+^?Y.7>3N:_KV?YW$UHQWRF81%"4I)C@+R1 M^]9!#!N1D40E?=CJWY0*55&_M![I".;QO\_B+";H*+40AJDL=IQYQY0 (W30 MC*)*]9S%+/N755+&;W=C/S:,+N M(;KK_VA_:X^-__N__A]02P$"% ,4 " @0-+8NW>*I/( #EX@D $0 M @ $ 879C82TR,#$W,#8S,"YX;6Q02P$"% ,4 " M@0-+IRQ5RT81 !%M0 $0 @ '"R 879C82TR,#$W,#8S M,"YX&UL4$L! A0#% @ ($#2W/M M#,4)/P :?4" !4 ( !R?8 &%V8V$M,C Q-S V,S!?9&5F M+GAM;%!+ 0(4 Q0 ( "! TO,34FX6K( .8%"0 5 " M 04V 0!A=F-A+3(P,3&UL4$L%!@ & 8 B@$ A/ @ $! end

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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 116 234 1 false 67 0 false 13 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.advocatinc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Interim Consolidated Balance Sheets Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheets Interim Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Interim Consolidated Balance Sheets (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheetsParenthetical Interim Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Interim Consolidated Statements of Operations Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperations Interim Consolidated Statements of Operations Statements 4 false false R5.htm 1002501 - Statement - Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperationsUnauditedParenthetical Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 1003000 - Statement - Interim Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfComprehensiveIncomeLoss Interim Consolidated Statements of Comprehensive Income (Loss) Statements 6 false false R7.htm 1004000 - Statement - Interim Consolidated Statements of Cash Flows Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfCashFlows Interim Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Business Sheet http://www.advocatinc.com/role/Business Business Notes 8 false false R9.htm 2102100 - Disclosure - Consolidation and Basis of Presentation of Financial Statements Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatements Consolidation and Basis of Presentation of Financial Statements Notes 9 false false R10.htm 2103100 - Disclosure - Recent Accounting Guidance Sheet http://www.advocatinc.com/role/RecentAccountingGuidance Recent Accounting Guidance Notes 10 false false R11.htm 2104100 - Disclosure - Long-Term Debt and Interest Rate Swap Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap Long-Term Debt and Interest Rate Swap Notes 11 false false R12.htm 2105100 - Disclosure - Commitments and Contingencies Sheet http://www.advocatinc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 2106100 - Disclosure - Stock-Based Compensation Sheet http://www.advocatinc.com/role/StockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 2107100 - Disclosure - Earnings (Loss) Per Common Share Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShare Earnings (Loss) Per Common Share Notes 14 false false R15.htm 2108100 - Disclosure - Equity Method Investment Sheet http://www.advocatinc.com/role/EquityMethodInvestment Equity Method Investment Notes 15 false false R16.htm 2109100 - Disclosure - Business Developments and Other Significant Transactions Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactions Business Developments and Other Significant Transactions Notes 16 false false R17.htm 2110100 - Disclosure - Subsequent Events Subsequent Events Sheet http://www.advocatinc.com/role/SubsequentEventsSubsequentEvents Subsequent Events Subsequent Events Notes 17 false false R18.htm 2202201 - Disclosure - Consolidation and Basis of Presentation of Financial Statements (Policies) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsPolicies Consolidation and Basis of Presentation of Financial Statements (Policies) Policies http://www.advocatinc.com/role/RecentAccountingGuidance 18 false false R19.htm 2306301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.advocatinc.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.advocatinc.com/role/StockBasedCompensation 19 false false R20.htm 2307301 - Disclosure - Earnings (Loss) Per Common Share (Tables) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareTables Earnings (Loss) Per Common Share (Tables) Tables http://www.advocatinc.com/role/EarningsLossPerCommonShare 20 false false R21.htm 2309301 - Disclosure - Business Developments and Other Significant Transactions (Tables) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables Business Developments and Other Significant Transactions (Tables) Tables http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactions 21 false false R22.htm 2401401 - Disclosure - Business (Narrative) (Details) Sheet http://www.advocatinc.com/role/BusinessNarrativeDetails Business (Narrative) (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables 22 false false R23.htm 2402402 - Disclosure - Consolidated and Basis of Presentation of Financial Statements (Details) Sheet http://www.advocatinc.com/role/ConsolidatedAndBasisOfPresentationOfFinancialStatementsDetails Consolidated and Basis of Presentation of Financial Statements (Details) Details 23 false false R24.htm 2403401 - Disclosure - Recent Accounting Guidance (Narrative) (Details) Sheet http://www.advocatinc.com/role/RecentAccountingGuidanceNarrativeDetails Recent Accounting Guidance (Narrative) (Details) Details 24 false false R25.htm 2404401 - Disclosure - Long-Term Debt and Interest Rate Swap (Narrative) (Details) Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwapNarrativeDetails Long-Term Debt and Interest Rate Swap (Narrative) (Details) Details http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap 25 false false R26.htm 2405401 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet http://www.advocatinc.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies (Narrative) (Details) Details http://www.advocatinc.com/role/CommitmentsAndContingencies 26 false false R27.htm 2406402 - Disclosure - Stock-Based Compensation (Narrative) (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation (Narrative) (Details) Details http://www.advocatinc.com/role/StockBasedCompensationTables 27 false false R28.htm 2406403 - Disclosure - Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Awards, Vested and Expected to Vest, Outstanding and Exercisable) (Details) Sheet http://www.advocatinc.com/role/ShareBasedCompensationShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsVestedAndExpectedToVestOutstandingAndExercisableDetails Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Awards, Vested and Expected to Vest, Outstanding and Exercisable) (Details) Details 28 false false R29.htm 2406404 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) Details http://www.advocatinc.com/role/StockBasedCompensationTables 29 false false R30.htm 2406405 - Disclosure - Stock-Based Compensation (Schedule of Awards Outstanding and Exercisable) (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfAwardsOutstandingAndExercisableDetails Stock-Based Compensation (Schedule of Awards Outstanding and Exercisable) (Details) Details http://www.advocatinc.com/role/StockBasedCompensationTables 30 false false R31.htm 2407402 - Disclosure - Earnings (Loss) Per Common Share (Basic and Diluted Net Income (Loss) Per Common Share) (Details) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareBasicAndDilutedNetIncomeLossPerCommonShareDetails Earnings (Loss) Per Common Share (Basic and Diluted Net Income (Loss) Per Common Share) (Details) Details http://www.advocatinc.com/role/EarningsLossPerCommonShareTables 31 false false R32.htm 2407403 - Disclosure - Earnings (Loss) Per Common Share (Narrative) (Details) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareNarrativeDetails Earnings (Loss) Per Common Share (Narrative) (Details) Details http://www.advocatinc.com/role/EarningsLossPerCommonShareTables 32 false false R33.htm 2408401 - Disclosure - Equity Method Investment (Narrative) (Details) Sheet http://www.advocatinc.com/role/EquityMethodInvestmentNarrativeDetails Equity Method Investment (Narrative) (Details) Details http://www.advocatinc.com/role/EquityMethodInvestment 33 false false R34.htm 2409402 - Disclosure - Business Developments and Other Significant Transactions (Narrative) (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsNarrativeDetails Business Developments and Other Significant Transactions (Narrative) (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables 34 false false R35.htm 2409403 - Disclosure - Business Developments and Other Significant Transactions (Schedule of Assets Acquired) (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsScheduleOfAssetsAcquiredDetails Business Developments and Other Significant Transactions (Schedule of Assets Acquired) (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables 35 false false R36.htm 2410401 - Disclosure - Subsequent Events (Details) Sheet http://www.advocatinc.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.advocatinc.com/role/SubsequentEventsSubsequentEvents 36 false false All Reports Book All Reports avca-20170630.xml avca-20170630.xsd avca-20170630_cal.xml avca-20170630_def.xml avca-20170630_lab.xml avca-20170630_pre.xml true true ZIP 57 0000919956-17-000039-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000919956-17-000039-xbrl.zip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�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�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�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